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Abstract
Both E2F and p53 are sequence specific transcription factors that play 
important roles in controlling early cell cycle progression. The pathway of control 
mediated through E2F governs the transition from G1 into S phase whereas p53 in 
response to genotoxic stress can facilitate cell cycle arrest or apoptosis. Here, I 
show that there is a physical and functional interaction between p53 and DP-1. p53, 
which interacts with a distinct form of DP-1, competes with E2F-1 for DP-1 leading 
to a reduction in the level of E2F-1/DP-1 heterodimer transcriptional activity. The 
results establish DP-1 as a common cellular target in two distinct pathways of 
growth control mediated through the activities of pRb and p53 tumour suppressor 
proteins.
From previous studies it is known that cells expressing aberrant levels of 
E2F-1 can undergo p53-dependent apoptosis. However, I demonstrate that E2F-1 
can induce apoptosis in p53~^' tumour cells and that DP-1 is able to augment the 
E2F-1-induced apoptosis, yet by itself it has no ability to induce apoptosis, 
consistent with the ability of DP-1 to enhance E2F-1-mediated transcriptional 
activation. Surprisingly, E2F-1-induced apoptosis requires DNA-binding but not 
tmns activation, suggesting that this apoptosis is not simply the consequence of the 
direct activation of genes required for apoptosis.
The mechanisms which influence the outcome of p53 induction are not clear, 
although transcription of the p53 target gene, encoding the cdk-inhibitor 
p2 i Wa/y/Ci/jy^  correlates with p53-mediated cell cycle arrest. Using a combination of 
biochemical and functional assays, I identify that p300 as a co-activator required for 
p53-dependent transcriptional activation of Wafl/CipL Furthermore, I show that the 
cdk-inhibitor p21 ^ afJ/Cipl autoregulates in a positive fashion transcription through 
modulating the activity of the p53/p300 complex, whilst negatively regulating the
activity of E2F by preventing cdk-dependent phosphorylation of pRb. Consistent 
with a role for p21 in the autoregulation of p53-dependent transcription,
p300 augments the ability of p53 to cause G1 arrest. In addition, I find that p300, 
which also functions as a co-activator for E2F/DP heterodimer, enhances the E2F-1- 
induced apoptotic activity. Thus, a functional interaction between p300 and either 
p53 or E2F-1 has a profound impact on early cell cycle progression, specifically in 
regulating the contrasting outcomes of cell cycle arrest and apoptosis.
p300/CBP proteins have been implicated as critical regulators of distinct 
cellular pathways, such as those leading to differentiation, cell cycle arrest and 
apoptosis. To elucidate the mechanisms of transcriptional activation by p300, it was 
considered possible that additional control may be exerted through proteins that 
physically interact to regulate the activity of p300. I demonstrate that a newly 
identified protein, termed JMY, makes a physiological complex with p300 in 
mammalian cells. Also, this new protein functionally co-operates with p300 in the 
transcriptional activation of p53, and possesses the properties of a co-activator for 
p53. I find that JMY has potent effects on certain p53-dependent genes, such as bax, 
and physiologically JMY co-operates with p300 in promoting apoptosis. These 
results reveal a new level of control that is important in dictating the cellular 
response to p53.
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Chapter 1.Introduction
In all eukaryotes, cell cycle progression is regulated not only through the 
activity of transcription factors, but also through the activity of activators and 
repressors which might modulate their activity (La Thangue, 1994; Hartwell and 
Kastan, 1994; Dynlacht, 1997). Co-ordination of these complex processes is 
thought to be important for growth-related decisions which will influence whether 
the cell proliferates, enters quiescence, or differentiates (Nevins, 1992; La Thangue, 
1994). A critical period for integrating growth regulating signals occurs during early 
cell cycle progression where, in the appropriate conditions, cells become committed 
to the division cycle (Nevins, 1992; La Thangue, 1994). The transition from G1 into 
S phase is governed by a number of cell cycle regulatory proteins with established 
roles in controlling proliferation, such as the tumour suppressor protein p53, the 
E2F transcription factors, and the retinoblastoma tumour suppressor protein pRb 
(Nevins, 1992; La Thangue, 1994; Lam and La Thangue, 1994; Weinberg, 1995).
In addition, pathways that act positively and negatively are exerted during 
physiological processes such as development, differentiation, senescence, and 
apoptosis (Hunter and Karin, 1992; Lam and La Thangue, 1994; Raff, 1996; 
Vousden, 1996; White, 1996). In many cases, arrest of cell proliferation takes place 
under circumstances in which the integrity of the genome has been compromised, 
and failure to arrest proliferation would release cells with highly unstable genomes 
that could evolve into tumour cells or trigger the apoptotic signals (Hartwell and 
Kastan, 1994; Weinberg, 1995; White, 1996).
Apoptosis plays an indispensable role during embryogenesis, in adult tissue 
homeostasis, in the regulation of the immune system and in the development of the 
nervous system so as to eliminate unwanted, potentially dangerous cells or 
superfluous cells from the organism (Fisher, 1994; Hoffman and Liebermann, 1994;
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Steller, 1995; Vaus and Strasser, 1996). The mechanisms which control apoptosis 
are thought to be highly conserved in all mammalian cells, and must therefore be 
tightly regulated. The genes regulating and executing the apoptotic programme are 
just beginning to be identified and are currently an area of intense investigation (Ko 
and Prives, 1996; Hansen and Oren, 1997). However, the events which determine 
whether a particular cell should arrest the cell cycle or activate the apoptosis 
pathway are not fully understood.
1-1. p53, the cellular mediator for growth control 
and cell death
The human tumour suppresor gene p53  encodes a 393 amino acid 
phosphoprotein that exhibits sequence-specific DNA binding and directly interacts 
with various cellular and viral proteins (Ko and Prives, 1996; Levine, 1997) (Table 
1-1 and Figure 1-1). The p53 protein is a critical regulator of tumourigenesis, as 
evidenced by the fact that p53 is lost through mutation or inactivation by viral 
oncoproteins in more than half of human cancer. Moreover, individuals with Li- 
Fraumeni syndrome, who inherit a mutant p53 allele, are highly predisposed to 
various cancers (Malkin, 1993). Homozygous disruption of p53 alleles in the mouse 
does not result in developmental defects but leads to a dramatically increased 
incidence of diverse tumours (Donehower et a l,  1992), this being consistent with 
the postulated role of p53 as a guardian of genomic integrity (Lane, 1992; Pietenpol 
and Vogelstein, 1993).
At the physiological level, p53 has been implicated as a key mediator of the 
cellular response to DNA damage. DNA damage induces accumulation of active
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p53, which can eventually lead to a G1 arrest or to apoptosis (Kastan et a i,  1992; Lu 
and Lane, 1993; Pietenpol and Vogelstein, 1993; Crook et al, 1994; Macleod et al, 
1995; Polyak et al,  1996; Chen et al, 1996; Ko and Prives, 1996). It has been 
shown that p53 senses DNA damage and arrests the cell cycle in either the Gl/S or 
G2/M checkpoints to allow DNA repair to take place. If repair is not successful, p53 
initiates apoptosis thus preventing the propagation of genetic defects to successive 
generations of cells. In addition, there is evidence that p53 can affect the initiation 
of apoptosis in a dose-dependent manner when induced by agents that cause DNA- 
strand breakage (Ko and Prives, 1996). However, p53 appears to be necessary for 
some, but not all forms of apoptosis (Clarke et al,  1993; Allday et al, 1995; 
Macleod et al, 1996).
The choice between cell cycle arrest and apoptosis mediated by p53 is not 
completely understood. Therefore, the factors governing how a cell responds to p53 
activation is a subject therefore of great interest.
1-1.1. Cell cycle arrest mediated by p53 is dependent on its transcriptional
activity.
The wild-type p53 protein is a sequence-specific transcription factor which 
can activate genes possessing p53 consensus sites. The biochemical activity of p53 
most tightly associated with tumour suppression and growth arrest involves a 
damage-dependent activation of sequence-specific transcriptional activity. p53 
induces the transcription of a number of genes (Table 1-1), the products of which 
directly mediate growth arrest as is the case of p21^‘^ / /^^ y^  ^ (Pietenpol et al, 1994; 
Crook et al, 1994).
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Table 1-1 Proteins that have a functional relationship with p53.
Viral and cellular proteins interacting with p53 
SV40 T antigen Blocks p53 DNA binding domain
Blocks p53 transcriptional activation domain 
Promotes the degradation of p53 
p53-mediatcd cell cycle arrest 
Binds amino and carboxyl termini of p53 
TFIIH (XPB, XPD) Helicase modulated by wild type p53, not mutant p53 
WTl (Wilms Stabilizes p53 protein, and inhibits apoptosis although
tumour- 1 ) permitting growth arrest
AdElB 55kDa 
HPV E6  
c-Abl
TFIID/TBP
The products o f p53-responsive genes.
p2 \^^fVCipJ Inhibit several cyclin-dependent kinases; bind cdk's,
cyclins, and PCNA; arrest the cell cycle 
MDM2 Product of an oncogene; inactivates p53-mediated transcription
and so forms an autoregulatory loop with p53 activity 
GADD45 Induced upon DNA damage; binds to PCNA and can arrest the
cell cycle; involved directly in DNA nucleotide excision repair 
Cyclin G A novel cyclin (it does not cycle with cell division) of
unknown function and no known cyclin-dependent kinase 
Bax A member of the Bcl2 family that promotes apoptosis; not
induced by p53 in all cell types 
IGF-BP3 The insulin-like growth factor binding protein-3; blocks
signalling of a mitogenic growth factor
Data in this table are compiled together with data from Hall et al. (1996), Ko and 
Prives (1996), Hansen and Oren (1997), and Levine (1997).
1) Sequence-specific DNA binding activity.
p53 binds to promoters containing TGCCT repeats, the so-called RGC 
sequence (Kern et al,  1991; Maheswaran et al,  1995), present in the promoter of 
the muscle creatine kinase (MCK) gene (Weintraub et al,  1991; Zambetti et al ,
1992). Analysis of multiple genomic p53 target sites has also led to a consensus 
binding site, defined as two copies of the motif 5'-PuPuPuC(A/T)(T/A)GPyPyPy-3' 
separated by 13 bp (El-Deiry et al,  1992; Sturzbecher and Deppert, 1994). The 
central region of p53 (comprising amino acid residues from 102 to 292) contains the 
DNA-binding (core) domain (Pavletich and Pabo, 1993; Prives, 1994) (Figure 1-1). 
It hss a protease-resistant core and independently folded domain containing a Zn^+ 
ion that is required for its sequence-specific DNA-binding activity (Cho et al,  1994; 
Vogelstein and Kinzler, 1994; Prives, 1994). More than 90% of the missense 
mutations in p53 reside in this core domain, and fall into two classes. The mutations 
in amino acid residues such as R248 and R273, the two most frequently altered 
residues in the protein, result in defective contacts with the DNA and loss of the 
ability of p53 to act as a transcription factor (Ko and Prives, 1996). A second class 
of p53 mutations disrupts the structural basis of the |3 sheet and the loop-sheet helix 
motif that acts as a scaffold in the domain (Hupp et al,  1992; Cho et al, 1994; 
Prives, 1994; Levine, 1997). Interestingly, the carboxy-terminal domain of p53 
recognizes certain types of damaged DNA including short single strands which also 
activate the sequence-specific DNA binding function of p53 (Lee et al,  1995; 
Jayaraman et al,  1995).
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Transcriptional
activation/repression Sequence-specific DNA-binding
D NA-PK,
CKI site
Ad E1B 55kD
M D M 2
T F IID /T B P
TFIIH
RP-A
100 200L,
S V 40 T  antigen 
P53-B P1  
-BP2
Tetramerization 
Transformation 
Non-specific DNA binding
300 393
DDKs site CKII
PKC
HPV E6-targeted
degradation
TBP
TFIIH
Figure 1-1
Structural organization of the p53 protein.
Hatched boxes I to V represen t evolutionarily  conserved  regions. 
Indicated above are the positions o f  defined phophorylation sites by DNA-PK, 
cyclin-dependent kinases (CDKs), CKI, CKII, and PKC. Some of the proteins 
which interact with particular regions of  p53 are shown at the bottom (see Table 
1 -1 for further details).
2) Transcriptional suppression / transcriptional activation of specific target genes.
The first 42 amino acids at the amino-terminus constitute a transcriptional 
activation domain that interacts with the basal transcriptional machinery and 
positively regulates gene expression (Fields and Jang, 1990; Lin et al, 1995).
This region makes contacts the TATA-associated factors TAFII70 and TAFII31 (Lu 
and Levine, 1995), TAFII40 and TAFII60 (Thut et al,  1995), which are subunits of 
TFIID, and also the TATA-binding protein, TBP (Chen et al,  1993; Lin et al ,  
1994). These interactions are thought to contribute to the ability of p53 to repress 
general transcription in the absence of a cognate recognition site.
Various downstream target genes of p53 have been identified. A summary 
of them is given in Table 1-1. As mentioned previously, the p53 gene is induced in 
response to DNA damage or under conditions unfavourable for DNA synthesis, 
under certain circumstances this will result in a halt in the cell cycle which allows 
the cell to repair its DNA or to await for more favourable conditions (El-Deiry et a l , 
1993; Harper et al,  1993; Dulic et al,  1994; Waldman et al, 1995; Chen et al,
1996). The main player in the cell cycle arrest is the cyclin dependent kinases 
(CDKs) inhibitor Upregulation of p2 1  WVC/j»7 expression by p53 in
response to radiation can inhibit cyclin-dependent kinase activities (Dulic et a l ,
1994). As result of this inhibition, hypophosphorylated pRb accumulates (Sherr, 
1993; Pines, 1995; Weinberg, 1995), and a G1 arrest is induced by the consequent 
repression of E2F responsive genes (Koh et al,  1995; Lukas et al,  1995) (Figure 1- 
2). It is known that the phosphorylation of pRb is an important step for growth 
stimulation of quiescent cells (Nevins, 1992; Lam and La Thangue, 1994). 
Members of the CDK family are responsible for phosphorylating pRb (Figure L2).
p2 i Wfl/7/Cî/?7 inhibits not only the G 1-acting cyclinE-CDK2 complex but 
also Gl/S-acting cyclinA-CDK2, cyclinA-cdc2 that acts in S and early G2, and it 
also showns inhibitory activity against cyclinD-CDK4/6 complex (Hinds et al,  
1992; Dowdy et al,  1993; Ewen et al ,  1993; Cox and Lane, 1995; Sherr and
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Figure 1-2
Model for activation of cell cycle arrest in GI by p53.
p53 protein can transcriptionally induce p21 expression, which 
inhibits cyclin/CDK phosphorylation o f pRb. Hypophosphorylated pRb 
sequesters the transcription factor E2F (complex E2F/DP), and thereby 
blocks progress through G1 by inhibiting expression o f E2F-responsive 
genes (see Figure 1-5 for further details).
Roberts, 1995). The two known pRb-related proteins p i07 (Ewen et al., 1991) and 
p i30 (Hannon et ai,  1993; Li et al., 1993) are also substrates of cyclin/CDK. Thus, 
p2 iWafl/Cipl inhibition of cyclinDLCDKT and cyclinE-CDK2 can affect the 
activities of pl07 and p i30, which regulate the other E2F family members E2F-4 
and -5 (Beijersberger et al,  1994; Ginsberg et al,  1994; La Thangue, 1994). The 
repressive hypophosphorylated form of pRb is targeted by DNA viral oncoproteins 
such as adenovirus El A, simian virus 40 large T antigen, and human papillomavirus 
E7, which bind directly to and inactivate pRb (La Thangue and Rigby, 1987; 
Nevins, 1992; Tommasino and Crawford, 1995; Levine, 1997). In that way, the 
DNA tumour viruses stimulate quiescent cells to undergo DNA replication, thereby 
providing an environment permissive for viral replication.
Interestingly, ^Iso binds to PCNA (proliferating cell nuclear
antigen) (Waga et al,  1994; Gulbis et al,  1996) and these complexes block the role 
of PCNA as a DNA polymerase processivity factor in DNA replication, but not its 
role in DNA repair (Figure 1-3). Thus, p2 1 ^<T///6 (/;/ can act on cyclin-CDK 
complexes and PCNA to stop DNA replication.
Mice deficient in the Wafl/Cipl gene {Wafl/Cipl-^-) develop normally, and 
mouse embryo fibroblasts derived from these mice are partially deficient in their 
ability to arrest cells in G1 in response to DNA damage (Deng et al,  1995).
By contrast, the removal of both Wqfl/Cipl alleles from a cancerous cell line in 
culture that contained a wild-type p53 allele completely eliminated the DNA 
damage-induced G 1 arrest in these cells, indicating that p2 1 h/qfy/G/p/ sufficient to 
enforce a G1 arrest in this situation (Polyak et al,  1996; Levine, 1997),
mdm2 is a protooncogene, amplified in valions tumours, which possesses 
two p5 3  response elements in its first intron and can be transcriptionally induced by 
p53 (Momand et al, 1992; Juven et al,  1993). The MDM2 protein directly interacts 
with p53 (in amino acid residues 18 to 23) (Figure 1-1), and thereby abolishing p53's 
transcritpional activity (Momand et al,  1992; Lin et al,  1994; Thut et al,  1997).
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Figure 1-3
p53-dependent pathways for cell cycle arrest and apoptosis.
(Data  in this figure are com piled  together with data from Cox and Lane (1995), 
Hall et al. (1996), Ko and Prives (1996), Hansen and Oren (1997), and Levine 
(1997))
This interaction participates in a negative feedback loop in which both the activity of 
p53 and the expression of MDM2 are regulated in the cells (Chen et al,  1994) 
(Figure 1-3). In addition, MDM2 regulates the stability of p53 protein, possibly 
through a mechanism that involves export from the nucleus and thereafter ubiquitin- 
dependent degradation of p53 (Haupt et ai, 1997; Kubbutat et al, 1997; Roth et al, 
1998). Although induced by UV light in a p53-dependent manner, the time of mdml 
induction actually correlates with the recovery of cellular DNA synthesis (Perry et 
al,  1993). Thus MDM2 may be involved in cell recovery after damage, rather than 
repair. The over-express ion of MDM2 in tumours reduces the p53-dependent G1 
arrest (Chen et al,  1994; Cox and Lane 1995). Moreover, the interaction between 
p53 and MDM2 is influenced by phosphorylation of the p53 activation domain 
which has been suggested to be mediated by kinases induced by genotoxic stress 
(Shieh et al, 1997), thus enabling the negative growth regulating effects of p53 in 
response, for example, to irradiation to be overcome.
In addition, gadd45 also contains a p53 binding site in its intron 3 and is 
induced by DNA damaging a p53-dependent manner (Kastan et a l ,  1992), 
Although the function of GADD45 in the cell cycle is not completely clear, recent 
evidence suggests that it can directly interact with the replication and repair factor 
PCNA and to inhibit the entry of cells into S phase (Smith et al,  1994; Kastan et al,
1992). The over-expression of the product of the gadd45 gene in some cell types 
promotes G1 arrest (Figure 1-3). Perhaps, it is possible that GADD45 plays the 
backup role for p21^dfVCip] ^
1-1.2. p53 is not the only determinant of the cell cycle checkpoints.
Cells could be arrested by p53-independent mechanisms, as has been 
suggested by different lines of evidence (Strasser et al,  1994). Apoptosis in 
proliferating T lymphoma cells is accompanied by cell cycle arrest.
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Dexamethasone-treated cells accumulated only in G l, but irradiated cells 
accumulated in G2, as anticipated from studies on p53'^~ fibroblasts (Kastan et ai,
1992). It seems likely therefore that p53 is not the only determinant of the cell cycle 
checkpoint triggered by DNA damage. Furthermore, it has been found that 
p2 1 VKrt///Ci>7 expression during development and in the adult mouse can induced by 
DNA-damaging agents through p53-independent mechanism and that the gene can 
be induced by serum or upon differentiation in the absence of p53 function (Macleod 
et al,  1995). So, it is possible that the p53-independent Gl arrest might be mediated 
by p21 Wq/7/C;;)7 ^ qj- other cyclin-CDKs inhibitors such as or
(Serrano et al, 1993; Sherr and Roberts, 1995; Kamb, 1995).
1-1.3. Apoptosis induced by p53.
The question of whether transcriptional activation is important for p53- 
dependent apoptosis has been addressed in a number of elegant studies (Lowe et a l , 
1994; Symonds etal ,  1994; Bates and Vousden, 1996; Ko and Prives, 1996; Hansen 
and Oren, 1997; Levine, 1997). Two of the genes that are regulated by p53 may 
influence the decision to commit to an apoptotic pathway : bax and IGF-BP3 
(insulin-like growth factor-binding protein 3) (Miyashita and Reed, 1995; 
Buckbinder et al,  1995).
The Bax gene has been implicated as a direct target for p53 (Miyashita and 
Reed, 1995) , and the over-expression of Bax can efficiently induce apoptosis 
(Ludwig et al,  1996) (Figure 1-3 and Table 1-1). Furthermore, it has been reported 
that Bax binds to Bcl-2 and antigonizes its ability to block apoptosis, so p53- 
dependent synthesis of Bax has been suggested to be a stimulus for cell death 
(Oltavi et al,  1993; Miyashita and Reed, 1995). The over-expression of anti- 
apoptotic proteins, Bcl-2 or the adenovirus ElB 19kDa protein, abrogates p53- 
mediated apoptosis without impairing p53-mediated Gl arrest and prevents the
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apoptosis seen with deregulated c-Myc (Fanidi et al,  1992; Debbas and White, 
1993; Chiou et al,  1994; Wagner et al ,  1994; Han et al,  1996; Ko and Prives,
1996). The balance of Bcl-2 to Bax may therefore be a critical factor in determining 
proliferation or apoptosis. At high levels, Bcl-2 protein may compete for the p53- 
induced Bax to protect cells from p53-induced apoptosis. Induction of Bax in 
response to irradiation (IR) appears to correlate with p53 status in human cells and 
p53'^' mice exhibit increase levels of Bcl-2 and decreases in Bax protein levels in 
several cells and tissues (Ko and Prives, 1996). Moreover, tumour growth is 
accelerated and apoptosis drops dramatically in 6 ax-deficient mice, indicating that it 
is probably required for a full p53-mediated response (Yin et al,  1997).
The IGF-BP3 also has been identified as a p53 responsive gene induced in 
cells after DNA damage (Figure 1-3 and Table 1-1). IGF-BP3 inhibits the insulin­
like growth factor (IGF) mitotic signalling by binding to IGF and preventing its 
interaction with its receptor (Buckbinder et al,  1995). IGF has been shown to 
function as an efficient survival factor, protecting cells from p53-dependent, myc- 
induced apoptosis (Harrington et al ,  1994). Thus, it is possible that the effect of 
activation of IGF-BP3 by p53 is to abrogate survival signals, rather than growth 
signals, to make the cell more sensitive to other apoptotic functions of p53.
A lot of evidence supports a correlation between apoptosis and 
transcriptional activity by p53. Tumour-derived mutant alleles of p53 (with the 
mutation Ala 143, Hisl75, or Trp248) encode proteins that fail to induce apoptosis in 
transiently transfected H I299 cells (Friedlander et al,  1996). In addition BRK cell 
lines transformed by E l A and expressing a temperature-sensitive p53 Vail 35 
mutant undergo apoptosis after shift to 32“C (the permissive temperature to form the 
wild-type conformation of p53), whereas cells expressing a transcriptionally 
defective p53 Gln22, Ser23 (p53^^^23) were dramatically impaired for the ability to 
mediated ElA-induced apoptosis in the same conditions (Sabbatini et al,  1995). 
Moreover, experiments in transgenic mice expressing a p53 mutant harboring only 
the carboxy-terminal domain p53 (amino acid residues 302 to 390) results in mice
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developing aggressive brain tumours by the inactivation of endogenous p53 
(Bowman et al,  1996). Thymocytes from transgenic mice expressing a T antigen 
capable of binding to p53 have also been shown to be resistant to radiation-induced 
apoptosis (McCarthy et al,  1994).
1-1.4. p53 induction is not necessary for apoptosis in some circumstances.
It has been found that p53 induction is not the only trigger for cell death 
following DNA damage. Thymocytes, cells which enter apoptosis in response to 
DNA damage through a p53-dependent pathway, also undergo p53-independent cell 
death during the normal process of lymphoid development (Clarke et al,  1993; 
Lowe et a l ,  1993), providing evidence that p53 is not the sole contribution to 
apoptosis. Cells from T lymphomas derived from p53-^~ mice are killed rapidly and 
efficiently by irradiation and DNA-damaging agents (Strasser et al., 1994). 
Furthermore, it was shown that apoptosis is p53-dependent in the central nervous 
system but p53-independent in the peripheral nervous system (Macleod et al,  1996). 
Experiments using human B cell lines treated with cisplatin resulted in DNA 
damage that induced apoptosis, during the Gl/S boundary of cell cycle, when p53 is 
transcriptionally active, and G2/M phase, when p53 is transcriptionally inactive 
(Allday et al,  1995), suggesting the existence of another cell cycle checkpoint at 
G2/M phase. More clearly, the mutant p53 Gln22, Ser23 (p53^^^^^), which 
abrogates the transcriptional activating function of p53, triggered apoptosis in HeLa 
cells (Haupt et al,  1995b), and p53 dl214, which contains only the first 214 amino 
acid residues of murine p53, can induce apoptosis, despite lacking the major portion 
of the DNA-binding domain (Haupt et al ,  1995b). Interestingly, the over­
expression of MDM2 failed to abolish p53-mediated apoptosis in HeLa cells, despite 
a complete abrogation of its trans activation ability, while MDM2 dramatically 
inhibited p53-mediated apoptosis in H I299 cells (Haupt et al,  1996). Thus, taken
35
together it appears that the transcriptional activity of p53 is not necessary for the 
induction of apoptosis in all cells. Nevertheless, this does not exclude the possibility 
that several pathways co-operate to induce cell death. The evidence suggests that 
different p53 functions, both transcriptionally-dependent and -independent, play a 
role in activating these pathways.
1-1.5. Cell cycle arrest and apoptosis by p53 may be differentially regulated 
functions.
Numerous studies have shown that growth arrest and apoptosis are 
independent functions of p53. Murine hematopoietic cell lines undergo Gl arrest in 
response to irradiation in the presence of survival factors or growth factors, but when 
they are absent, p53-dependent apoptosis ensues (Gottlieb et al,  1994; Canman et 
a l ,  1995). Uncoupling growth arrest and apoptosis has also been demonstrated 
through the use of several mutants forms of p53 (Haupt et al,  1995b; Rowan et al,  
1996; Friedlander et al,  1996). In particular, p53 175P, a mutant which was 
originally isolated from a human papilloma virus type 16 (HPV 16) positive 
metastasis of a cervical carcinoma, can induce a cell cycle arrest in some cell lines 
but shows loss of apoptotic function (Rowan et al,  1996; Ludwig et al,  1996), 
indicating that the loss of p53 apoptotic function without concomitant loss of growth 
arrest can suffice to relieve p53 dependent tumour suppression and thereby 
contribute to tumour development. Furthermore, Bcl-2 has been shown to prevent 
p53-mediated apoptosis without impairing p53-mediated growth ai'rest (Chiou et al,  
1994; Debbas and White, 1994). In addition, it also has been documented that the 
activation of p53 Vail35 in rat REF52 cells caused the growth arrest at G2/M phase, 
without inducing apoptosis (Stewart et a l ,  1995), further highlighting the 
complexity of p53 functions in different cell types and tissues (Zhan et al,  1994; 
Allday et al,  1995).
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Various studies suggest that apoptosis often occurs as a default mechanism 
when cells fail cell cycle checkpoints in the presence of p53 function. Whereas loss 
of pRb function and over-expression of E2F are known to disrupt the Gl arrest and 
favour apoptosis (Wu and Levine, 1994; Qin et al,  1994; Shan et al, 1996; Macleod 
et a l ,  1996; Lee at al., 1998), a similar effect has also been shown for pll'^^fFCipl 
deficiency (Macleod et al,  1995; Chen et al,  1996; Donatella et al,  1996; Polyak et 
al ,  1996). In particular, experiments on fibroblasts from Wafl/Cipl-^- mice have 
shown them to be defective in Gl arrest in response to DNA damage (Deng et al,
1995). However, thymocytes from the same mice showed no defect in response to 
DNA damage-induced apoptosis, in marked contrast to p53-^- thymocytes. 
Recently, hybrid assay studies using p53 expressing cancer cell lines, which yielded 
growth arrest in some lines or apoptosis in others suggest, however, that some cells 
can experience a dominant apoptotic signal which renders them refractory to rescue 
by growth-inhibitory proteins (Polyak et al, 1996).
1-1.6. Accumulation or modulation of p53.
In normal circumstances, the p53 protein remains in a latent state but, 
following genotoxic, irradiation with either ionizing radiation or UV light, 
cytokines, hypoxia, metabolic changes, or other forms of stress (Figure 1-3), post- 
transcriptional mechanisms result in an accumulation of p53 and/or increased half- 
life, and thereafter cell cycle arrest or apoptosis, effects that contribute to the 
suppression of malignant disease (Ko and Prives, 1996).
In addition to increasing p53 protein levels, cells may respond to DNA 
damage by modulating the function of the protein, at least in part by phosphorylation 
as p53 is multiply phosphorylated at serines and threonines within its amino- and 
carboxy-terminal regions in vivo and in vitro (Cox and Lane, 1995; Hall et al,  1996; 
Ko and Prives, 1996).
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The following protein kinases have been shown to phosphorylates p53; 
CDKs, casein kinase I and II (CKI and CKII), double-stranded DNA-activated 
protein kinase (DNA-PK), and protein kinase C (PKC) (Hall et al ,  1996; Ko and 
Prives, 1996) (Figure 1-1). For example, recently it was shown that phosphorylation 
of human p53 at serine 15 (by DNA-PK) occurs after DNA damage and that this 
leads to reduced interaction of p53 with its negative regulator, MDM2 (Shieh et al,
1997). In contrast with E2F, phosphorylation dramatically stimulates the binding of 
p53 to its target sites in the Wafl/Cipl and gadd45 genes (Wang and Prives, 1995). 
Phosphorylation thus induces a conformational change, conferring sequence 
selectivity on a relatively nonspecific DNA-binding protein (Hupp et al,  1992; 
Wang and Prives, 1995; Ko and Prives, 1996). The transcriptional potential of E2F 
and p53 can thus be modified by cell cycle specific cyclin/CDK combinations. 
Furthermore, p53 function can be activated by some cellular proteins, such as c-Abl 
tyrosine kinase (Yuan et al,  1996; Liu et al,  1996). Ionizing radiation stimulates 
the phosphorylation of DNA-PK by c-Abl inhibiting the ability of DNA-PK to form 
a complex with DNA (Kharbanda et al,  1997), and c-Abl binds to p53 and enhances 
its transcriptional activity (Goga et al,  1995). Moreover, the stabilization of p53 has 
been observed with the expression of either adenovirus El A or E7 protein of 
oncogenic forms of HPV, both which bind pRb but not p53 (Lowe and Ruley, 1993; 
Demers et al,  1994). Also, the cellular product of the Wilms' tumour gene, WTl, 
another tumour suppressor, also stabilizes p53 (Maheswaran et al, 1995).
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1-2. The E2F pathway
A variety of data suggest that the ability to activate a Gl cell cycle 
checkpoint in transformed cells is more important than the ability to influence the 
expression of apoptosis mediators. Therefore, it seems more likely that p53- 
mediated growth arrest and apoptosis are tightly inter-related at the cellular level. In 
particular, members of the E2F/DP transcription factor family and of the pRb 
family appear to play an important role in the decision as to whether a cell will 
respond to wild-type p53 activation by executing a viable Gl arrest or undergoing 
apoptosis.
1-2.1. Cell cycle progression is coupled to the regulation of E2F.
Studies on the mechanisms of how the cell cycle is co-ordinated have 
provided important information on how physiological processes influence 
proliferation. The transcription factor E2F is believed to play a crucial role in the 
growth-promoting and growth-arresting processes (Nevins, 1992; Girling e t a l ,  
1993; Bandara et al,  1993; La Thangue, 1994; Muller, 1995; Buck et al,  1995) 
(Figure 1-4). E2F is a heterodimeric factor which results from the interaction of two 
families of proteins: E2F (1 to 5) and DP (1 to 3), where each E2F protein requires a 
DP protein as an obligate heterodimeric partner, heterodimerization producing a 
significant increase in DNA binding activity (Girling et al,  1993; Bandara et al,
1993).
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Figure 1-4.
Sequence comparison of E2F and DP proteins.
Shaded regions or hatched boxes correspond to sequences conserved in E2F 
family or DP family, respectively. Note that E2F-1, -2, and -3 preferentially bind to 
pRb, and E2F-4 and -5 to pl07 and pl30. E2F-1, -2, and -3 include a cyclin A binding 
site. 'A' and 'B' are both areas of sequence similarity which as yet have no clear function. 
DP proteins also contain a region of homology to E2F-1 to -5. 'C and 'D' are regions of 
sequence similarity in all DP proteins. The heterodimerization domain of E2Fs and DPs 
is located in DNA binding.
Many of the genes which are believed to play an important role in regulating 
early cell cycle progression contain binding sites, TTTCGCGC. for the E2F 
transcription factor in their transcriptional control sequences. Among these are the 
proto-oncogenes c-myc, N~myc and B~myb, genes encoding enzymes required for 
DNA synthesis such as DHFR, thymidine kinase, thymidylate synthase and DNA 
polymerase a, and genes encoding cell cycle regulators such as cdc-2, cyclinA, E 
and D1 (La Thangue, 1994; Adams and Kaelin, 1995; Muller, 1995) (Figure 1-5). 
By deletion or mutation of E2F sites in many of these promoters, it has been 
demonstrated that E2F sites are important for the correct temporal expression pattern 
of the target gene. However, given the different times at which these target genes 
are expressed, it is clear that distinct mechanisms must be responsible for the timing 
of their activation (Figure 1-5). One of these mechanisms may be based on the fact 
that five E2F and three DP subunits heterodimerize in various combinations to form 
functionally active DNA-binding complexes (Bandara et al,  1993; La Thangue, 
1994; Muller, 1995; de la Luna et ai,  1996; Allen et al,  1997).
The potential role of E2F and DP proteins in cell cycle control is underscored 
by the properties of the proteins which are known to influence the transcriptional 
activity of E2F (Figure 1-6). For example, a group of proteins which negatively 
regulate the cell cycle, including the retinoblastoma tumour suppressor protein (pRb) 
and its relatives p i07 and p i30 bind to and inactivate the transcriptional activity of 
E2F (Bandara and La Thangue, 1991; Chellappan et al,  1991; Zamanian and La 
Thangue, 1992; Nevins, 1992; Schwarz etal., 1993; Cobrinik et al., 1993) (Figure 1 - 
4).
It has been known that several viral oncoproteins, such as the adenovirus 
El A protein, SV40 large T antigen and the E7 proteins of certain human papilloma 
viruses, bind to the pocket which mediates binding to the E2F binding region in 
pRb, relieving the transcriptional inactivation and subsequently releasing the E2F 
transcriptionally active form (La Thangue and Rigby, 1987; Bandara and La 
Thangue, 1991; Nevins, 1992; Lam and La Thangue, 1994; Vousden, 1995;
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Mymryk, 1996). Thus, the DNA tumour viruses deregulate E2F activity so as to 
stimulate quiescent cells to undergo DNA replication.
Another group of these regulators which control cell cycle progression are 
the cyclins and CDKs which affect both basal and activated transcription (Bandara et 
al., 1991; Sherr, 1993; Pines, 1995; Dynlacht, 1997). As described previously, 
cyclin/CDKs complexes are believed not only to influence the activity of the 
pocket proteins but also to form complexes directly at least with the E2F-1, -2, and 
-3 subfamily members. This results in the phosphorylation of the DP subunit 
(Dynlacht et al,  1994; Ki*ek et al,  1994 and 1995) and a subsequently inactivation 
of E2F/DP function which allows exit from S phase.
Ectopic expression of E2F-1 results in the expression of genes necessary for 
DNA synthesis and progression into S phase as described (Figure 1-5) (Kowalik et 
al,  1995; Almasan et al,  1995). Further evidence that E2F promotes entry into S 
phase derives from studies with Drosophila melanogaster lacking E2F-1 function in 
which cells are arrested in the Gl phase of the cell cycle after the seventeenth 
embryonic division (Duronio et al,  1995).
1-2.2. E2F and DP family possess proto-oncogenic activity.
Considerable evidence suggests that E2F-1 can be oncogenic. E2F-1 
transformed rat embryo fibroblast (REF) cells display anchorage-independent 
growth and form colonies in agarose, and injection of the transformed REF-E2F-1 
cells into nude mice cause tumours (Singh et al,  1994). In addition, in conjuction 
with an activated ras oncogene, and an E2F-1 chimeric protein, in which pRb 
binding region replaced with VP 16 activation domain, exhibits increased 
transformation activity (Johnson et al,  1994), suggesting that regulation of E2F 
activity by pRb may be critical in maintaing normal cellular growth control. 
Furthermore, DP-1 or DP-2 can co-operate with activated Ha-ra^ in the
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transformation of rat embryo fibroblasts, and this oncogenic activity is unlikely to be 
due to the regulation of E2F site transcription, suggesting an E2F-independent 
effector function for DP (Jooss et al,  1995). More recently, it has been shown that 
Ras and Myc can co-operate in inducing accumulation of E2F and resulting in cell 
cycle progression (Leone et al., 1997). The inhibition of Ras activity blocks the 
normal growth-dependent activation of Gl CDK, and prevents activation of the 
target genes of E2F. However, although expression of Ras gene alone is not 
sufficient to induce S phase, co-expression of Ras with Myc allows the generation of 
cyclinE-dependent kinase activity and the induction of S phase (Leone et al, 1997), 
demonstrating a functional relationship between Ras/Myc and E2F-1 in oncogenic 
transformation.
1-2.3. E2F-1, a possible link between the loss of pRb and the activation of p53.
Apart from the role of E2F-1 in stimulating proliferation, over-expression of 
E2F-1 in some tissue culture cells can induce apoptosis that is p53-dependent (Wu 
and Levine, 1994; Qin et al,  1994; Kowalik et al,  1995; Almansan et a l ,  1995; 
Shan et a l ,  1996). The E2F-1/DP-1-induced cell death correlates with an 
accumulation of the p53 protein, suggesting that E2F may activate p53 to induce 
death (Almansan et al,  1995; Kowalik et al,  1995). Interestingly, an E2F-1 mutant 
that is defective in binding pRb but active in trans activation is a more potent 
activator of apoptosis (Shan et al,  1996). The combined over-expression of E2F-1 
and its heterodimeric DP-1 partner drives apoptosis in 32D cells even in the 
presence of survival factors such as IL-3 (Hiebert et al,  1995; Almasan et al,  1995). 
Moreover, E2F-1 mediated apoptosis is suppressed by co-expression of wild-type 
pRb or a dominant negative mutant of p53 (DeGregori et al,  1997). In contrast, co­
expression of a natural occuring pRb mutant or wild-type p53 did not suppress the 
induction of apoptosis (Qin et al,  1994; Wu and Levine, 1994; DeGregori et al,
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1997). Therefore, the inhibition of E2F-1-dependent apoptosis may explain the anti- 
apoptotic activity of pRb.
The co-operation between E2F-1 and p53 has lead to the suggestion that 
apoptosis may be mediated by a conflict of growth stimulatory signals activated by 
E2F-1 and the growth inhibitory functions of p53 (Qin et ai,  1994; Wu and Levine, 
1994; Shan et a l ,  1996; Lee et al,  1998). In addition, in experiments using 
Drosophila melanogaster imaginai discs, ectopic E2F-1 expression induces S phase 
and apoptosis, suggesting that the down-regulation of E2F-1 upon entry into S phase 
may be necessary to prevent the induction of apoptosis (Asano et al,  1996). 
Although p53 can augment E2F-1-induced apoptosis in several systems, recent 
studies have suggested that the pro-apoptotic effects of E2F-1 are not entirely 
dependent on p53 and pRb (Qin et al, 1994; Hass-Kogan et al,  1995; Asano et al,  
1996; Lee et al,  1998). In particular, the introduction of E2F-1 in SAOS-2 cells 
cause a significant levels of apoptosis (Lee et al,  1998). Thus, it may be possible 
that the E2F-1-mediated induction of apoptosis appears to result from the activation 
of a cell death pathway.
1-2.4. The physiological role of E2F-1.
Despite considerable progress in elucidating the multiple functions of E2F-1, 
it is uncertain whether the predominant function of E2F-1 is to promote entry into S 
phase, suppress Gl arrest, and/or regulate apoptosis.
E2F-I'^- mice develop and reproduce normally, although they display a 
defect in thymocyte apoptosis indicating that E2F-1 may function to suppress cell 
proliferation (Field et al ,  1996). In addition, E2F-F^' mice develop a broad and 
unusual spectrum of tumours including reproductive tract sarcoma, lung 
adenocarcinoma, and lymphomas (Yamasaki et al,  1996). Although over­
expression of E2F-1 in tissue culture cells can stimulate cell proliferation and
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oncogenic transformation, that loss of E2F-1 in mice results in tumourigenesis 
suggests that E2F-1 also functions as a tumour suppressor (Johnson et al,  1994; 
Field et al,  1996; Yamasaki et al,  1996). However, under normal circumstances 
E2F-1 may have a dual role as a suppressor of cell proliferation in GO/Gl and an 
activator of proliferation in Gl/S.
The fact that a deletion of E2F-1 leads to a decrease in apoptosis and 
enhanced proliferation suggests that in vivo the negative effects of E2F-1 on cell 
cycle progression may be more important than the positive effects. Nevertheless, the 
fact that E2F-1 is a member of a large family of related genes leaves open the 
possibility that E2F-1 also plays an important role in promoting S phase entry in 
many cell types but that in its absence this role is compensated for by other family 
members.
1-2.5. Cell cycle regulation of pRb and its relatives by phosphorylation.
The retinoblastoma protein (pRb) is a 110 kDa nuclear phosphoprotein that is 
inactivated in retinoblastomas and a variety of other tumour types (Lee et al,  1987; 
Hu et al,  1990). pRb has the ability to suppress cell proliferation, and this activity 
is controlled by its cell cycle dependent phosphorylation (Weinberg, 1992; Whyte, 
1995; Wang, 1997). A variety of studies shown that pRb phosphorylation begins in 
late Gl and continues until M phase (Dowdy, 1993) (Figure L 6 ). In GO and early 
Gl, pRb is maintained in a state of low phosphorylation. Late in G l, pRb becomes 
extensively phosphorylated on a number of serine and thereonine residues (Lees et 
al,  1991). During mitosis, pRb is rapidly dephosphorylated by an anaphase-specific 
phosphatase (Ludlow et al,  1993). It has also been suggested that the growth 
suppressing activity of pRb is mainly mediated by binding and inhibiting the 
transcription factor E2F (Chellappan et al,  1991; La Thangue, 1994; Bandara et al,  
1994; Whyte, 1995).
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Figure 1-6
Cell cycle dependence of E2F containing complexes.
The diagram, which presents a summary o f  E2F control during the cell 
cycle , show s free E2F (transcriptionally active) accum ulating towards the end o f  
G i to peak during S phase. The regulation o f  pRb, p l0 7 , and p i 30 to E2F are 
indicated.
The interaction of pRb with E2F-1 alone or DP-1 alone is weak, whereas interaction 
with the E2F-1/DP“1 heterodimer is highly stable (Bandara et al,  1993; Helin et al,
1993).
Interestingly, pRb and two of its homologs, p i07 and p i30, seem to interact 
with specific E2F proteins : pRb with E2F-1, -2, -3 / DP-1, -2, -3 ; pl07 with E2F-4, 
-5 / DP-1, -2, -3 ; and pl30 with E2F-4, -5 / DP-1, -2, -3 (La Thangue, 1994; 
Bandara et al,  1994; Muller, 1995; Allen et al,  1997) (Figure 1-4 and Table 1-2). 
This interaction forms a ternary complex that prevents E2F-mediated transcription 
by RNA polymerase II (Chellappan et al ,  1991; Lam and La Thangue, 1994; 
Weintraub et al,  1995). The significance of the different interactions between pRb 
family and E2F family member is unclear. But, pl30/E2F complexes are abundant 
in quiescent or differentiated cells but are less common in populations of cycling 
cells (Cohnnik et al,  1993; Smith et al,  1996) (Figure 1-6). Conversely, pl07/B2F 
complexes are most readily detected in cycling cells, together with a cyclin/CDK 
containing complex during S-phase (Cobrinik et al,  1993; Ginsberg et al,  1994) 
(Figure 1-6). pRb/E2F complexes have been found in extracts of differentiated cells, 
quiescent cells, Gl phase cells, and possibly even in S-phase cells (Schwarz et al,
1993). Recently, it has been shown that pRb and pl07/pl30 provide different 
functions in E2F regulation by identifing target genes that are dependent on pRb 
family proteins for their normal expression in mouse knockout studies (Hurford et 
al,  1997).
The inhibition in E2F activity by pRb binding may be the result of (1) a 
block of the E2F trans activation domain, (2) a block in the interaction with the 
basal transcriptional machinery and (3) the decrease in histone acétylation promoted 
by the binding of pRb to histone deacetylase 1 (HDACl) (Weintraub et al,  1995; 
Chow and Dean, 1996; Luo et al,  1998). The pRb and E2F family interaction is 
normally controlled during the cell cycle by altering the phosphorylated status of 
pRb: the hypophosphorylated forms bind E2F, whereas the hyperphosphorylated 
forms do not (La Thangue, 1994; Bandara et al,  1994; Whyte, 1995) (Figure 1-2).
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The phosphorylation of pRb family of proteins is carried out by cyclinA/CDK2, 
cyclinE/CDK2, or cyclinD/CDK4/6, thus co-ordinating transcription regulation and 
cell cycle control (Bandara et al,  1991; Sherr and Roberts, 1995; White, 1995). 
Progression through the G 1/S phase involves the activation of cyclinD/CDK4, 
cyclinD/CDK6 , cyclinE/CDK2 and cyclinA/CDK2. CyclinD (Dl, D2 and D3) 
complexed with CDK4 or 6  are involved in the phosphorylation of pRb during Gl 
and in response to mitotic agents which in turn accelerate progression through the 
Gl phase. CyclinE peaks at the G 1/S transition indicating a role in entry into S- 
phase (Sherr and Roberts, 1995; Pines, 1995; Whyte, 1995). Thus, the different 
cyclin-CDK complexes may exert distinct effects on pRb family function.
The activity of the CDKs is negatively regulated by CDK inhibitors such as 
pl^lNK4b^ ^\(yINK4a  ^ p2 \htafl/Cipl^ p27'^ P^-^  (Serrano et al, 1993; Harper et al,
1993; Xiong et al,  1993; Hannon and Beach, 1994; Sherr and Robert, 1995; 
Weinberg, 1995) (Figure 1-3). The genes encoding p l 5 WAT4 Z? ^nd p i a r e  
mutated in certain tumour cell lines, such as those derived from oesophageal, 
squamous cell carcinomas, glioblastomas, lung and bladder carcinomas (Schmidt et 
al,  1994; Kamb et al,  1994; Nobori et al,  1994; Zhou et al., 1994; Jen et al,  1994). 
Mutant alleles in the plô^^^'^'^ gene fail to inhibit kinase activity and arrest growth 
and, furthermore, arrest by wild-type plh^^^'^'^ correlates with the expression of 
wild-type pRb (Serrano et al,  1995; Lukas et al,  1995; Koh et al,  1995). Thus, the 
effect of these kinase inhibitors is likely to mediated by modulating the activity of 
pRb.
Numerous experiments have demonstrated a critical role for both Myc and 
Ras activities in allowing cell cycle progression (Alevizopoulos et al,  1997; Leone 
et al,  1997). Recently, it was shown that the inhibition of Ras activity blocks the 
normal growth dependent activation of CDK, prevents the activation of the target 
genes of E2F, and results in the cell cycle arrest in Gl (Alevizopoulos et al,  1997; 
Leone et a l ,  1997). Furthermore, co-expression of Ras and Myc induce the 
accumulation of active cyclin/CDKs and E2F, coincident with the loss of the
49
, which allows the induction of S phase (Alevizopoulos et al., 1997; Leone 
et ai,  1997). These results suggest that pRb is a crucial link between Ras / Myc and 
E2F pathway in tumourigenesis. Therefore, pRb represents an important 
intermediary between the cell cycle proteins and the transcriptional machinery that 
regulates growth progression.
1-2.6. Regulation of pocket proteins by cellular and viral oncoprotein.
pRb requires a domain termed the pocket domain from amino acid 395 to 
876, in order to interact with many of its cellular binding proteins and exert growth 
suppression (Figure 1-7 and Table 1-2). Indeed, most of the retinoblastoma tumours 
involve mutation in this pocket region disrupting the ability of pRb to bind to 
proteins such as E2F (Hu eta l ,  1990; Bandara and La Thangue, 1991; Chellappan et 
a l ,  1991; Zamanian and La Thangue, 1992) (Figure 1-7). Further, viral 
oncoproteins such as SV40 large T antigen, adenovirus El A, and HPV E7, proteins 
which contains the LXCXE motif involved in pRb binding (Whyte, 1995; Vousden, 
1995; Wang, 1997), may transform cells in part by binding to this pocket, rendering 
pRb incapable of binding to E2Fs and promoting their growth progression (Bandara 
and La Thangue, 1991; Zamanian and La Thangue, 1992; Chellappan et al,  1992; 
Kaelin et al,  1992; Vousden, 1995). The role of hypophosphorylated pRb in the 
negative regulation of cell growth is supported by the observation that these viral 
oncoproteins preferentially bind to this form of pRb (Vousden, 1995; Whyte, 1995). 
Therefore, either the sequestration of pRb by viral oncoproteins or mutations in the 
pocket region can eliminate normal pRb function and contribute to the development 
of many different types of human cancers (Hu et al, 1990; Vousden, 1995).
Two pRb homologs, pl07 and p i30, also contain a pocket region that allows 
binding to the same cellular and viral oncoproteins, suggesting these relatives of pRb 
are involved in a similar mechanism of pRb function.
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Figure 1-7.
Functional domain in pRb.
The domain for growth suppression from am ino acid residue 395 to 876  
contains for viral oncoproteins, E2F, D -type cyciin , and histone deacetylase 
binding. NLS and c-Abl or M D M -2 binding region are within the C region. The 
binding o f  c-Jun involves in the B pocket as w ell as a carboxy-terminal domain. 
A m ino acids, D EA D G , are the consensus cleavage site for Ced-3/ICE proteases.
Table 1-2 Cellular proteins interacting with pocket proteins.
pRb E 2 F -L -2 ,-3 /
D P -1,-2, -3 
ATF2
MyoD (myogenic FILH 
transcription factor) 
c-Abl
Elf-1
MDM-2
PU.l
UBF
BRG-1 (Brabma- 
related protein) 
C y clin sD l,D 2 , D3 
HDAC (histone 
deacetylase) 
c-Jun 
p l0 7  E2F-4, -5 /
D P -1,-2, -3 
c-Myc
Cyclins A, D l, D2, 
D3, E 
p l30  E2F-4, -5 / 
D P -1 ,-2 ,-3 
Cyclins A, D l, D2, 
D 3 ,E
Repression of transcription via E2F binding sites
Increased transactivation by ATF2 dimers 
Co-operate in the induction of myogenic differention 
and cell cycle arrest
Repression of tyrosine kinase activity and 
transcriptional activation; c-Abl induces ceil cycle 
arrest
T-cell specific transcription factor; E lf-1 regulates the 
activity of T-ceil genes 
Inhibition of pRb growth regulatory function 
Transcription factor
Transcription factor (RNA polymerase I)
Disruption of nucleosome structure; co-operate in the
induction of cell cycle arrest
Regulatory subunits for CDKs
Deacetylating hi stones and disrupting nucleosome
structure
Stimulates c-Jun transcriptional activity 
Repression of transcription via E2F binding sites
Repression of transactivation by c-Myc; proto­
oncogene
Regulatory subunits for CDKs
Repression of transcription via E2F binding sites
Regulatory subunits for CDKs
Data in this table are obtained from Muller (1995), Whyte (1995), La Thangue ( 1997), Wang 
(1997), Luo et a i  (1998), and Nead et al. (1998).
But, despite the ability of pl07 and p i30 to restrict cell cycle progression, neither 
p i07 or p i30 have been shown to act as tumour suppressor or be mutated in natural 
occuring tumours.
The pocket region of pRb contains at least three distinct protein binding sites, 
for the LXCXE motif, for E2F, and for c-Abl or MDM2 (Wang, 1997) (Figure 1-7 
and Table 1-2). A domain in the carboxy-terminus of pRb (residues 768 to 928) 
binds to the ATP-binding lobe of the c-Abl tyrosine kinase, abrogating pRb-induced 
growth arrest. Phosphorylation of pRb at Gl/S releases c-Abl, leading to the 
activation of this kinase (Welch and Wang, 1993 and 1995). The carboxy-terminal 
region of pRb (residues 792 to 928) also binds MDM2, resulting in the inhibition of 
pRb growth regulatory function (Xiao et al,  1995). Interestingly, this carboxy- 
terminal region of pRb is required for the growth suppression function of pRb and 
for a stable interaction with E2F-1. Thus, MDM2 neutralizes the Gl arrest activity 
of two important tumour suppressor proteins p53 and pRb.
Many other proteins have been reported to bind pRb, included MyoD, ATF- 
2, Spl, BRGl, and c-Myc (Wang, 1997) (Table 1-2). But, in most of these cases, 
the significance of pRb binding is not yet clear. However it has been demonstrated 
that pRb through its pocket region also interact with histone deacetylase (Luo et ai,
1998). Therefore, pRb may repress transcription of endogenous cell cycle genes 
containing E2F sites through recruitment of histone deacetylase, which deacetylates 
histoires on the promoter, thereby promoting formation of nucleosomes that inhibit 
transcription (Luo et al,  1998). Interestingly, it has been recently reported that the 
B pocket and carboxy-terminal domain of pRb directly interact with the leucine 
zipper region of c-Jun, and thus this interaction stimulates c-Jun transcriptional 
activity, providing evidence of a new role for pRb as a transcriptional activator 
(Nead et al,  1998). But, this complexes are only observed in terminally 
differentiating kératinocytes and cells entering the Gl phase of cell cycle after 
release from serum starvation (Nead et al,  1998).
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However, given the fact that many cellular transcription factors bind to the 
pRb pocket region, it may assemble into a number of different transcription 
complexes to regulate the growth control. Surprisingly, all natural pRb mutations in 
cell lines derived from retinoblastomas, osteosarcomas, small cell lung carcinoma, 
bladder carcinomas and prostate carcinomas are occurred in this pocket region (Hu 
et al,  1990), suggesting that pRb pathway in tumour cells is deregulated through the 
pocket.
1-2.7. The role of pRb in apoptosis and differentiation.
Even though the function of pRb is dispensable in tumour cells, in addition 
to suppressing growth, pRb also appears to inhibit apoptosis and facilitate 
differentiation. Mice carrying a targeted disruption of the Rb gene die between days 
13.5 and 14.5 of gestation, exhibiting defects in fetal liver hematopoiesis as well as 
in lens and nervous system development with increased levels of apoptosis (Clarke 
et al., 1992; Jacks et al., 1992; Morgenbesser et al., 1994). Similarly, in tissue 
culture cells inactivation of pRb through the El A protein induces apoptosis (Debbas 
and White, 1993; Sabbatini et ai,  1995), and targeting the E7 protein to lens fiber 
cells promotes an apoptotic outcome (Pan and Griep, 1994). Subsequent 
inactivation of p53, either by co-expression of the E6 protein (Pan and Griep, 1994) 
or targeted disruption of the p53 gene (Morgenbesser et al,  1994), overcomes the 
apoptosis evident in conditions of Rb loss.
Neuronal differentiation correlates with elevated levels of pRb in embryonal 
carcinoma cells (Slack et al,  1993) and is impaired in Rb~ '^ embryos (Lee et al,
1994). These results underscore the delicate balance that pRb may help maintain 
between proliferation, apoptosis, and differentiation. Moreover, recent work has 
suggested that loss of Rb activates both p53-dependent and independent cell death 
pathways in the developing mouse nervous system (Macleod et al,  1996). Other
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interesting results have shown that the treatment of anti-neoplastic drugs caused the 
accumulation of p53 in the nuclei of both and Rb'^- mouse embryonic
fibroblasts, and while p53 induction led to apoptosis in Rb^ ~^ cells, and 
cells underwent cell cycle arrest without apoptosis (Almason et al, 1995).
It was shown that activated E2F-1 and p53 can act to induce apoptosis (Wu 
and Levine, 1994), and this may explain how mutations in Rb and p53 co-operate in 
the development of certain tumour types (Williams et al,  1994; Macleod et al, 
1996). Death resulting from the loss of Rb can be blocked by the elimination of p53 
(Weinberg, 1995). Therefore, the combined loss of Rb  and p53  is highly 
tumourigenic in mice (Williams et al,  1994). Interestingly, pRb contains a 
consensus Ced-3/ICB cleavage site at the carboxy-terminus (Wang, 1997) (Figure 1- 
7). Programmed cell death results from the activation of a family of cysteine 
pro teases, as exemplified by the C. elegans Ced-3 and the mammalian ICE proteins 
(Martin and Green, 1995; White, 1996). Cleavage of pRb closely parades death and 
could be blocked by Ced-3/ICE inhibitors (Bing and Don, 1996), suggesting that 
pRb is a target of the death-effector proteases and is cleaved during apoptosis. 
However, no functional significance has been attributed yet to this pRb cleavage.
1-3. Co-activator p300/CBP, an integrating signal 
with cell cycle regulatory transcription factors
The oncogenic products of DNA tumour viruses are involved in a variety of 
cellular processes including transcriptional activation and repression, growth 
control, cell differentiation, and transformation (Moran, 1993; Vousden, 1995).
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Recently, it has become apparent that these activities are the result of interactions 
between viral oncoproteins and various cellular proteins involved in the control of 
cell growth and the regulation of transcription as described previously. Among 
these targets are p53, pRb and its relatives pl07 and p i30, all of which exhibit 
properties of negative regulators of cellular proliferation (Lam and La Thangue, 
1994; Cobrinik et al,  1996; Vousden, 1995). In addition, another targets of more 
recent interest is the p300/CBP family.
The p300 protein and the related CBP, referred to below as p300/CBP, are 
highly homologous nuclear proteins that were originally identified by their ability to 
interact with adenovirus El A and with the transcription factor CREB, respectively 
(Kwok et al,  1994; Eckner et al,  1994). Comparison of the p300 and CBP 
sequences indicates that they have 75% similarity and 63% identity across their 
entire length (Arany et al,  1994). In addition to sequence-specific DNA binding 
factors and the RNA polymerase II transcriptional machinery, co-activators are 
involved in the process of transcriptional activation (Roeder, 1996; Ptashne and 
Gann, 1997). It is thought that some co-activators, but not all, facilitate 
transcriptional activation by promoting interactions between sequence-specific 
activators and the RNA polymerase II transcriptional machinery (Roeder, 1996; 
Ptashne and Gann, 1997). This function has been well characterized for the 
p300/CBP proteins.
1-3.1. p300/CBP are transcriptional co-activators involved in growth control 
and signal transduction pathways.
Many studies have demonstrated that p300/CBP proteins act as 
transcriptional co-activators. The over-expression of p300 or CBP results in 
transcriptional activation by viral as well as cellular enhancers/promoters (Eckner et 
al ,  1994; Arany et al,  1995; Lundblad et al,  1995). Furthermore, p300/CBP
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proteins can directly interact with a variety of viral and cellular proteins to 
physically bridge sequence specific binding factors and the basal transcription 
machinery, resulting in transcriptional activation (Shikama et al,  1997) (Figures 1-8 
and 1-9). In addition, a number of cellular enhancers and promoters found to be 
subject to ElA-mediated inactivation (Braun et ai,  1992; Hen et al,  1985; Stein and 
Ziff, 1987), correlate well with the ability of the incumbent El A protein to bind to 
p300/CBP (Stein et a l ,  1990). Moreover, the transcriptional activation by 
p300/CBP can be abolished directly and specifically by El A binding (Arany et al,  
1995; Yang et al,  1996; Cook et al,  1996). ElA  mutants which lack the p300 
binding site have lost the properties of ElA-driven cell cycle progression and its 
transforming potential (Moran, 1993). Thus, it makes good sense for a viral 
oncoproteins to possess such a mechanism since the suppression of differentiation 
favours the retention of cells in a proliferative state contributes to the oncogenic 
state (Figure 1-10).
Studies on another viral oncoprotein, simian virus 40 (SV 40) T antigen, 
demonstrated that the deletion of its amino-terminal domain impaired its 
transforming potential, albeit without affecting p53 and pRb binding (Manfredi and 
Prives, 1990; Marsilio et al,  1990). Moreover, this T antigen mutant can restore the 
transforming activity lost by El A mutants which have lost the ability to interact with 
p300 (Yacink and Moran, 1991). These studies implicated p300/CBP as a target for 
T antigen, and subsequent studies have found that T antigen can associate with a 
hypophosphorylated but ubiquitinated form of p300 (Avantaggiati et al,  1996).
A variety of genes induced by cAMP share a conserved motif in their 
transcriptional control sequences, referred to as the cAMP-response element (CRE). 
The CRE binds the CRE-binding protein, CREB, which is directly phosphorylated 
by activated protein kinase A (Gonzalez and Montminy, 1989). Phosphorylation at 
Ser 133 stimulates the transcriptional activity of CRE-dependent genes in part by 
enabling the kinase-inducible domain (KID) in CREB to interact with a co-activator
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Figure 1-8
Schematic representation of p300/CBP.
The diagram represents pSOO/CBP together with recognized cysteine/histidine-rich 
domains, C H I, CH2 and CH3, and bromodomain. Note that the numbers indicate the 
amino acid residues in human p300. The region in p300/CBP required ('or binding to 
target proteins are indicated.
(Data in this figure are compiled together with data from Shikama et a i  (1997) and 
.Tanknecht and Hunter (1996))
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Figure 1-9
p300/CBP co-ordinate transcription with chromatin remodeling.
Transcription factors (TFs) recruit the co-activators p300/C BP, which are 
able to acetylate all histone com ponents o f  the nucleosom e. Thereby, altered 
chromatin integrity may facilitate the assem bly o f  general transcription factors, 
such as T BP and TFIIB, which can associate with p300/C BP. In addition, 
T A F ii250  also functions as a histone acetyltransferase. The histone deacetylase
(H D A C l) continually deacetylates hi stones in chromatin, therefore, persistent 
activity o f  the co-activator/hi stone acetyltransferase is required to maintain gene 
activity.
CBP (Chrivia et al,  1993). Therefore, it is clear that p300/CBP are intimately 
involved in growth control, progression of cell cycle, and cell differentiation. These 
two co-activators make contact with, and connect the functions of many well-studied 
proteins such as c-Jun, c-Myb, c-Fos, CREB, MyoD, Stat 2, YYl, and nuclear 
hormone receptors (Shikama et aL, 1997) (Figure 1-8). Previous studies suggested 
that CBP can associate with c-Jun, specifically with the form of c-Jun 
phosphorylated by Jun N-terminal kinase (Arias et al,  1994), and similarly with a 
carboxy-terminal region in the c-Fos transcription factor (Bannister and Kouzarides,
1995). Fos and Jun proteins heterodimerize to form a group of mitogen-regulated 
transcription factors known as AP-1. Because Fos and Jun proteins, by virtue of 
their role in mitogenesis, are implicated in proliferation control, it is somewhat 
surprising that ElA, which confers oncogenic properties on cells, counteracts the 
interaction between Fos and Jun with CBP (Arany et al., 1995; Lundblad et al,
1995).
The c-Myb proto-oncogene product also utilizes CBP as a co-activator, and 
again this interaction compromised by ElA  (Oelgeschlager et al,  1996; Dai et al,
1996). Recent data found that p300/CBP not only stimulates the activity of c-Myb 
and C/EBPP individually, but establishes synergy between them, presumably by 
simultaneously binding both transactivators (Mink et al,  1997). Furthermore, 
C/EBP associates with other p300/CBP targets in addition to c-Myb, such as 
CREB/ATF family of transcription factors (Vallejo et al,  1993), NF-A:B (Stein et al,
1993), and TBP (Neiiov and Ziff, 1995).
The basic helix-loop-helix protein MyoD also appears to interact with p300 
through the region that is bound by ElA, and this interaction is critical for muscle 
and B cell differentiation (Eckner et al,  1996; Puri et al,  1997).
Signal transduction mediated by the JAK-STAT pathway involves p300/CBP 
(Bhattacharya et al,  1996). Interferon a  (INF-a) induces the transcription of a 
variety of genes required to produce antiviral effects, many of which require a 
transcription factor called ISGF 3/STAT 1 and STAT 2 (Darnell et al,  1994). ElA
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impedes transcriptional activation mediated by INF-a by inactivating p300/CBP, 
which binds through its amino-terminal region to STAT 2 (Bhattacharya et al,
1996). Interestingly, it is known that interferons cause cell cycle arrest; thus the 
inactivation of ISGF 3 may contribute to the observed stimulation of DNA synthesis 
that correlates with the integrity of the amino-terminal region of ElA.
The ElA  protein acts positively in combination with the transcription factor 
YYl (Lee et al,  1995). No direct interaction between ElA  and YYl has been 
reported, but rather p300 can bind to both proteins at the same time, resulting in a 
tripartite complex. Although YYl-binding sites are frequently present in 
transcriptional control regions, some sites function to repress transcription and, in 
these cases, p300 is believed to be responsible for the repressive activity that can be 
relieved by ElA  (Lee et al,  1995).
There is also a connection between p300/CBP and another class of sequence-
'specific transcription factors, namely the ligand-dependent nuclear receptors 
including the retinonic acid (RAR and RXR), oestrogen (ER), progesterone (PR), 
thyroid hormone (TR) and glucocorticoid (GR) receptors (Kamei et al ,  1996;
Chakravarti et al,  1996; Janknecht and Hunter, 1996). These nuclear receptors 
depend upon the p300/CBP for their ability to stimulate transcription (Kamei et al,
1996; Chakravarti et al,  1996). Several other co-activators have been implicated in 
the hormone-dependent activation of nuclear receptors which, interestingly, may 
interact with receptor bound to p300/CBP. For example, SRC-1 (steroid receptor 
co-activator 1) recognizes a carboxy-terminal p300/CBP region while nuclear 
receptors occupy the amino-terminal (Kamei et al,  1996) establishing the important 
idea that multiple interfaces within p300/CBP may be occupied stimultaneously by 
different factors. Consistent with this idea, co-expression of CBP with SRC-1 
stimulates the activities of oestrogen and progesterone receptor in co-operative 
manner (Smith et al,  1996), raising the possibility that p300/CBP may function 
together with diverse co-activators in a common pathway of transcriptional 
activation.
61
1-3.3. p300/CBP as modulators of chromatin.
The DNA in the cell is organised into chomatin. The principle repeat 
element of chromatin is the nucleosome core, which consists of an octamer of 
histones, H2A, H2B, H3, and H4, supporting 1.65 turns of the DNA. Nucleosomes 
are potent repressors of transcription, presumably by physically interfering with the 
binding of transcription factors. A central question in eukaryotic transcription has 
been how transcription factors gain access to the DNA tightly "wrapped" or "wound 
up" in chromatin. Targeted histone acétylation (HAT) is thought to neutralize the 
positive charge of the histone tails and affect internucleosomal geometry by relaxing 
the interaction between histones and negatively charged DNA. Thus, the acétylation 
of histones is involved in the destabilization and restructuring of nucleosomes.
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1-3.2 The phosphorylation of p300/CBP by cell cycle dependent kinase.
p300/CBP phosphorylation levels change during the cell cycle, and during 
mitosis, hyperphosphorylation has been observed (Yacink and Moran, 1991). 
Another study showed that not only is p300 phosphorylated in a cell cycle dependent 
manner but is a substrate for cyciin dependent kinase in vivo, and is required for the 
induction of p53-independent Wafl/Cipl gene expression during cellular 
differentiation (Wang et al, 1993). Interestingly, p300 mediates a biochemical and 
functional interaction between the Rel A subunit of NF-/:B and cyclinE-CDK2, with 
the NF-^B-dependent gene expression being enhanced by expression of p300 in the 
presence of p21^4/VC(p7 (Perkins et al,  1997). Thus, this result suggests that the 
interaction of NF-fcB and cyciin dependent kinase through p300/CBP provides a 
mechanism for the co-ordination of transcriptional activation with cell cycle 
progression.
which is probably a crucial event in the control of accessibility of DNA templates to 
transcription factors (Wade et al, 1997; Shikama et al, 1997) (Figure 1-9).
However, only a few proteins with HAT activity have been found to date; 
p300/CBP comprise two of the seven known human HATs (Ogryzko et al,  1996; 
Bannister and Kouzarides, 1996) (Figure 1-9). Interestingly, p300/CBP proteins are 
also the only HAT capable of acetylating all four core histones in vitro. In addition 
to their own intrinsic HAT activity, p300/CBP may also indirectly influence 
chromatin remodeling by its ability to recruit additional co-activators containing 
HAT activity. Three of the other HAT's, the P/CAF (p300/CBP-associated factor), 
SRC-1 (steroid receptor co-actovator-1), and ACTR co-factors, bind to each other as 
well as with p300/CBP (Yang et al,  1996; Jenster et al,  1997; Chen et al., 1997; 
Spencer etal ,  1997) (Figure 1-9). One possible scenario is that transcription factors 
need to recruit multiple HATs in order to overcome the repressive effects of 
deacetylation on promoter activity.
Furthermore, recent research into the enzymatic activities of p300/CBP, 
P/CAF, and TAFII250 show that they are all able to directly acetylate the basal 
transcription machinery components TFIIEp and TFIIF (Imhof et al,  1997) (Figure
1-9), but the physiological significance of these acétylation events are unclear yet. 
These results suggest that our current understanding of the molecular mechanisms 
underlying transcriptional regulation underrate the role of co-factors such as 
p300/CBP.
1-3.4. p300/CBP in cancer and other human diseases.
The autosomal dominant Rubinstein-Taybi Syndrome (RTS) is associated 
with the mutation of one CBP allele, and exhibits a complex phenotype typically 
including mental retardation, physical abnormalities and increased incidence of 
neoplasia (Petrij et al, 1995) (Figure 1-10).
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In addition, bi-allelic inactivating somatic mutations of the p300 gene have been 
observed in gastric and colon cancers (Muraoka et al., 1996) (Figure 1-10).
Furthermore, the loss of heterozygosity (LOH) of informative markers at 
chromosome band 22ql3, which corresponds with the p300 locus (Eckner et al.,
1994), has been observed in 80% of informative glioblastomas. Loss of p300/CBP 
might therefore allow uncontrolled cell growth. Likewise, LOH around the CBP 
locus has been observed in hepatocellular carcinomas (Sakai et al, 1992) (Figure 1- 
10). As opposed to the germline chromosomal rearrangement reported in RTS 
patients, the CBP and p300  genes are also involved in somatic translocations 
associated with various types of hematological malignancies (Giles et al,  1995; Ida 
et al,  1997). The fact that p300/CBP is prone to translocations, inversions, and 
deletions suggests the presence of elements confering genomic instability.
Therefore, how altered p300/CBP function, resulting from a chromosomal
'rearrangement, could result in uncontrolled cell growth in myelomonocytic cell 
lineages can be partly explained by studying at p300/CBP targets.
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1-4. Objectives
Little is known about the function of the tumour suppressor p53 in the 
control of normal cell cycle progression. The balance between the activities of E2F 
and tumour suppressors such as pRb and p53 is crucial to ensure the normal 
progression of the cell cycle. In cells, the transcriptional activity of p53 and E2F are 
believed to be regulated mainly at the protein level. However, other cellular factors 
might also regulate the transcriptional avtivity of p53 and E2F.
Recent studies have shown that the over-expression of E2F-1 can induce 
apoptosis in co-operation with p53, as described previously. In addition, studies on 
the physiological outcomes of deregulating the E2F pathway suggest that the 
unscheduled cell cycle progression induced by E2F-1 itself leads to apoptosis. 
Therefore, an important aim of this study is to understand the mechanisms through 
which E2F-1 induces apoptosis.
Different transcription factors activated by diverse signalling pathways may 
interfere with one another by competing for a limiting common factor, namely 
p300/CBP. This regulatory mechanism may more often than anticipated, provide an 
important level of control in transcription. Furthermore, it is also possible that 
competition for p300/CBP may allow cross-talk between different cell cycle control 
pathways. Another aspect of this research investigated the role of p300 in p53 and 
E2F dependent transcriptional activation. It was found that both E2F and p53 utilise 
p300 as a transcriptional co-activator. Furthermore, the interaction of p300 with 
either p53 or E2F-1 had a profound impact on early cell cycle progression, possibly 
through the activation domains of p53 and E2F-1 competing for p300.
Finally, a question of considerable importance relates to the mechanistic and 
physiological role of p300/CBP in regulating the p53 response. In this respect, I 
have studied the role of a novel p300 target protein, JMY, which physically and 
functionally co-operates with p300 in the p53 response. The data suggest that JMY
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has potent effects on certain p53-dependent genes, such as bax and, physiologically, 
co-operates with p300 in promoting p53-dependent apoptosis.
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Chapter 2.Materials and Methods
2-1. Plasmids
The following plasmids have been previously described; pCMV-pRb wt 
(Zamanian et al,  1992), pCMV-pl07 (Beijersbergen et al, 1994), pCMV-HApl30 
(Vairo et al,  1995), pCMV-p300 (Eckner et al,  1996), pCMV-HA-JMY (Shikama 
et al,  1998), pCMV-E2F-l (Kaelin et al,  1992), pCMV-E2F~4 (Beijersbergen et al,
1994), pCMV-E2F-5 (Buck et al ,  1995), pCMV-p2 1  (El-Deiry et al,
1993), pCMV“Pgal (Zamanian et al,  1992), and pGal4-p53 (Fields and Jang, 1990). 
pCDK2-MSPE and pCDK4-MSPE were kindly provided by R. Muller.
To construct pTG13-GL, first, the Bam HTBgl II fragment of the HSVl-tk 
minimal promoter element (-81 to +52) was inserted to the Bgl II site of pXP2 
vector (Nordeen, 1988) resulting in pT-luc. Then, the 13 copies of the consensus 
p53-binding site from pG 13-CAT (Kern et al,  1992) were subcloned into the Hind 
III and Sma I sites of pT-luc. For the Gal4 reporter construct, the Gal4 DNA 
binding sites and Elb TATA minimal elements from pG5Elb-CAT (Fields and 
Jang, 1990) were excised by Xho I and Bam HI digestion, and cloned into the pGL3 
(Promega). pDHFR-luc has been described previously (Sprensen et al,  1996). 
pBax-luc and pMDM2-luc, pWWP-luc, and pGADD45-luc were a gift from M. 
Oren (Haupt et al,  1955b ; Friedlander et al,  1996), B. Vogelstein (El-Deiry et al,  
1993), and C. Prives (Chen etal ,  1995) respectively.
To construct pCMV-HA-DPl, three copies of HAl epitope sequences from 
pGTEP-1 (a gift from B. Futcher) were amplified by PCR and cloned into the 
pCDNA3 (Invitrogen) with a consensus Kozak sequence introduced immediately 5' 
of the initiating AT G codon to create pCMV-HAl. The 5' primer used was (5' to 3') 
GCTGGAATTCTTTTACCCATACGATGTTC and the 3' primer (5' to 3')
CATGCTCGAGAGCAGCGTAATCTGGAAC. PCR amplication was carried out 
using PWO polymerase (Boehringer Mannheim) and the manufacturer's incubation 
buffer for 31 cycles as follows : 5min dénaturation at 94°C as first step, followed by 
31 cycles of dénaturation at 92°C for Imin; annealing at 55°C for Imin; extension at 
72°C for 1.5min (last cycle 5min). The DP-1 cDNA sequence (Girling et al., 1993) 
in frame was introduced into pCMV-HA to generate an expression plasmid encoding 
an amino-terminal HA-tagged full-length DP-1. pCMV-DP-l/NLS was made by 
inserting a fragment containing the Bell bi-partite nuclear localization signal (amino 
acid residues 194 to 227) of human foamy virus (Lee et al,  1994) into Kpn I site 
(residue 327) of the DP-1 in pCMV-DP-1.
For the mammalian two-hybrid assay, several plasmids were constructed as 
follows: the PCR fragments of VP 16 trans activation domain, amino acid residues 
423 to 490, from Gal4-VP16 (Fields and Jang, 1990) were subcloned in-frame to the 
pCMV-HA to generate pCMV-VP16. The 5' primer used was (5' to 3') 
GCTCGGATCCGAGCTCCACTTAGACGGCGA and 3' primer (5' to 3') 
GCTCCTCGAGCTACCCACCGTACTCGTCAAT. Two p53 PCR fragments 
encoding amino acids 1 to 393 and 159 to 393 from pCMV-p53, and two E2F-1 
PCR fragments encoding amino acids 1 to 437 and 1 to 413 from pCMV-E2F-l 
were fused to the VP 16 trans activation domain in pCMV-VP16 to generate pCMV- 
p53/VP16, pCMV-p53A159/VP16, pCM V -E2Fl/V P16, and pCMV-
E2F1A413/VP16, respectively. pCMV-GAD was made by the insertion of Hind III 
and Eco RI fragment encoding Gal4 trans activation domain, amino acid residues 
768 to 881, from pACT II (Clontech) into the pCDNA3. The Nde I and Xba I 
fragments from pCMV-E2Fl were fused in-frame into pCMV-GAD to make the 
pCMV-GAD/E2F1. To construct pG4 -p3 0 0 ^^  l “2284^  the Nde I fragments from 
pCMV-p300 were fused in-frame to the Gal4 DNA-binding domain sequence of 
pG4m-polyII vector (Bandara et al ,  1993). pCMV-E2F-lA413 was made by 
internal deletion from pCMV-E2Fl. To construct the Gal4-p300 derivatives, pG4- 
p3 0 0 ^^ "^*257^  „p3QOl302-1572  ^ _p3 0 0 1572-2284^  and -p300^^22-i903 were made by
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internal detection from  pG4-p300^^ 1-2284^ respectively. Also, to generate pCM V- 
H A -p300611-1257 and pCM V -H A -p3 0 0 1257-2284  ^ Afl III and X ba I, and Bam  HI and 
Xho I fragm ents from  pG 4-p300^l 1-2284^ and Sma I and Xba I fragm ent from  pG4- 
p 3 0 0 1^22-2284^ were inserted into the pC M V -H A l, respectively. pVP16-JMY469-558 
has been described previously (Shikam a et al, 1998).
Two ElA expression vectors, pCMV-ElA and pCMV-ElAA2-36 were a gift 
from J.R. Ne vins (Kraus et al, 1992). pCMV-p53 was made by the insertion of p53 
cDNA from php53 (Zakut-Houri et al,  1985) into the pCDNAS. pCMV-p5 322/23 
was kindly provided by A.J. Levine (Lin et al,  1994). In order to map the region in 
p53 to which DP-1 binds a panel of p53 mutants (Figure 4-3), GST-p53 1-73, 1-143,
1-235 and WT, were made by PCR using human p53 cDNA as template (php53c-l ; 
Zakut-Houri et al,  1985). PCR products were cloned in frame into a pGEX-KG 
(Pharmacia). The protein expression and stability of each construct was verified by 
western blotting.
2-2. Transfection
For transfection (including flow cytometry), U20S and SAOS-2 cells were 
grown inDulbecco’s modified eagles medium (DMEM) supplemented with 10% 
foetal calf serum (FCS). Cells were plated out 24h before transfection at 2 x 10  ^
cells per 6-cm dish (for luciferase and P-galactosidase assays) or 1 x 10  ^ cells per 
10-cm dish (for immunoprécipitation and flow cytometric analyses). Three hours 
prior to the transfection, the medium from the cells was removed and replaced it 
with the fresh growth medium. The calcium phosphate-DNA precipitates, the 
indicated amounts of each plasmid DNA and 2M CaCh (for 6-cm dish ; 70{tll, for 
10-cm dish ; 160|il), dropwise added to 2xHBS solution (50mM Hepes pH7.1, 
280mM NaCl, and 1.5mM Na2HP04). Whenever required, pCDNA3, pCMV-HAl, 
or pSG5 was used to maintain a constant amount of DNA in each sample. All
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transfections were included an internal control pCMV-Pgal. Cells were harvested 
34-40h post transfection.
2-3. Luciferase and p-galactosidase assays
For luciferase assay, the cell culture supernatant was aspirated, and the cells 
were rinsed twice with phosphate-buffered saline (PBS). Cell extracts were 
prepared in reporter lysis buffer (25mM Tris-H3P04 pH7.8, 2mM 1,2- 
diaminocyclohexane tetra acetic acid, 2mM DTT, 10% glycerol and 1% Triton X- 
100). The solubilized cells transferred to a microcentrifuge tube and incubated at 
room temperature for 15min. After removing cell debris, extracts were assayed for 
luciferase activity by mixing 300|il luciferase assay reagent (1:4, Promega) with 
60|il cell extracts and measuring the activity with a luminometer (Berthold Lumat).
To measure p-galactosidase activity, 60|il cell extracts were mixed in 6fxl 
lOOxMg solution (O.IM MgClz and 4.5M P-mercaptoethanol), 70]li1 O-nitrophenyl- 
P-D-galactopyranoside (4mg/ml) and 200|ll O.IM sodium phosphate (pH7.5). The 
reaction mixtures were incubated at 37°C until a faint yellow color has developed. 
The reaction was stopped by adding 500pl of IM NazCOs to each sample, and the 
activity was measured at 420nm.
2-4. Immunofluorescence
Transfected cells were fixed in 4% paraformaldehyde at 4°C for 20min, 
rinsed and permeabilised in PBS containing 0.2% Triton X-100 at 4°C for lOmin. 
Fixed cells were washed three times with cold-PBS and incubated in primary 
antibody diluted in Tween buffer (0.5M NaCl, 1% BSA, 5mM Na(P04) pH6.5 and 
0.5% Tween 20) at 4°C for 2hr. Subsequently, cells were washed three times with
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cold-Triton buffer (0.3% Triton in PBS) and further incubated in secondary 
antibody, goat anti-mouse or rabbit IgG conjugated to fluorescein isothiocyanate 
(FITC) or tetramethylrhodamine isothiocyanate (TRITC) (Southern Biotechnology 
Associates Inc.) for Ih at room temperature. And then, cover slips were washed 
three times in PBS, mounted, and viewed under the fluorescence microscope 
(Olympus).
2-5. Flow cytometry
For flow cytometry analysis about lOpg of an expression vector for the cell 
surface protein CD20 was co-transfected into cells (grown in 10% PCS) together 
with 15|ag of the each expression vector for p53 or p300 (details given in Figure 5- 
7). Cells were washed and refed after 16h and harvested 40h later by washing in 
PBS and thereafter treating with cell dissociation medium (Sigma) for 15min. Cells 
were washed in DMEM by centrifuging at 2000rpm and resuspended in a small 
volume of DMEM containing the anti-CD20 antibody leu 16 (Becton Dickinson) 
coupled to fluorescein isothiocyanate (FITC). Cells were incubated upon ice for 
45min, further washed twice in PBS and then resuspended in 50% PBS in ethanol at 
20°C for 30min. Cells were collected by centrifugation and treated with RNase 
(125U/ml) for 30min, harvested by centrifugation and suspended in propidium 
iodide (20jag/ml) in PBS at 4°C for Ih. Flow cytometry was performed on a Becton 
Dickinson fluorescence activated cell sorter. The intensity of propidium iodine 
staining was analysed in cell populations that were positive for FITC staining to 
determine the cell cycle profile of the transfected population using the Consort 30 
software. The data presented show a representative example from multiple assays.
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2-6. Immunoprécipitation
U20S cells were transfected with plasmids encoding Gal4-p300, HA-DPl, 
E2F-1 or p53 (as indicated in Figures 5-2 and 5-3) by the calcium phosphate 
procedure. After 48h, cells were washed twice in PBS and harvested by scraping 
into cold TNN buffer (50mM Tris-HCl pH7.4, 120 niM NaCl, 5mM EDTA, 0.5% 
NP-40, 50mM NaF, ImM DTT, ImM PMSF, 0.2mM sodium orthovanedate, 
leupeptin (0.5|lg/ml), protease inhibitor (0.5jlg/ml), trypsin inhibitor (l.Opg/ml), 
aprotinin (O.Sjiig/ml) and bestatin (40pg/ml)) and incubated on ice for 30min. The 
cell extract was centifuged for 10 min at 12,000g and pre-cleared by incubating with 
protein-G agarose for Ih at 4°C with constant rotation. The supernatant was 
harvested and 2pl of anti-mouse Gal4 monoclonal antibody (lOOpg/ml, Santa-Cruz) 
added for Ih at 4°C. Protein-A agarose (50% v/v) (Boehringer Mannheim) was 
added and the incubation continued for another Ih at 4°C. The agarose beads were 
collected by centrifugation for 30sec at 5,000g, the supernatant was removed and the 
pellet was washed three times in TNN buffer. 2xSDS loading buffer (250mM Tris- 
HCl, pH6.8, 20% glycerol (v/v), 4% SDS (w/v), 0.1% bromophenol blue (w/v), 
200mM DTT and 5% P-mercaptoethanol) was added to the final pellet, the sample 
denatured and loaded onto a 8-10% SDS-polyacrylamide gel. Western blotting was 
subsequently performed with either anti-mouse p53 (421, kindly supplied by Julian 
Gannon), anti-mouse HAl (12CA5, Boehringer Mannheim), or anti-mouse E2F-1 
(KH95, Santa-Cruz) monoclonal antibody.
As indicated in Figure 5-2d, SAOS-2 cells were transfected with plasmids 
encoding p53, pCMV-HA-p300611-1257 or pCMV-HA-p3001572-2284 by the 
calcium phosphate procedure. Cells were harvested in TNN buffer and extracts 
were prepared as described above. The supernatant immunoprecipitated with anti­
mouse p53 (421) which was harvested with protein-A agarose. Western blotting 
was subsequently performed with anti-mouse HA monoclonal antibody (12CA5).
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In Figure 6-2a, U20S cells were transfected with expression vectors pG4- 
p3 0 0 ^^  ‘^2283^  pG4, or pCMV-JMY (containing the HA epitopes). After 48h, cells 
were harvested in TNN buffer and incubated on ice for 30min. The cell extracts 
were pre-cleared by incubating with protein-G agarose (Pharmacia) for 30min at 
4°C, and the supernatant immunoprecipitated with anti-mouse Gal4 monoclonal 
antibody (Santa-Cruz) which was harvested with protein-A agarose. The agarose 
beads were collected and washed three times in the extraction buffer before 
dénaturation and SDS-polyacrylamide (7.5%) gel electrophoresis. Immunobiotting 
was subsequently performed with an anti-mouse HA monoclonal antibody or an 
anti-peptide rabbit antibody against a peptide taken from JMY (kindly supplied by 
N. Shikama).
To immunoprecipitate from non-transfected cells (Figure 6-2b), HeLa cells 
were harvested in nuclear extraction buffer (20mM Hepes pH7.6, 20% glycerol, 
250mM NaCl, 1.5mM MgCh, ImM EDTA, 0.1% Triton X-100, ImM DTT, ImM 
PMSF, leupeptin (lOjLtg/ml), pepstatin (lOfXg/ml), aprotinin (lOpg/ml) and trypsin 
inhibitor (lOjXg/ml)) and immunoprécipitations performed as described above. An 
anti-p300 monoclonal antibody (Ab-1; Calbiochem) was used in the 
immunoprécipitation and, after SDS-polyacrylamide gel electrophoresis, 
immunobiotting was performed with an anti-peptide JMY antibody.
To measure the levels of p53 protein (Figure 6-5), SAOS-2 cells were 
transfected with the indicated expression vectors and extracts thereafter 
immunoblotted with the anti-p53 monoclonal antibody DO-1 (Santa-Cruz). The 
effect of p300 on the level of p53 and E2F-1 was assessed by performing the 
transfection as indicated and monitoring the level of exogenous protein by 
immunobiotting with either 421 or KH95.
As a secondary antibodies in immunobiotting, the blots were incubated with 
alkaline phosphatase-conjugated goat-rabbit or -mouse IgG (1:5,000, Promega), or 
horseradish peroxidase-conjugated goat anti-rabbit or -mouse IgG (1:4,000) for ECL 
reagents system (Amersham) as recommended by the manufacturer.
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2-7. Metabolic in vivo labelling
2-8. Apoptosis assays
At 24-3Oh post-transfection, the tissue culture medium was aspirated, and 
the cells were washed twice with methionine-free medium, replaced with serum-free 
and methionine-free medium for Ih. Cells were metabolically labelled with 
methionine (0.2mci for 6-cm dish ; 0.5mci for 10-cm dish, Amersham) medium 
containing 5% dialyzed foetal calf serum for Ihr, washed three times, and chased for 
0, 1.5, 3.0, or 4.5hr in normal medium. Cells were harvested in TNN buffer and 
immunoprecipitated with the 421 monoclonal antibody.
For apoptosis assays, SAOS-2 and U20S cells were grown in serum 
starvation conditions on 3cm-diameter dish either with (for TUNEL assay) or 
without (for cell death detection ELISA) coverslips and transfected with the each 
expression plasmid as indicated in figure legends. After 16h incubation with the 
precipitates, the cells were washed twice with DMEM and further incubated for 24h 
in DMEM supplemented with 0.2% foetal calf serum . For TUNEL (TdT-mediated 
dUTP nick end labelling) analysis, cells were washed and fixed in 4% 
paraformaldehyde for 15min at room temperature, rinsed and permeabilized in PBS 
cantaining 0.1% Triton X-100 and 0.1% sodium citrate for 2min on ice. 
Subseqently, cells were incubated in a C&2+ reaction buffer containing fluorescein- 
dUTP and dNTP, and terminal deoxynucleotidyl transferase (Boehringer 
Mannheim) at 37“C for Ih in a humid chamber. And then, cells were further 
incubated in DAPI (2 pg/ml, Sigma) for DNA staining. Cover slips were washed 
three times in PBS, mounted, and viewed under the fluorescence microscope.
The qualitative measurement of mono- and oligo-nucleosomes in the 
cytoplasm of the ap opto tic cells was performed by cell death detection ELISA
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(Boehringer Mannheim) using anti-histon-biotin-antibody and anti-DNA-POD- 
antibody as recommended by the manufacturer.
In Figure 6-9, SAOS-2 cells, grown in 10% foetal calf serum, were transfected 
with pCMV-p53 (3pg) either alone or together with pCMV-JMY (5|Llg), pCMV- 
p300 (5jig) or both. After 14h incubation, cells were washed and further incubated 
for 24h in the presence of 0.2% serum. Cells were fixed in 4% paraformaldehyde at v
4°C for 20min, rinsed and permeabilised in PBS containing 0.2% Triton X-100 at 
4°C for lOmin. Subsequently, cells were treated with the anti-p53 monoclonal 
antibody 421, washed and further incubated in tetramethylrhodamine-conjugated 
goat anti-mouse (Southern Biotechnology Associates Inc.) for 2h at room 
temperature. And then, the TUNEL assay was performed as described above.
2-9. Purification of p53 protein from insect cells
Spodoptem frugiperda cells (Sf9 cells) were cultured at 21°C in EX-CELL 
400 medium (JRH Biosciences) supplemented with 5% foetal calf serum. Cells 
were subcultured and infected with recombinant baculovirus pVL1393p53 (kindly 
provided by C. Midgley and D. Lane). Cells were scraped in PBS after 4 days and 
collected by centrifugation at ISOOrpm. Cell lysis was carried out at 4°C for 30min 
in lysis buffer (0.15M NaCl, 1% Nonidet P-40, 5mM EDTA, ImM PMSF, 50mM 
Tris-HCl pH7.5, 5mM DTT, lOmM NaF and ImM benzamidine). After 
centrifugation of the lysate, the supernatant was diluted 3-fold in 15% (v/v) glycerol, 
25mM Hepes, 0.1% Triton X-100, 5mM DTT and ImM PMSF, and p53 protein was 
purified from the lysate on Hi-Trap heparin sepharose (Pharmacia) in a linear KCl 
gradient from 0.1 to 0.9M KCl (Hansen et al,  1996).
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2-10. Glutathione S-transferase recombinant protein
A 500ml mid-logarithmic culture (the transformed DH5a in LB-broth) was 
induced by the addition of ImM (a final concentration) isopropyl-p-D- 
thiogalactopyranoside (IPTG) and incubated for 6hr at 30°C. Bacterial pellets were 
re suspended in 10ml PBS containing lysozyme (lOmg/ml), 5mM PMSF, 50niM 
DTT, leupeptin (0.5pg/ml), apotinin (0.5|ig/ml), bestatin (40|ig/ml) and trypsin 
inhibitor (l.Opig/ml) while kept cool on ice, and then sonicated briefly (double 5 
second burst) on ice. Bacterial debris were pelletted by centrifugation and re­
centrifugation at 12,000rpm for 20min (at 4°C) each. 300|li1 of glutathione-agarose 
beads (33% v/v) in suspension (0.05% NaNs in PBS) were added to the supernatant 
and mixed with constant rotation at 4°C for Ihr. The suspension was placed in a 
50ml-Falcon tube and washed once with 50ml PBS containing 0.5% NP-40 (or 
Igepal) and twice with PBS only, by spinning in a bench-top centrifuge at 5,000rpm 
for 5min (at 4°C) each time. The washed beads were placed in an eppendorf tube at 
4“C.
2-11. In vitro binding assay
For the in vitro binding reaction shown in Figure 4-3, approximately lOjlg 
of GST or GST-fusion protein bound to glutathione-agarose beads were added to 
15jal of in v/fro-translated DP-1 in reaction buffer (50mM Tris-HCl pH 8.0, 150mM 
NaCl, 0.5% NP-40, ImM PMSF, ImM DTT and aprotinin (2|ig/ml)). In vitro- 
transcription and translation was carried out in a TNT T7/SP6 coupled reticulocyte 
lysate system (Promega) as recommended by manufacturer. After incubation for 
2.5hr at 4°C, the beads were collected and washed four times in reaction buffer. 
Proteins were released in SDS-sample buffer, electrophoresed, and immunoblotted
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with an anti-DP-1 (A) or an anti-DP-1 (D) polyclonal antibody (Sprensen et al,
1996).
Using the baculovirus expressed p53 protein, 50pl of protein-A agarose 
(50% v/v) was incubated either with or without anti-p53 monoclonal antibody 421 in 
reaction buffer at 4“C for 2hr. This immuno-complex was mixed with in v/rre­
translated / 25s_methionine labelled DP-1, E2F-1 or luciferase and 100p.g of cell 
extracts derived from NIH3T3 cells for a further Ihr incubation at 4°C with constant 
rotation. The beads were prepared and electrophoresed on 10% SDS- 
polyacrylamide gel, and the assay was monitored by autoradiography.
2-12. Histidine tagged protein
His-tagged proteins were purified from the pellet of IPTG-induced 500ml- 
bacterial culture. The bacterial pellets were resuspended in 10ml of denaturing 
buffer (lOOmM Sodium phosphate, lOmM Tris base, 6M Guanidine hydrochloride 
and 30mM imidazole (pH8.0)) and gently stirred for 2hr at room temperature. 
MgCU was added to the final concentration of 5mM, and cellular debris were 
cleared by repeated centrifugation at 4°C. 400|il of nickel-agarose (solid, Qiagen) 
was added to the supernatant, which was then rotated for Ihr at room temperature. 
The resin was washed stepwise with two 50ml volumes each of denaturing buffer 
(pH8.0), denaturing buffer (pH6.4), and renaturing buffer (25mM Sodium phosphate 
pH7.0, 300mM NaCl and lOmM p-mercaptoethanol) containing IM, then O.IM, and 
lastly no guanidine hydrochloride. Protein was eluted off the resin by sequential 
washes with imidazole buffer (150mM Imidazole, lOOmM NaCl and 50mM Tris- 
HCl (pH7.9)).
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2-13. Gel retardation assays
To supershift the E2F binding activity, the binding sequence for E2F derived 
from the adenovirus (ad5) E2a promoter from -71 to -50, 5'-GATCTAGTTTTCGCG 
CTTAAATTTGA-3' and 3'-ATCAAAAGCGCGAATTTAAACTCTAG-5', was 
radio-labelled with 22p_(x-GTP (Amersham) as described previously (La Thangue et 
a l ,  1990). Each gel shift reaction was made up to a final volume of 20|il and 
reaction mixtures generally contained reaction buffer (4x; 200mM Tris-HCl pH7.9, 
24mM MgCli, 0.8mM EDTA, 4mM DTT and 60% glycerol (v/v)), in vitro- 
translated DP and E2F proteins, and additional 2|ig of sonicated-salmon sperm DNA 
(Sigma) to remove the non-specific DNA binding activity. The mixture was 
incubated for lOmin at 30“C, and added with approximately 6ng of 22p_(x-GTP- 
labelled oligonucleotide probe for a further lOmin incubation at 30°C. Reaction 
mixtures were loaded on to a non-denaturing 4% polyacrylamide Tris-acetate EDTA 
(TAE) gel at 4“C.
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Chapter 3.Nuclear accumulation is necessary for E2F-dependent apoptosis.
3-1. Introduction.
The function of individual E2F/DP heterodimers is not known. While all 
E2F/DP complexes stimulate transcription of reporter genes from consensus E2F- 
binding sites, different B2F complexes may regulate E2F-dependent cellular 
promoters through different E2F-binding sites (La Thangue, 1994; Muller, 1995). 
Functional distinctions between heterodimeric E2F/DP transcription factor 
complexes include tissue-specific patterns of expression (Bandara et al ,  1994; La 
Thangue, 1994; Wu et al,  1995), differences in the time of expression during the 
cell cycle (Schwarz et al,  1993; Cobrinik et al,  1993; Hartwell and Kastan, 1994), 
and preferential association with different members of the pocket proteins or other 
cell cycle regulators (Chellappan et al,  1991; Cobrinik et al,  1993; Bandara et al,  
1994, Lam and La Thangue, 1994; Vairo et al,  1995; Lee et al,  1998). Thus, there 
are distinct specificities in the activation of genes by individual E2F family members 
(DeGregori etal ,  1997).
Recent studies have shown that the over-expression of E2F-1 can induce 
apoptosis in co-operation with p53 (Qin et al,  1994; Wu and Levine, 1994; Kowalik 
et al,  1995). However, studies on the physiological outcomes of deregulating the 
E2F pathway suggest that the unscheduled cell cycle progression induced by E2F-1 
itself leads to apoptosis (Krek et al., 1995; Hass-Kogan et al., 1995; Shan et al., 
1996; Berry et al., 1996). Moreover, the observation that E2F-r^- mice show an 
impaired apoptotic function and increased incidence of cancer development (Field et 
al., 1996; Yamasaki et al., 1996), however, suggests that E2F-1 may play a more 
direct role as a tumour suppressor, independent of E2F-induced cell proliferation. In
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this study, I have investigated the nuclear accumulation of E2F family protein, and 
the mechanisms through which E2F-1 induces apoptosis.
3-2. Results.
3-2.1 Intracellular localization of E2F/DP proteins.
To address the role of intracellular localization in E2F function, 
hemagglutinin (HA)-tagged E2F-1, -4, -5 and DP-1 were expressed by transient 
transfection in U20S cells and their cellular distribution determined by indirect 
immunofluorescence. In these conditions, E2F-1 was found exclusively in nuclei 
(Figure 3-la). In contrast the majority of E2F-4 and -5 were distributed throughout 
the cytoplasm, whilst a small percentage of cells expressing E2F-4 and -5 exhibited 
some nuclear staining (Figure 3-la). Thus, these results imply that protein in the 
E2F family can be divided into two functional subgroups, as suggested from their 
primary sequence and functional properties (Buck et ai,  1995; de la Luna et al, 
1996; Allen et al, 1997). E2F-1 possesses an intrinsic nuclear localization signal 
(NLS) (Krek et al,  1994) and, consequently, non NLS-containing E2F family 
members are likely to rely on other proteins to provide NLS activity. Furthermore, 
immunostaining also showed that the intracellular distribution of the exogenous DP- 
1 failed to be localized in nucleus (Figure 3-lb). The absence of DP-1 in nuclei was 
probably due to the lack of a NLS since the exogenous DP-1 could efficiently 
accumulate in nuclei after attaching a foreign NLS (Figure 3-lb), the bi-partite NLS 
taken from the Bell protein of human foamy virus (Lee et al,  1994). These data 
suggest that DP-1 is not actively retained in the cytoplasm but rather its cytoplasmic 
location is passive.
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Figure 3-1
The intracellular localization of E2F proteins.
a) Cartoon representation of the HA-tagged E2F family members E2F-1, 4 and 
5. DNA binding and dimerization domains are indicated by yellow and blue, 
respectively. U20S cells were transfected with 4jig of the relevant expression 
plasmid and the intracellular location of exogenously expressed HA-tagged E2F-1, 4 
and 5 was assessed by immunofluorescence with an anti-HA monoclonal antibody.
b) The intracellular distribution of exogenous DP-1 (left panel) or DP-1/NLS 
(right panel), which DP-1 had been attached a foreign NLS taken from the Bel 1 
protein in U20S cells was assessed by immunofluorescence using anti-HA 
monoclonal antibody . The position of the NLS is indicated by red.
c) The cellular localization of exogenous E2F-1 and DP-1 in U20S cells 
expressing both proteins was assessed by immunofluorescence using either anti-HA 
monoclonal antibody or the anti-E2F-l polyclonal antibody. Anti-HA 
immunoreactivity was visualized with fluorescein-conjugated anti-mouse 
immunoglobulin (left panel) and anti-E2F-1 immunoreactivity with rhodamine- 
conjugated anti-rabbit immunoglobulin (right panel). Note that co-expression of 
both E2F-1 and DP-1 within the same cell caused DP-1 to efficiently accumulate in 
the nucleus.
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3-2.2. Co-expression of DP-1 with E2F-1 causes DP-1 to efficiently accumulate
in nucleus.
It was reasoned that in the absence of an autonomous NLS a possible 
mechanism to promote the nuclear accumulation of DP-1 may involve an interaction 
with one of its physiological partners, the E2F-1 protein. To test this idea, I studied 
the location of the E2F-1 protein in U20S cells and thereafter the effect of co­
expressing E2F-1 and DP-1 in the same cells. A HA-tagged E2F-1 protein 
visualised by immunostaining with an anti-HA antibody was exclusively nuclear 
(Figure 3-la). To assess the influence of E2F-1 on DP-1, both proteins were co­
expressed and their intracellular distribution determined by double immunostaining 
with anti-HA monoclonal antibody for DP-1 and anti-E2F-1 polyclonal antibody for 
E2F-1 (Figure 3-lc). Neither the fluorescein-conjugated anti-mouse 
iimnunoglobulin or rhodamine-conjugated anti-rabbit immunoglobulin cross-reacted 
with the anti-E2F-1 polyclonal or anti-HA monoclonal antibody (de la Luna et a l , 
1996). There was a striking difference in the distribution of DP-1 upon co­
expression of E2F-1; cells expressing the B2F-1 protein contained nuclear DP-1 
(Figure 3-lc), in contrast to its cytoplasmic location in the absence of E2F-1 (Figure
3-lb). These data strongly suggest that upon forming a DP-1/E2F-1 heterodimer, 
E2F-1 has a dominant influence on recruiting DP-1 to a nuclear location, and 
nuclear localization may provide an additional level of control over E2F activity.
3-2.3. E2F-1 can induce apoptosis independent of p53.
Although E2F-1 over-expression can induce apoptosis in co-operation with 
p53 (Qin et al, 1994; Wu and Levine 1994; Kowalik et al,  1995), recent studies 
have suggested that the growth inhibitory effects of E2F-1 are not entirely dependent 
on p53 (Melillo et a l,  1994; Qin et al, 1994; Berry et al, 1996) and pRb has been
85
shown to protect p53'^- cells from apoptosis in an E2F-1 binding dependent manner 
(Hass-Kogan et al, 1995). Furthermore, a p53-independent apoptotic activity of 
E2F is strongly supported by a recent study, showing that deletion of Rb in mice and 
therefore deregulation of E2F result in apoptosis in both p53 positive and negative 
embryos (Macleod et al, 1996).
Here, I was interested to understand the role of E2F in apoptosis in p53'^' 
cells. SAOS-2 cells, p53 null (p53'/‘) human tumour cell line expressing a carboxy- 
terminal truncated pRb that is defective for E2F binding (Hass-Kogan et ai, 1995), 
were transiently transfected with E2F-1 expression plasmid and cultured in serum 
starvation conditions, conditions favour that apoptosis (White, 1996). The 
transfected cells were determined by immunoflorescence labelling of the cells 
expressing exogenous E2F-1 (Figure 3-2a right panel), and the level of apoptosis 
measured by TdT-mediated dUTP nick end labelling (TUNEL) assay (Figure 3-2a 
left panel). Over-expression of E2F-1 alone, in the absence of p53, was sufficient to 
induce apoptosis (Figure 3-2a). There was a three- to five-fold increase in apoptotic 
cells in E2F-1 transfected SAOS-2 cells compared to cells transfected with a control 
vector (data from TUNEL assay not shown).
3-2.4. Properties of E2F required for apoptosis.
E2F-1 and DP-1 have been shown to form a tight complex when both genes 
are over-expressed by co-transfection in the same cells (Bandara et a l,  1994), and 
this heterodimer has been suggested to be the physiologically significant form of 
E2F activity (Bandai’a et al, 1994; Wu et al, 1995; Shan et al, 1996).
To investigate the effect of DP-1 expression on E2F-1-induced apoptosis, 
SAOS-2 cells were co-transfected with DP-1 and E2F-1 expression plasmids. Co­
expression of DP-1 and E2F-1 dramatically increased the level of apoptosis 
compared to E2F-1 alone (Figure 3-2a).
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Figure 3-2
E2F-1 induces p53-independent apoptosis in SAOS-2 cells.
a) Cells were transiently transfected with 3pg of each expression plasmid for 
E2F-1 and DP-1 as indicated, and grown in conditions of serum starvation (0.2% 
FCS). Cells were fixed and treated with the anti-E2F-l antibody (right panel) or 
assayed for the level of apoptosis by TUNEL (left panel).
b) To quantify the apoptotic effect of E2F-1 and/or DP-1, SAOS-2 cells were 
grown in 3cm-diameter dishes and transfected with 2jig of each expression plasmids 
as indicated. 16h after post-transfection, cells were further incubated for 12h in 
0.2% or 10% FCS. Nucleosomes in the cytoplasm of the apoptotic cells were 
assayed by cell death detection ELISA. The values indicated represent the average 
of three different readings. Error bars indicate standard deviations of triplicate 
transfections.
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To quantify this effect, SAOS-2 cells were transfected as described above. 
Mono- and oligo-nucleosomes in the cytoplasm of the apoptotic cells were prepared 
and measured by cell death dection ELISA (see Materials and Methods). As shown 
previously, E2F-1 alone clearly induced apoptosis, whereas combined expression of 
DP-1 and E2F-1, in agreement with the morphological data, significantly increased 
the level of apoptosis (Figure 3-2b). In contrast DP-1 alone did not show any 
significant apoptosis in the absence of E2F-1 (Figure 3-2b, track 2). Furthermore, to 
confirm the ability of DP-1 to enhance E2F-1-induced apoptosis, I tested two DP-1 
mutants in which the DNA-binding domain (DP-1 dll71) or both the DNA-binding 
and the E2F-1 dimerization domains (DP-1 dl242) were deleted (Figure 3-3a). As 
shown in Figure 3~3b, it was clear that two mutants failed to augment the E2F-1- 
induced apoptosis. Therefore, these results may suggest that the increase in 
apoptosis seen with E2F-1 and DP-1 was occured as the result of an increase in the 
DNA binding and transcriptional activation ability of E2F-L
In an attempt to understand the machanism of E2F-1-mediated p53- 
independent apoptosis, I tested the apoptotic function of a panel of E2F-1 mutants, 
E2F-1(1-413), E2F-l(l-380), E2F-1Y411C, E2F-1A24, and E2F-1(152-438) (Figure
3-4a). Because the ability of E2F-1 to drive cells through cycle has been shown to 
require an intact DNA-binding and trans activation domain (Bandara et al, 1993; 
Helin et a l,  1993), it was necessary to determine the importance of E2F-1 trans 
activation activity to the apoptotic function. Using the TUNEL assay, it was clear 
that the trans activation defective mutants, E2F-1(1-413) and E2F-1( 1-380), were 
both competent to induce apoptosis in transfected SAOS-2 cells (Figure 3-4b and 3- 
4c). Their ability to induce apoptosis was much more than that of the wild-type 
E2F-1. But, interestingly, the DNA-binding defective mutant, E2F-1( 152-438), 
failed to induce apoptosis. These results indicate that E2F-1-induced apoptosis 
requires DNA-binding but not trans activation, results that are consistent with 
recently published data from others (Phillips et al, 1997; Hsieh et al, 1997).
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Figure 3-3
The dimerization of E2F-1 and DP-1 augments apoptosis.
a) A diagram of DP-1 mutants used in the apoptosis.
b) Quantitative comparison the effect on apoptosis in SAOS-2 cells caused by 
E2F-1 with DP-1 wild-type or mutants are shown. DP-1 dll71 and dl242 are a 
carboxy-terminal truncated mutants. DP-1 dll71 lacks the DNA-binding region, and 
DP-1 dl242 is deleted of both DNA-binding and E2F-1 heterodimerization region. 
Cells were transiently transfected with 3pg of E2F-1 and DP-1 expression plasmid. 
The percentages of E2F-1 positive cells were determined by polyclonal anti-E2F-l 
antibody, and further assayed for the level of apoptosis by TUNEL (tracks 1 to 4). 
The apoptotic effects by DP-1 wild-type or mutant in the absence of E2F-1 was 
determined by the comparison of TUNEL-positive population to the number of 
DAPI-positive cells (tracks 5 to 8). The level of apoptosing cells represents the 
average of three independent readings.
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Figure 3-4
Trans activation is not necessary for E2F-1 induced apoptosis.
a) A diagram of E2F-1 mutants used in the apoptosis and the transcriptional 
activation assays. E2F-1(1-413) is a carboxy-terminal truncated E2F-1 mutant. It 
lacks the p300~binding domain and part of the trans activation domain. E2F-1(1- 
380) is a trans activation domain truncated mutant, and is competent for DNA- 
binding. E2F-1Y411C is a point mutant of E2F-1 that is defective for pRb binding, 
E2F-1A24 is an internal deletion mutant which deleted of cyclinA-binding site. 
E2F-1( 152-438) is an amino-terminal truncated mutant that is defective for DNA- 
binding.
b) 3pg of each expression vector for E2F-1 wild-type or mutant was introduced 
in SAOS-2 cells as indicated. Cells were fixed and treated with the anti-E2F-1 
polyclonal antibody and assayed for the absolute percentage level of apoptosis by 
TUNEL assay.
c) The E2F reporter pDHFR-luc (Ipg) together with expression vectors for 
wild-type or mutant E2F-1 (Ipg) were transfected into SAOS-2 cells as indicated. 
The value shown are the average of duplicate readings and represent the relative 
level of luciferase to the p-galactosidase activity from the internal control.
Moreover, as expected, the E2F-1Y411C, which is defective for pRb binding, also 
retained the ability to induce apoptosis (Figure 3-4b).
Previous studies have shown that loss of negative regulation of E2F-1 DNA 
binding activity by cyclinA-associated kinase results in the inability of cells to leave 
S-phase and eventual apoptosis (Ki'ek et al, 1995). Conversely, the analysis of an 
E2F-1 mutant deleted of the cyclin A-binding site (E2F-1A24) was indistinguishable 
from the activity of the wild-type E2F-1 protein in the apoptosis assay (Figure 3-4b), 
suggesting that cyclinA-binding is not necessary for this faction.
Because it was shown that E2F-1-induced apoptosis required DNA-binding 
but not trans activation (Figure 3-4), it is unlikely that the inhibition of E2F-1- 
induced apoptosis by pRb occurs through its suppression of E2F-1 trans activation. 
Nevertheless, existing data imply that pRb appears to be involved in apoptotic 
function (Clarke et al, 1992; Jacks et al, 1992; Morgenbesser et al, 1994; Haupt et 
a l,  1995a; Shan et al, 1996; Macleod et a l,  1996). For instance, p53-mediated 
apoptosis could be overcome by excess pRb, whereas co-expression of p53 appeared 
to enhance the ability of E2F-1 to induce apoptosis (Qin et al, 1994; Haupt et al, 
1995a). Moreover, the loss of pRb function and over-expression of E2F are known 
to disrupt the G1 arrest and favour apoptosis (Shan et al, 1996; Macleod et a l,  
1996). Additional studies have provided convincing evidence that SAOS-2 
derivatives expressing wild-type pRb exhibited increased viability and decreased 
apoptosis following treatment at a variety of radiation doses (Hass-Kogan et al, 
1995). Therefore, the effect of pRb on E2F-1 was investigated using TUNEL and 
luciferase assays. As shown in Figure 3-5, pRb significantly inhibited E2F-1- 
induced apoptosis (compare tracks 1 and 3) in consistent with the ability of pRb to 
repress E2F-1-mediated transcriptional activation (compare tracks 7 and 9).
In contrast, p300 functions as a transcriptional co-activator for the E2F/DP 
heterodimer (in this thesis and Lee et a l,  1998). Thus, it is possible that cells 
expressing p300 can promote E2F-1-induced apoptosis, as it has been shown to
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Figure 3-5
p300 and pRb have different effects on E2F-1 mediated apoptosis.
a) 2jxg of E2F-1 expression plasmid together with 4pg of pRb or p300 
expression plasmid were transfected into SAOS-2 cells. Cells were fixed and treated 
with the anti-E2F-l polyclonal antibody and further assayed for the absolute 
percentage level of apoptosis by TUNEL assay (tracks 1 to 3). The apoptotic effects 
by p300 or pRb in the absence of E2F-1 was determined by the comparison of 
TUNEL-positive population to the number of DAPI-positive cells (tracks 4 and 5)
b) The E2F reporter pDHFR-luc (Ipg) together with expression vectors for 
E2F-1 (0.1 |ig) and DP-1 (Ipg) either alone or together with p300 (6|ig) or pRb 
(6pg) were transfected into SAOS-2 cells as indicated. The value shown are the 
average of duplicate readings and represent the relative level of luciferase to the p- 
galactosidase activity from the internal control.
stimulate the trans activation of E2F-1 (figures 3-5b and 5-3). When p300 was co­
expressed with E2F-1 there was a significant increase in the proportion of apoptotic 
cells, compared to E2F-1 alone (Figure 3-5, compare tracks 1 and 2), in contrast to 
the effect of pRb on E2F-1.
3-3. Conclusion.
E2F DNA-binding activity arises when a member of two families of proteins, 
E2F and DP, form heterodimeric complexes, an interaction which results in co­
operative transcriptional and DNA-binding activity (La Thangue, 1994). From the 
data presented here, I conclude that the activity of E2F is mediated at the level of 
intracellular location through a dependence on heterodimer formation for nuclear 
translocation. Therefore, these data define a new level of control in the E2F 
transcription factor whereby interplay between E2F heterodimers dictates the levels 
of nuclear DNA-binding activity.
In addition, I demonstrated that E2F-1 can induce apoptosis in p53-/- tumour 
cells and that DP-1 is able to augment the E2F-1-induced apoptosis, yet by itself it 
has no ability to induce apoptosis, consistent with the ability of DP-1 to enhance 
E2F-1-mediated transcriptional activation, while inducing little trans activation by 
itself. Although it was clear that the apoptotic function of E2F-1 requires DNA- 
binding but not trans activation, the over-expression of p300 dramatically enhanced 
the E2F-1-induced apoptotic activity, in contrast to pRb which suppressed the E2F- 
1-induced apoptosis. These results suggest that E2F-1-induced apoptosis is not 
simply the consequence of apoptotic gene activation by E2F-1, but is regulated by 
several pathways. However, it clearly appears that E2F-1 provides an apoptosis- 
promoting signal independent of p53.
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Chapter 4.Functional relationship between p53 and E2F-1/DP-1.
4-1. Introduction.
The cellular transcription factors E2F/DP and the tumour suppressor protein 
p53 play important roles in controlling early cell cycle events (Nevins, 1992; La 
Thangue, 1994; Weinberg, 1995). E2F/DP are believed to co-ordinate and integrate 
the transcription of cell cycle regulating genes, for example, those involved in DNA 
synthesis (La Thangue, 1994; Muller, 1995). In contrast, p53 is thought to monitor 
the integrity of chromosomal DNA and when appropriate interfere with cell cycle 
progression, for example, in response to DNA damage (Ko and Prives, 1996). 
However, little is known about the function of the p53 in the control of normal cell 
cycle progression, although transcription of the p53 target gene, encoding the CDK- 
inhibitor p21^'^/^/^'P^, correlates with p53-mediated cell cycle arrest (Sherr, 1993; 
Dulic et a l ,  1994; Koh et a l ,  1995; Lukas et al,  1995; Weinberg, 1995). 
Nevertheless, p53 has been shown to be able to repress the transcriptional activity of 
the promoters of thymidine kinase, c-myc and DNA polymerase a  (Lin et ai, 1992; 
Moberg et a l,  1992; Yuan et a l ,  1993). Interestingly, these are also the genes 
which can be trans activated by E2F. This suggests that p53 may be able to interfere 
with E2F function in the normal cell cycle. Thus, I have the possibility that p53 can 
suppress E2F transcriptional activity, and further that E2F can associate with p53.
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4-2. Results.
4-2.1. DP-1 associates with p53.
Cell extracts were prepaied from SAOS-2 cells expressing wild-type p53 and 
the HA-tagged DP-1, and immunoprecipated with the anti-p53 monoclonal antibody 
421 followed by immunoblotting with the anti-HA antibody (Figure 4-1). DP-1 was 
specifically detected in the p53 immunocomplex (Figure 4-1, compare tracks 1 and 
2). Furthermore, immunoblotting analysis from the same cell extract, was 
performed with the anti-HA antibody to confirm the HA-DP-1 expression level. The 
level of HA-DP-1 was constant in these experimental condition (Figure 4-1, 
compare tracks 3 to 4 and 5). Further evidence was obtained by using F9EC cell 
extracts which were incubated with the anti-p53 antibody, and where DP-1 was also 
present in this immunoprecipitates (Sprensen et al, 1996). However, the data do not 
address whether the interaction is direct or indirect but, nevertheless, do indicate that 
the association occurs in physiological conditions.
4-2.2 An immunochemically distinct form of DP-1 associates with p53.
The minimal region in DP-1 capable of effcientiy binding to p53 occurs 
within residues 171 to 331 (Sprensen et al,  1996). This region of DP-1 contains 
several domains which are conserved between other members of the DP family, and 
a critical region involved in heterodimerization between DP-1 and E2F family 
members (Figure 1-4).
Similarly, to define the region in p53 required for the association with DP-1, 
an in vitro binding assay was developed in which the ability of p53 to interact with 
in vitro translated DP-1 was monitored. Sprensen et al (1996) characterized the 
two forms of DP-1 polypeptides, referred to as p55L (lower) and p55U (upper), from
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Figure 4-1
p53 associates with DP-1.
The expression vectors encoding p53 and HA-tagged DP-1 were transfected 
into SAOS-2 cells and after 36hr immunoprécipitation performed with the anti-p53 
monoclonal antibody 421 (tracks 1 and 2) followed by gel electrophoresis. 
Immunoblotting was performed with the anti-HA monoclonal antibody 12CA5; cell 
extracts alone shown in tracks 3, 4 and 5. Note that the common band present across 
tracks 3, 4 and 5 results from non-specific activity with 12CA5. The HA-tagged 
DP-1 polypeptides are indicated.
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extracts of asynchronous cultured 3T3 and F9EC cells. In that study, it was shown 
that polyclonal anti-DP-1 (D) recognises p55L, in contrast to anti-DP-1 (A) which 
revealed both forms of p55. Specifically, p55L appeared towards the end of G1 as 
cells begin to enter S phase, and evidence was presented that p55L is a significant 
component of E2F DNA-binding activity and that p55U is a form of DP-1 which 
binds less efficiently to E2F site (Bandara et al, 1994; Sprensen et al, 1996).
The results shown in Figure 4-2a confirm these conclusions as p55U is a 
form of DP-1 recognised by anti-DP-1 (A) but not anti-DP-1 (D). In a similar 
fashion, two immunochemically distinct forms of DP-1 could be defined after in 
vitro translation using same two antisera. Specifically, in the absence of translated 
exogeneous DP-1, anti-DP-1 (A), but not anti-DP-1 (D), recognised the endogenous 
DP-1 protein (Figure 4-2a, compare tracks 4 and 3 respectively; indicated by □). 
After translation, both antisera recognised the in vitro translated DP-1 protein, the 
exogeneous polypeptide being resolved with marginally faster mobility (Figure 4-2a, 
tracks 1 and 2; indicated by arrow head).
Evidence that at least two immunochemically distinct forms of DP-1 were 
present after in vitro translation was obtained upon studying the interaction with 
p53. When p53 was added to the in vitro translate, the DP-1 form recognised by 
anti-DP-1 (A), but not anti-DP-1 (D), was retained by p53 (Figure 4-2b, compare 
tracks 3 and 4) although DP-1 immunoreactive with both antisera was present in the 
input translate (Figure 4-2b, compare tracks 5 and 6); the GST portion failed to 
interact with DP-1 (Figure 4-2b, compare tracks 1 and 2). These data indicate that 
two distinct forms of DP-1 are present after in vitro translation and further that p53 
preferentially interacts with the form defined by anti-DP-1 (A). Importantly, this 
result reflects tha data derived by immunopreeipitation from mammalian cell 
extracts where p53 co-immunoprecipitated with p55U, a form of DP-1 recognised 
by anti-DP-1 (A) but not anti-DP-1 (D) (Sprensen et al, 1996). The specificity of 
p53 for DP-1 in the in vitro binding assay therefore possesses some similarity
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Figure 4-2
p53 binds to an immunochemically distinct form of DP-1.
a) Reticulocyte lysate programmed either with (tracks 1 and 2) or without 
(tracks 3 and 4) DP-1 was probed with and anti-DP-1 (aDP-1) antibody, either anti- 
DP-1(D) (D; tracks 1 and 3) or anti-DP-1(A) (A; tracks 2 and 4). The in vitro 
translated (IVT) DP-1 polypeptide is indicated by the arrowhead; note that the 
antisera were affinity purified. The polypeptide indicated by the box and recognized 
by anti-DP-1(A) in track 4 is probably endogenous DP-1; the asterisk indicates a 
non-specific polypeptide. Lane M contains molecular' weight markers, the positions 
of which (in thousands) are indicated on the right.
b) Either GST-p53 (tracks 3 and 4) or GST alone (tracks 1 and 2) was incubated 
with in vitro translated wild-type DP-1, and the bound DP-1 was assessed by 
immunoblotting with either anti-DP-1(A) (tracks 1 and 3) or anti-DP-1(D) (tracks 2 
and 4). Each track was cut in half along the middle, probed with either antiserum, 
and realigned. In tracks 5 and 6, the input (In) reticulocyte containing in vitro 
translated DP-1 was probed with anti-DP-1(A) and anti-DP-1(D), respectively; DP-1 
is indicated by the arrowhead. Note that GST-p53 binds a form of DP-1 recognized 
by anti-DP-1(A) but not anti-DP-1(D).
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with the interaction in mammalian cells, and supports the conclusion that p53 
interacts with an immunochemically distinct form of DP-L
4-2.3 An amino-terminal region in p53 is required for binding to DP-1,
I used GST-pull down assays to define the domain in p53 required for the 
association with DP-1. As much as 250 amino acid residues could be deleted from 
carboxy-terminus of p53 without any detrimental effect on the interaction with DP-1 
(Figure 4-3b, compare tracks 3, 4 and 5). A further deletion from residues 143 to 73 
abolished the interaction (Figure 4-3a and b, compare tracks 2 and 3), thus defining 
a region in p53 required to bind DP-1. Since the amino-terminal region of p53 
contains the MDM2 binding domain (Momand et al, 1992; Oliner et al, 1993; Chen 
et a l,  1994), a domain in p53 necessary for the interaction with DP-1 can therefore 
be distinguished from that required for MDM2 binding.
4-2.4. p53 can modulate E2F site-dependent transcription.
As DP-1 is a frequent component of E2F (Girling et al, 1993; La Thangue,
1994), I assessed the functional consequence of the interaction of p53 with DP-1 by 
studying the effects on E2F site-dependent transcription driven by DP-1 and E2F-1, 
a situation in which it is known that both proteins co-operate in transcriptional |
activation as a DNA binding heterodimer (Figure 4-4, compare lanes 1 to 6 and 11).
In these assay conditions DP-1 alone possesses insignificant transcriptional activity 
(Figure 4-4, compare lanes 1 to 16). When a wild-type p53 expression vector was 
co-transfected into SAOS-2 cells the level of trans activation mediated by either 
E2F-1 alone, or DP-1 together with E2F-1, was compromised in a p53 
concentration-dependent fashion (Figure 4-4, compare lanes 6 through 10 and 11
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DP-1
Figure 4-3
Domains in p53 required for the interaction with DP-1.
a) A panel of GST-p53 fusion proteins were used in an in vitro binding assay 
with DP-1.
b) The indicated p53 fusion proteins (tracks 2 to 5) or control GST (track 1) 
was incubated with in vitro translated wild-type DP-1 (track 6), and the bound DP-1 
was assessed by immunoblotting with anti-DP-1(A). Lane M contains molecular 
weight markers (xlO“3) the positions of which are indicated on the left. In, input
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Figure 4-4
p53 modulates E2F binding site-depedent transcription.
SAOS-2 cells were transfected with expression vectors encoding E2F-1 (bars 
6 to 15; 0.2pg) and DP-1 (bars 11 to 20; 2.0jlg), together with an increasing amount 
of the p53 expression vector (bars 2, 7, 12, and 17, 0.5pg; bars 3, 8, 13, and 18, 
1.25p.g; bars 4, 9, 14, and 19, 3.75pg; bars 5, 10, 15, and 20, 7.5p,g). The reporter 
constructs were pDHFR-luciferase, containing positions -270 to +20 from the DHFR 
promoter, or p3xMT-GL, and pCMV-(3gal was included in each transfection as an 
internal control; in values shown are based on the activity of pDHFR-luc or p3xMT- 
GL (luciferase) relative to that of pCMV-pgal (p-galactosidase). The p53 
expression vector suppressed the activity of pCMV-pgal, which was taken into 
consideration in determining the effect of p53 on DP-1 and E2F-1. The values 
shown represent the means of two readings.
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through 15). The activity of a comparable promoter construct deriven by mutant 
E2F binding sites, p3xMT-GL, was not significantly affected by p53 (Figure 4-4, 
compare lanes 21 through 25). Furthermore, since this inactivating effect of p53 is 
calculated as a ratio of the reporter to the transcriptional activity of an internal 
control (pCMV"Pgal) within the same transfection treatment, it is a specific effect of 
transcriptional activation through the E2F site.
4-2.5. Regulation of p53-dependent transcription by E2F and pRb.
To address the interplay between E2F and p53, it was considered that insight 
may be gained into the mechanisms involved by evaluating the effects of E2F on 
p53-dependent transcription. Thus, I introduced wild-type p53 into the SAOS-2 
cells, and thereafter monitored the activity of a p53 reporter which was dependent 
upon p53 for transcriptional activity. The reporter of choice, pTG13-GL, contains 
p53 binding sites immediately upstream of the herpes virus minimal thymidine 
kinase {tk) promoter together with the SV40 enhancer driving the luciferase, and in 
SAOS-2 possessed minimal activity in the absence of p53 but responded favourably 
to exogenous wild-type p53 (for example Figure 4-5a, compare tracks 1 and 2); 
similar data were obtained from transfection studies in U20S cells.
To establish the influence of the E2F pathway on p53, I introduced 
increasing levels of E2F-1 or pRb and thereafter assayed p53 activity. Increased 
levels of E2F-1 caused a concomitant decline in the transcriptional activity of p53 
(Figure 4-5a, compare track 2 to 3, 4 and 5) whereas, in contrast, increased levels of 
pRb stimulated p53-dependent transcription (Figure 4-5a, compare track 2 to 6, 7 
and 8). Further support for this idea was provided by co-expressing E2F-1 in the 
presence of pRb. In these conditions, pRb antagonised the effects of E2F-1 so that a 
reduction in p53-dependent transcription was no longer apparent (Figure 4-5a, 
compare track 3 to 9, 10 and 11).
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Figure 4-5
Regulation of p53-dependent transcription by E2F-1 and pRb.
a) The p53 reporter pTG13-GL (containing 13 copies of a synthetic p53 
consensus binding sites derived from the promoter of Wafl/Cipl) was introduced 
into SAOS-2 cells together with expression vectors encoding p53 (1 pg; tracks 2 to 
17), in the presence of E2F-1 (0.5pg in tracks 3, 9, 10 and 11; 1.0 pg in tracks 4, 12, 
13 and 14 or 2.0 pg in tracks 5, 15, 16 and 17), and/or pRb (l.Opg in tracks 6, 9, 12 
and 15, 6pg in tracks 7, 10, 13 and 16, and 12pg in tracks 8, 11, 14 and 17). The 
data presented reflect averages from two sets of values. Throughout pCMV-pgal 
was included in each transfection as an internal control. The relative activity of 
luciferase to p-galactosidase is presented.
b) The influence of E2F-1 on p53 protein level was assessed in SAOS-2 cells 
transfected with expression vectors encoding p53 (3pg; tracks 1 to 8), E2F-1 (3pg; 
tracks 1 to 4), or the control vector HAl (3pg; tracks 5 to 8), metabolically labelled 
with 3^S-methionine as described and thereafter chased for the indicated times. The 
levels of p53 were resolved by immunopreeipitation. A non-transfected treatment is 
shown in track 9.
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4-2.6. The regulation of p53 activity requires the E2F-1 and p53 trans 
activation domains.
An outcome of the interaction between pRb and E2F-1 is the inactivation of 
the cai’boxy-terminal transcription activating domain, which is integrated with the 
domain recognised by pRb (Flemington et al, 1993; Helin et al,  1993; Kaelin et al, 
1992). Since the regulation of p53 activity by E2F-1 was overcome by pRb (Figure
4-5a), we reasoned that the E2F-1 activation domain may be influential in regulating 
p53 activity. To assess this possibility, a mutant E2F-1 protein which lacks the
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At the same time, the stimulation of p53 activity by pRb was less when co-expressed 
with E2F-1 (Figure 4-5a, compare tracks 6, 7 and 8 to 9, 10 and 11), and a titration 
of E2F-1 levels in the presence of pRb provided additional evidence for this view, 
since upon increased levels of E2F-1 there was a proportional decline in the 
transcriptional activity of p53 (Figure 4-5a, compare tracks 9, 10 and 11 to 12, 13 
and 14, and 15, 16 and 17). Thus, the transcriptional activity of p53 is influenced by 
the levels of E2F-1 and, moreover, the presence of pRb overcomes this effect, 
suggesting that the p53 and pRb/E2F pathways of growth control are functionally 
integrated.
Certain control treatments were performed to establish the specificity of E2F- 
1 on p53. For example, the effects on p53 transcriptional activity were dependent 
upon exogenous p53 since without p53 no changes in activity on the pTG13-GL 
reporter in the presence of E2F-1 or pRb were apparent. The half life of exogenous 
p53 protein was not affected by co-expression of E2F-1 (Figure 4-5b, compare 
tracks 1 to 4 with 5 to 8) and, further, each transfection treatment was internally 
controlled with pCMV-pgal to rule out general effects of p53, E2F-1 or pRb on the 
transcription apparatus. Having established the specificity of the E2F-1 effect upon 
p53-dependent transcription, I went on to investigate the mechanism involved.
4-3. Conclusion.
These data allow a number of important conclusions to be made. Thus, DP-1 
can complex with p53 both in vitro and in vivo, and because both proteins are key 
regulators of cell cycle progression, these functional interactions are of potential
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carboxy-terminal activation domain, due to truncation up to amino acid residue 413 
(E2F-1A413), was studied. As expected E2F-1A413 had greatly reduced ability to
. 1-
stimulate the transcription of the E2F-responsive DHFR promoter in the absence or 
presence of DP-1 (Figure 4-6a, compare tracks 1 through 5). When assessed for its 
effect upon p53 activity, and in contrast to wild-type E2F-1, E2F-1A413 failed to 
cause a reduction but rather increased p53-dependent transcription (Figure 4-6b, 
compare tracks 3 and 4 with 5 and 6). Thus, the integrity of the transcriptional 
activation domain is necessaiy for the reduction in p53 activity by E2F-1.
Since the regulation of p53 required the E2F-1 transcriptional activation 
domain, it was possible that the activation domain in p53 may be involved.
Therefore, I tested whether a fusion protein containing the amino-terminal 
transcription activation domain (amino acid residues 1 to 73) of p53 was sensitive to 
the effects of E2F-1. In a similar fashion to wild-type p53, the activity of Gal4-p53 
was reduced by E2F-1 (Figure 4-6c, compare tracks 2 and 3).
It was important to determine the specificity of the effect of E2F-1 on p53.
To this end, I studied whether E2F-1 caused a reduction in the activity of other 
transcription activation domains. A variety of activation domains were assessed as 
Gal4 fusion proteins including, of which the p53 activation domain was by far the 
most sensitive. Further, the inactivation of p53 was not caused through general 
effects, such as protein stability, because a hybrid protein in which the VP 16 
activation domain was fused to the wild-type p53 protein became far less sensitive to 
the effects of E2F-1 (Figure 4-6c, compare tracks 5 and 6 with 8 and 9).
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Figure 4-6
Regulation of p53 activity requires the E2F-1 and p53 activation domains.
a) The E2F reporter pDHFR-luc was introduced into SAOS-2 cells together 
with expression vectors encoding E2F-1 (0.2 pg; tracks 2 and 3) or E2F-1A413 (0.2 
pg; tracks 4 and 5) together with DP-1 (2 pg; tracks 3 and 5). The data presented 
reflect averages from two sets of values. Throughout pCMV-pgal was included in 
each transfection as an internal control, the relative activity of luciferase to P- 
galactosidase being presented.
b) The p53 reporter pTG13-GL was introduced into SAOS-2 cells together with 
expression vectors encoding E2F-1 (1 pg in track 3, and 3 pg in 4 and 7 ) or E2F-1 
A413 (1 pg in tracks 5, and 3 pg in tracks 4, 6 and 8 ). Values were calculated as 
described in (a).
c) Either the Gal4 reporter pG5-luc (1 pg; tracks 1 to 3) or pTG13-GL (1 pg; 
tracks 4 to 9) was introduced into SAOS-2 cells together with expression vectors 
encoding Gal4-p53 (1 pg; tracks 2 and 3), p53 (1 pg; tracks 5 and 6) or p53-VP16 
(1 pg; tracks 8 and 9) in the presence of E2F-1 (2 pg; tracks 3, 6, and 9). The data 
presented reflect averages from two sets of values. pCMV-Pgal was included in 
each transfection as an internal control, and the relative activity of luciferase to P- 
galactosidase activity is presented.
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importance in the overall control of the cell cycle. Furthermore, p53 interacts with 
and immunochemically distinct form of DP-1 and, further, this form of DP-1 is an 
infrequent component of E2F DNA-binding activity (Bandara et al,  1994; Sprensen 
et al, 1996), suggesting that p53 competes with E2F-1 for DP-1 with a consequent 
reduction in DNA-binding activity. These results suggest that p53 plays a regulatory 
role in the normal cell cycle by limiting E2F/DP transcriptional activity, possibly 
through pRb-dependent and -independent pathways. Conversely, p53-dependent 
transcriptional activity is also inhibited by the expression of E2F-1 and, moreover, 
the presence of pRb overcomes this effect. Interestingly, the regulation of p53 
activity requires the E2F-1 and p53 trans activation domains. In normal cells, the 
transcriptional activity of p53 is believed to be regulated mainly at the protein level 
through its short half life. However, these results, combined with the evidence that 
the trans activation domains of E2F-1 and p53 were involved, imply that other 
cellular factors might be also involved in the regulation of p53 activity by competing 
with E2F-1 for a rate limiting transcription target.
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Chapter 5.Cell cycle regulation and apoptosis by p53 and E2F-1/DP-1 through co­activator p300
5-1. Introduction.
A number of different lines of evidence indicated that the p300/CBP family 
of proteins function as pleiotrophic co-activators that facilitate activation by a wide 
variety of sequence-specific transcription factors that are involved in the cell cycle, 
differentiation, and signal transduction (Eckner et a l,  1994; Arany et ai,  1995; 
Lundblad et al., 1995; Shikama et ai, 1997). Recent studies have shown that p300 
is phosphorylated in a cell cycle dependent manner and is a substrate for cyclin 
dependent kinase (Yacink et a l,  1991; Wang et a l,  1993; Perkins et a l,  1997), 
suggesting that p300 is critical regulator of cell cycle control. In addition, it is 
known that p300/CBP proteins are targets for the adenovirus El A and SV40 large T 
antigen oncoproteins (Eckner et al,  1994; Arany et al,  1995; Avantaggiati et al, 
1996). Interestingly, a common region of the T antigen is critical for binding both 
p300/CBP and p53 (Lill et al, 1997), suggesting a link between the functions of p53 
and p300.
The results presented in chapter 4 raise the possibility that competition for a 
shared transcription target is responsible for the effect of E2F-1 on p53-dependent 
transcription. The potential identity of such a molecule was addressed by 
determining which proteins, when co-expressed with E2F-1 and p53, relieved the 
repression of p53 activity. Therefore, I focused on the understanding of functional 
interplay between p53 and E2F/DP through p300.
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5-2. Results,
5-2.1. p300 relieves the inactivation of p53 by E2F-1,
Expression of the co-activator p300 (Shikama et al,  1997), a molecule 
previously implicated in E2F-1 mediated transcriptional activation (Tronche et al, 
1996), effectively relieved the repression of p53 (Figure 5-la, compare tracks 3, 4 
and 5) and enhanced in p53-dependent transcription in the absence of E2F-1 (Figure 
5-la, compare tracks 3, 4, 5, 6 and 7). These data argue that p300 functions as a 
transcriptional co-activator for p53 and, further, suggest that a limiting level of p300 
is in part responsible for the inactivating effect of E2F-1 on p53.
To confirm that p300 can provide a co-activator function for E2F-1, the 
effect of p300 on E2F-1-dependent activity of DHFR promoter was assessed. As 
expected, co-expression of p300 enhanced transcriptional activity in an E2F-1- 
dependent fashion (Figure 5-lb, compare tracks 2 through 6). Thus, the combined 
conclusion from these studies suggested that p300 is a shai'ed co-activator utilised by 
p53 and E2F-1 and therefore a likely target involved in mediating the effect on p53 
by E2F-1. That co-expression of pRb relieved the effect of E2F-1 on p53 (Figure 4- 
5a) is consistent with this result since pRb inactivates the transcriptional activity of 
E2F-1 (Flemington et al,  1993; Helin et al, 1993), presumably causing the release 
of p300.
5-2.2. p300 physically associates with p53 and E2F-1.
Having established a functional relationship between p53 and p300, and 
E2F-1 and p300, I wished to determine if this was due to the physical interaction 
between each pair of proteins. To test this possibility, I used a p300 derivative, 
pG4-p300^^ 1-2284^  in which the region between amino acid residue 611 and 2284 is
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Figure 5-1
p300 rescues E2F-1 inactivated p53 and enhances the transcriptional activity of 
p53 and E2F-1.
a) The p53 reporter pTG13-GL was introduced into SAOS-2 cells together with 
expression vectors encoding p53 (1 jig; tracks 2 to 9) in the presence of E2F-1 (2 pg; 
tracks 3, 4 and 5) with p300 (2, 8 and 16 pg in tracks 4, 5 and 6, and 7, 8 and 9 
respectively). The data presented reflect averages from two sets of values. 
Throughout pCMV-pgal was included within each transfection as an internal 
control, and the relative activity of luciferase to P-galactosidase presented.
b) The E2F reporter pDHFR-luc was introduced into SAOS-2 cells together 
with expression vectors encoding E2F-1 (0.2 pg; tracks 2, 3 and 4) together with 
p300 (2 and 10 pg in tracks 3 and 4, and 5 and 6 respectively). Values were 
calculated as described in (a).
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fused to the Gal4 DNA-binding domain. I chose pG4-p300^^ 1-2284 fQj- these studies 
because it is efficiently expressed in a variety of mammalian cells. Extracts were 
prepared from U20S cells expressing pG4-p300^^ 1-2284 ^nd the interaction between 
p53 and pG4-p300^^l"^284 assessed using a binding assay where in vitro translated 
and radiolabelled p53 or the control luciferase was added to the U20S cell extract 
and the association with p300 determined by immunoprécipitation using an anti- 
Gal4 antiserum (Figure 5-2a, compare tracks 5 and 6). An interaction between p53 
and pG4 -p3 0 0 ^l ‘^2284 was detected but not between luciferase (Figure 5-2a, 
compare tracks 3 and 4), suggesting a specific association between p53 and p300. 
The detection of p53 in the immunoprecipitate was dependent upon 
immunoprécipitation since in the absence of the anti-Gal4 antiserum p53 was no 
longer apparent (Figure 5-2a, compare tracks 2 and 4).
To confirm that p300 and p53 can physically associate in vivo, I co­
expressed G4-p300')^ 1-2284 and p53 in U20S cells, immunoprecipitated with anti- 
Gal4 followed by immunoblotting with anti-p53 monoclonal antibody 421. Again, 
p53 was specifically detected in the p300 immunocomplex (Figure 5-2b, compare 
tracks 2, 3 and 4) establishing that p300 and p53 can physically associate in 
mammalian cells. Furthermore, the immunoprécipitation was confirmed with anti- 
p53 antibody using the SAOS-2 cell extracts expressing wild-type p53 and either 
HA-tagged p3 0 0 ^^  '^^^22 or HA-tagged p3 0 0 ^^ 22-2284 (Figure 5-2c).
Further evidence was obtained by taking a two-hybrid approach in U20S 
cells in which Gd-pdOO* !^ “^2284  ^ which is transcriptionally inactive in these 
conditions, in contrast to full-length p300 as a Gal4 hybrid which is a very potent 
transcriptional activator, was used as the “bait” (Figure 5-2d, compare track 2 to 7). 
For the “prey”, I fused wild-type p53 to VP 16 which, when expressed with the p300 
hybrid, caused a significant increase in the transcriptional activity of the reporter 
pG5-luc (Figure 5-2d, compare track 7 to 9). Transcription was dependent upon the 
hybrid p53-VP16 protein since neither p53 nor VP 16 caused a similar increase 
(Figure 5-2d, compare tracks 8, 9 and 10).
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Figure 5-2
p300 physically associates with p53.
a) The expression vector encoding G4 ~p3 0 0 *^  ^ was introduced into U20S 
cells and after 48h harvested as described. Either in vitro translated methionine- 
labelled luciferase (tracks 1 and 3) or p53 (tracks 2 and 4) was added to the extract, 
thereafter immunoprecipitated with the anti-Gal4 antiserum and further resolved by 
gel electrophoresis. Tracks 5 and 6 show the input in vitro translates for luciferase 
(track 5) or p53 (track 6).
b) The expression vector encoding G4-p300^i^'^284 (tracks 2, 3 and 4) together 
with either p53 (track 3) or p53-VP16 (track 4) was introduced into U20S cells and 
after 48h immunoprécipitation performed with the anti-Gal4 antiserum (tracks 2, 3 
and 4) followed by gel electrophoresis. Immunoblotting was performed with the 
p53 monoclonal antibody 421. Note that the common band present across tracks 2, 
3 and 4 results from non-specific activity for the immunoglobulin used in the first 
immunoprécipitation which obscures the wild-type p53 polypeptide in track 3. 
Track 1 shows the standard molecular weight polypeptides. The p53-VP16 
polypeptide is indicated.
c) The wild-type p53 expression vector together with either HA-tagged 
p300^l 1-1572 Qp HA-tagged p300^^^^“^ 284^ designated as HA-p300 N or HA-p300 C 
respectively, was transfected into SAOS-2 cells and after 40h immunoprecipation 
performed with the antibody 421 followed by gel electrophoresis. Immunoblotting 
was performed with the anti-HA monoclonal antibody. Furthermore, 
immunoblotting analysis from same cell extracts, which were used in 
immunoprécipitation, was performed with either the anti-HA antibody or the 
antibody 421 to confirm the expression levels of each transfected plasmid.
d) Two-hybrid assay in U20S cells where the Gal4 reporter pG5-luc was 
introduced together with expression vectors pG4 encoding either the Gal4 DNA 
binding domain (lp.g; tracks 2, 3, 4 and 5) or pG4-p300*^l 1-2284 (ip^g; tracks 7, 8, 9 
and 10) together with either wild-type p53 (Sjitg; tracks 3 and 8), p53-VP16 (5jlg;
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tracks 4 and 9) or VP16 (5|ig; tracks 5 and 10). The data presented reflect averages 
from two sets of values. Throughout pCMV-pgal was included within each 
transfection as an internal control, and the relative activity of luciferase to P- 
galactosidase presented.
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Importantly, the effect of p53-VP16 required p300 protein sequence as there was no 
apparent effect on the Gal4 DNA-binding domain alone (Figure 5-2d, compare 
tracks 2 to 5). Similar data from the two-hybrid assay were observed in SAOS-2 
cells.
An immunoprécipitation strategy was used to determine if E2F-1 and DP-1 
associate with p300. After immunoprecipitating G4-p300^^^‘^ 284^  immunoblotting 
was performed with antisera against either E2F-1 or the haemagglutin (HA) epitope 
to detect the DP-1 protein. Both E2F-1 and DP-1 eould associate with p300 since 
either protein co-immunoprecipitated with G4 -p3 0 0 ^^  '^2284 (Figure 5-3a, compare 
tracks 1 through 3 and 5 through 7).
I confirmed the interaction by taking the two-hybrid approach in which G4- 
p3 0 0 ^^  ^"2284 was assessed for an interaction with GAD-E2F-1, a construct in which 
the Gal4 tmns activation domain was fused to E2F-1. There was a significant 
increase in activity when pG4-p300'^^ 1-2284 and GAD-E2F-1 were expressed 
together (Figure 5-3b, compare tracks 6 and 8). The enhanced transcription was 
specific for the p300 (Figure 24b, compare tracks 4 and 8) and E2F-1 (Figure 5-3b, 
compare tracks 8 and 9) sequence in each hybrid protein. The overall conclusion 
from the biochemical and two-hybrid based assays strongly suggests that p53 and 
E2F-1 can form a stable physical complex with p300.
To confirm the interpretation from the earlier experiments, namely, that the 
trans activation domain of p53 and E2F-1 is a target for p300,1 studied in the two- 
hybrid assay the interaction between a mutant p53 protein which lacked the amino- 
terminal trans activation domain, p53A159-VP16, and a mutant E2F-1 protein which 
lacked the carboxy-terminal trans activation domain, E2F-1A413-VP16. Neither of 
the mutant hybrid proteins were capable of interacting with pG4-p30Q(^l 1-2284 
compared to the wild-type hybrid protein (Figure 5-3c, compare tracks 3 and 4, and 
5 and 6); similar two-hybrid assay results were obtained from SAOS-2 cells. Thus, I 
conclude that the interaction of p300 with either p53 or E2F-1 is mediated through 
binding to the trans activation domain,
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Figure 5-3
p300 physically associates with E2F-1 and DP-1.
a) The expression vector encoding (20 pg; tracks 1, 2, 3, 5, 6 
and 7) together with either E2F-1 (20 pg; tracks 1 and 5) or HA-DP-1 (20 pg; tracks 
2 and 6) were introduced into U20S cells and after 48h immunoprécipitation 
performed with the anti-Gal4 antiserum followed by gel electrophoresis. 
Immunoblotting was performed with either anti-E2F-l (tracks 1 through 4) or anti- 
HA (tracks 5 through 8) as described in Materials and Methods. Note that the 
common band present across tracks 1 to 3, and 5 to 7, results for non specific 
activity for the immunoglobulin used in the immunoprécipitation.
b) Two-hybrid assay in U20S cells where the Gal4 reporter pG5-luc was 
introduced together with expression vectors pG4 (1 pg; tracks 2, 3,4 and 5) or pG4- 
p300^^ 1-2284 (1 jig; tracks 6, 7, 8 and 9) together with either wild-type E2F-1 (5 pg; 
tracks 3 and 7), pGAD-E2F-l (5 pg; tracks 4 and 8) or GAD (5 pg; tracks 5 and 9). 
The data presented reflect averages from two sets of values. Throughout pCMV- 
Pgal was included within each transfection as an internal control, and the relative 
activity of luciferase to P-galactosidase presented.
c) Two-hybrid assay in U20S cells where the reporter pG5-luc was introduced 
together with expression vectors for pG4-p300^^^"2284 (ipg; tracks 2 through 6), 
p53-VP16 (5pg; track 3), p53A159-VP16 (5pg; track 4), E2F-1-VP16 (5pg; track 5) 
or E2F-1A413-VP16 (5pg; track 6). The data presented reflect averages from two 
sets of values, and throughout pCMV-pgal was included as an internal control.
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5-2.3. enhances p53-dependent transcription by the regulating the
p53/p300 interaction.
The Wafl/Cipl gene is transcriptionally activated by p53, containing 
functional p53 binding sites within its transcriptional control region (El-Deiry et al,  
1993; Macleod et al,  1995). It was of interest to test the idea that may
act in an autoregulatory fashion upon the p53/p300 interaction and thereby stimulate 
transcription. To assess this possibility, I used the two-hybrid assay between G4- 
p3 0 0 ^^  "^2284 and p53-VP16 (Figure 5-4a). Under conditions in which there was a 
clear interaction between G4-p300<^ll'^2^4 and p53-VP16 (Figure 5-4a, compare 
tracks 2 and 3), the levels of were titrated and effects on transcription
measured. As the level of p2lf^«///G/?7 increased, there was a concomitant increase 
in the transcriptional activity of the pG5-reporter (Figure 5-4a, compare tracks 3, 4, 
5 and 6). The effect of p21 lFaf7/Op7 was dependent upon the co-expression of p300 
and p53 because there was only a marginal effect on G4-p300^^^"^^^'^ by 
p2llF(3/7/Ci>7 (Figure 5-4a, compare track 2 with 7, 8 and 9). These data indicate 
that co-expression of enhances the activity of the p53/p300 interaction.
The conclusion that enhances the interaction between p53 and
p300 rests on the results from the two-hybrid assay. Therefore, it was necessary to 
demonstrate the effect of p21^^/^/^*7^^ on the activity of transcriptionally active 
wild-type p53. Increasing levels of p21 were introduced together with
wild-type p53 and p53-dependent transcription assayed. In the presence of 
p2 i Wa/7/Ci/?7 there was a marked stimulation of p53 transcriptional activity (Figure
5-4b, compare tracks 2, 3, 4 and 5), an effect dependent upon the presence of wild- 
type p53 (Figure 5-4b, compare tracks 1 with 6, 7 and 8). I conclude that the 
expression of p2ll^^/^^7^^ causes an increase in the transcriptional activity of wild- 
type p53, and that a likely mechanism based on the earlier results is through 
potentiating the activity of the p53/p300 co-activator complex.
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p2iW«/z/C/pl enhances the activity of the p53/p300 complex and p53-dependent 
transcription.
a) Two-hybrid assay in SA O S-2 cells where the Gal4 reporter pG5-luc was 
introduced together with pG4-p300^^ 1-2284 ^ g .  tracks 2 through 9) and p53-VP16
(5 pg; tracks 3 through 6) in the presence and increasing levels of (1 pg
in tracks 4 and 7, 5 pg in tracks 5 and 8 and 10 pg in tracks 6 and 9. The data 
presented reflect averages from two sets of values. Throughout pCMV-Pgai was 
included within each transfection as the internal control, and the relative activity of 
luciferase to P-galactosidase presented.
b) The p53 reporter pTG13-GL was introduced into SAOS-2 cells together with 
expression vectors encoding p53 (1 pg; tracks 2 to 5) in the presence of increasing 
levels of p21^<^^/^'^^ (1 pg in tracks 3 and 6, 5 mg in tracks 4 and 7 and 10 pg in 
tracks 5 and 8). Values were calculated as descibed in a).
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5-2.4. CH3 domain in p300 interact with p53.
To identify the region in p300 that physically interacts with p53, a panel of 
hybrid proteins were prepared in which different domains of p300 were fused to the 
Gal4 DNA-binding domain and co-expressed with the hybrid protein p53-VP16 
(Figure 5-5a). The p53 interaction domain mapped to the carboxy-terminal region 
of p300, specifically within the sequence from residue 1572 to 1903, since co­
expression of pG4-p3001572-1903 with p53-VP16 caused a 6-fold induction of 
transcription (Figure 5-5a). A similar level of induction was apparent with pG4- 
p300^-522-2284 n o t for pG4-p300^^^“^^^  ^ or pG4-p3001302-1572 (Figure 5-5a). 
Furthermore, in these conditions, all Gal4-p300 hybrid proteins expressed at similar 
level (Figure 5-5b). Thus, p300 contains a carboxy-terminal domain which is 
dedicated to a functional interaction with p53. Significantly, this region in p300 is 
known to bind to the El A protein (Eckner et a l,  1996), suggesting that a 
competitive mechanisms may account for the inactivation of p53-dependent 
transcription by El A through the sequestration of p300.
5-2.5. p300 is required for the activation of W afl/C ipl,
To investigate the role of p300 in the regulation of cellular genes, I used the 
p53-responsive promoter taken from Wafl/Cipl (El-Deiry et a l,  1993). The 
expression of the adenovirus El A protein in U20S cells expressing endogenous p53 
and p300 caused a significant reduction in the transcriptional activity of p53 (Figure
5-6a, compare tracks 1 and 2), consistent with the ability of El A to sequester the 
endogenous of p300 (Arany et al,  1995). In contrast, a mutant El A protein that 
lacks the amino-terminal p300 binding domain (Stein et a l,  1990; Arany et a l,  
1995) failed to reduce the transcriptional activity of W afl/C ipl  (Figure 5-6a, 
compare tracks 1 and 3), consistent with a role for p300 in regulating the
134
s0) o
è  &III
(D (£> 
% %
a  a
Û Ü
COX ,0
X01
CHUojg
Xo
§
COQ.
(0 oa
I
too
RQ.
oQ.
<o
0
1
Û.
ooCOQ .I
O
17822- ^ 061-
906I--2Z8I.
t7822-2Z8l.
2ZSI--20CI.
Z92I--H .9
17822-1-1.9
O I
Figure 5-5
Region of p300 required for the interaction with the trans activation domain of 
p53.
a) Diagrammatic representation of the functional region of p300 is shown in left 
side. The three cysteine/histidine-rich domain (CHI, CH2 and CH3) were indicated 
as shaded box. Each Gal4-p300 fusion plasmid (Iftg) was transfected with or 
without p53“VP16 (4pg) into SAOS-2 cells. pCMV-|3gal (2jig) was included in 
each transfection as an internal control. Cells were assayed for luciferase and p-gal 
activity 32~36h after transfection. The experiment were performed twice, and the 
results shown represent the average from two sets of value.
b) The expression of Gal4-p300 protein in transiently transfected SAOS-2 cells 
was determined by immunoblotting with anti-Gal4 monoclonal antibody. The 
arrows indicate Gal4-p300 hybrid proteins.
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Figure 5-6
p300 is required for the activation of p53 target genes.
a) Effect of endogenous p300 on p53 transcriptional activity by adenovirus 
ElA. 2|ig of each reporter plasmid, pWWP-luc or pTG13-luc, was transfected 
together with either pCMV-ElA wild-type or pCMV-ElA A2-36 (0.5|ig) into U20S 
cells expressing endogenous p53 and p300. pCMV-(3gal (1.5pg) was included in 
each transfection as an internal control. Cells were assayed for luciferase and P-gal 
activity 36~40h after transfection. The experiments were performed at least three 
times, and the results shown represent the average from two sets of value.
b) Inhibition of p53 transcription by the dominant negative mutant of 
p300. Expression plasmid encoding pSOO^ 572-1903 with increasing amounts (2|ig in 
tracks 2 and 6, bpg in tracks 3 and 7, and 12pg in tracks 4 and 8) was transfected 
with either 2jLLg of pTG13-luc or pT-luc (the backbone reporter plasmid of pTG13- 
luc) into U20S cells.
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transcription of Wafl/Cipl. This result was confirmed with pTG13-GL containing 
the 13 copies of synthetic p53 binding site originally taken from p2 1 ^ ‘^ / /^C//V 
promoter in same experiment condition (Figure 5-6a, compare tracks 4, 5 and 6), 
suggesting that p300 plays a significant role in regulating the transcriptional activity 
of Wafl/Cipl.
To gain more information on the co-activator properties of p300 for p53- 
dependent transcription, I used p300l572-l903 which contains the minimal regions of 
p53 binding and behaves in a fashion expected for a dominant-negative version of 
p300 (Figure 5-5b). This molecule might prevent the activation of p53-regulated 
promoters by interfering with complex formation between endogenous p53 and 
p300. The over-expression of p3 0 Ql572-1903 clearly inhibited the transcriptional 
activity of p53 in U20S cells (Figure 5-6b, compaie tracks 1 through 4), since this 
effect was no longer apparent with pT-luc, which was used as a control reporter 
containing only a minimal tk promoter placed upstream of the luciferase (Figure 5- 
6b, compai'e tracks 5 through 8). These results suggest that p3 0 0 5^72-1903 lively acts 
by competing with endogenous p300 for p53, and further that p300 is a crucial 
component of the p53 response.
5-2.6. Physiological consequences of p300 interacting with p53 and E2F.
The induction of transcription of the gene encoding p2lh^'W(7(p7 ^y p53 
correlates with cell cycle arrest by p53 (Chen et al, 1996; El-Deiry et al, 1993; 
Macleod et a l,  1995) and the expression of p21l7a///Ci/?7 is sufficient to prevent cell 
cycle progression (Dulic et al,  1994; Waldman et al, 1995). It was reasoned that 
the ability of p300 to interact with and enhance the transcriptional activity of p53 
may facilitate cell cycle arrest.
To test this idea, I introduced p53 into asynchronous cultures of SAOS-2 
cells and monitored the proportion of transfected cells in G l, S and G2/M, both in
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the presence and absence of co-expressed p300 (Figure 5-7a). Transfected cells 
were identified by the expression of the cell surface protein CD20 and subsequent 
staining with an anti-CD20 monoclonal antibody, and the percentage of cells in each 
phase of the cell cycle was measured after treatment with propidium iodide.
I performed the flow cytometry experiments in SAOS-2 where the 
introduction of p53 caused an accummulation of cells in Gl, usually resulting in a 
significant increase in Gl population (Figure 5-7a); similar results were obtained in 
U20S and 3T3 cells. Under these conditions p300 was expressed either alone or 
together with p53. When p300 was co-expressed with p53 there was a marked 
increase in the proportion of cells in G l, compared to p53 alone (Figure 5-7a and 
summarised in Table 5-1); p300 had little effect in the absence of p53. I conclude 
that p300 can facilitate cell cycle arrest by p53, and that a possible mechanism 
involves increased transcription of p53 target genes, such as the Wafl/Cipl gene, as 
a result of p300 enhancing the transcriptional activity of p53.
Next, the role of p300 in apoptosis was explored. For this, I used SAOS-2 or 
U20S cells that had been cultured in serum starvation conditions, conditions that 
favour apoptosis (White, 1996). The data presented were derived from SAOS-2 
cells, although very similar results were obtained from U20S cells. Two assays 
were used to measure the level of apoptotic cells, namely TUNEL and flow 
cytometry (cells with sub-genomic levels of DNA). Data derived from TUNEL 
assays are shown (Figure 5-7b and summarised in Table 5-2), similar conclusions 
being made from the other assay (Figure 5-7a). In SAOS-2 cells, the introduction of 
wild-type p53 caused a significant level of apoptosis (Figure 5-7b and Table 5-2) 
consistant with previous reports (Chen et ai, 1996; Rowan et al., 1996). When p300 
was assessed in the same cells, little difference was apparent from the untreated 
cells. Unexpectedly, the introduction of p53 together with p300 failed to increase 
the proportion of apoptosing cells but reduced this effect (Table 5-2). Thus, the 
binding of p300 to p53 in these experimental conditions appears to favour p53- 
niediated Gl arrest rather than apoptosis.
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Figure 5-7
Effect of p300 on cell cycle arrest and apoptosis.
a) Flow cytometry was performed on asynchronous cultures of SAOS-2 cells 
transfected with the CD20 expression vector (10 pg) together with p53 alone or p53 
and p300 together. 15 pg of each expression vector was introduced, the total 
amount of DNA for each treatment being equivalent and made up with empty vector 
(pcDNA3). Transfected cells were grown in either 10% (left panels) or 0.2% (right 
panels) foetal bovine serum and identified by staining with anti-CD20 and the cell 
cycle profile was assessed by staining with propidium iodide. The level of cell cycle 
arrest for each treatment is summarised in Table 5-1.
b) The effect of p300 on p53-dependent and independent apoptosis was 
assessed in both SAOS-2 and U20S cells transfected in conditions of serum 
starvation (see Materials and Methods) as indicated with 4pg of p53 and/or E2F-1 
expression vector in the absence or presence of the p300 expression vector, the total 
amount being made up with empty vector. Results for SAOS-2 cells are shown 
when assayed by TUNEL (left hand side of each treatment) and, for comparison, a 
DAPI stain of the same field of cells. The level of apoptosis for each treatment is 
sunmiarised in Table 5-2.
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Table 5-1. Effect of p300 on p53-mediated cell cycle arrest.
Treatment
% change
Gl S G2/M
p300 -2.9+0.2 7.3+2.T 4.1+1.1
p53 19.0+3.0 -47.7+2.0 -18.6+1.7
p53 + p300 38.1+4.5 -62.3+5.4 -50.4+7.6
A summary of the level of growth arrest caused by each treatment in 
SAOS-2 cells. The data shown represent the average of three different 
readings from the same treatment.
The percentage change compared to the control treatment (CD 20 
expression vector alone) is shown.
Table 5-2. Effect of p300 on apoptosis.
Treatment
Percent apoptotic cells 
(TUNEL/DAPI)
Exp 1 Exp 2 Exp 3
1.6(%) 2.8 (%) 2.0 (%)
p300 2.2 2.9 2.5
p53 17.1 18.5 11.8
p53/p300 11.8 16.6 10.1
E2F-1 7.5 " 6.8
E2F-l/p300 19.6 - 14.2
p53/E2F-l 29.2 " 21.2
p53/E2F-l/p300 23.6 - -
A summary of the level of apoptosis caused by each treatment in SAOS-2 cells. 
The percentage of apoptotic cells was determined by counting the number of 
TUNEL positive cells compared to the total cells examined from DAPI staining. 
The values indicated represent the average of readings made on three separate 
coverslips from the same treatment in which about 10 different fields for each 
coverslip were assessed. The expression of transfected plasmids was confirmed 
and the transfection efficiency established by indirect immunofluorescence.
I went on to study the effect of E2F-1 in SAOS-2 cells. As it was shown 
previously (Hass-Kogan et al,  1995; Kick et al, 1995; Shan et a l,  1996), E2F-1 
when expressed alone caused significant levels of apoptosis (Figures 3-2 and 5-7b 
and Table 5-2) indicating that the apoptotic activity of E2F-1 is independent of p53. 
In these conditions, the apoptotic activity of E2F-1 was enhanced by p300 (Figure 5- 
7b and Table 5-2), in contrast to the effect of p300 on p53 where it increased the 
efficiency of p53-dependent cell cycle arrest. Further, a clear stimulation in the 
proportion of apoptotic cells was apparent when E2F-1 and p53 were expressed 
together (Figure 5-7b and Table 5-2), a result which corroborates earlier reports (Qin 
et a l,  1994; Wu and Levine , 1994). That limiting levels of p300 may inpart be 
responsible for this enhanced apoptosis was suggested from introducing p300 into 
cells undergoing E2F-l/p53-dependent apoptosis, upon which the level of apoptosis 
was significantly reduced (Figure 5-7b and Table 5-2). Interestingly, this 
observation indicates that the binding of p300 to p53 favours p53-mediated cell 
cycle arrest whilst the binding of p300 to E2F-1 favours apoptosis.
5-3. Conclusion.
The p300 protein, which possesses the properties of a transcriptional co­
activator and is involved in regulating the activity of a variety of sequence specific 
transcription factors (Shikama et al ., 1997), overcame the down-regulation of p53 
and, moreover, enhanced the activity of both B2F-1 and p53-dependent 
transcription, an effect dependent on a physical association between the trajts 
activation domain of each protein and p300. Furthermore, I showed that the cdk- 
inhibitor autoregulates in a positive fashion transcription through
modulating the activity of the p53/p300 complex, whilst negatively regulating the 
activity of E2F by preventing cdk-dependent phosphorylation of pRb. My 
conclusions relating to the biological significance of the interaction between p53 and
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p300 suggested that p300 augments the ability of p53 to cause G1 arrest in 
consistent with a role for p300 as a p53 co-activator in the transcription of 
Wafl/Cipl. In addition, I also demonstrated that p300, which also functions as a co­
activator for E2F/DP heterodimer, enhances the E2F-1-induced apoptotie activity. 
Thus, a functional interaction between p300 either p53 or E2F-1 has a profound 
impact on early cell cycle progression, specifically in regulating the contrasting 
outcomes of cell cycle arrest and apoptosis. These results suggest a critical role for 
p300 in integrating and co-ordinating the functional interplay between the pathways 
of growth control mediated by E2F and p53.
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Chapter 6.JMY, a new co-activator for p300, regulates the p53 response.
6-1. Introduction.
To elucidate the mechanisms of transcriptional activation by p300/CBP, it is 
possible that additional control may be exerted through proteins that physically 
interact with and regulate the activity of p300/CBP. Using yeast two-hybrid with 
pLexA-p300^^ 1-2284^  Shikama et al  (1998) screened and identified a new p300 
binding protein, called JMY (junction-mediating and regulatory protein). The 
sequence of JMY possesses a number of interesting features, such as a cluster of 
potential phosphorylation sites for S/T-P directed kinases including three consensus 
sites for cyclin-dependent kinases in the amino-terminal region, a central region 
which contains a motif that resembles conserved region 2 (CR2) in the adenovirus 
El A protein, and a carboxy-terminal domain rich in proline residues (Figure 6-1). 
In this study, I explored several aspects of JMY biochemistry and function.
6-2. Results. 
6-2.1. JMY forms a physical complex with p300.
To determine whether p300 and JMY can interact in mammalian cells, I co­
transfected expression plasmids encoding pG-p3 0 0 *^  ^ and HA-JMY in U20S 
cells, immunoprécipitation with anti-Gal4 monoclonal antibody followed by 
immunoblotting with anti-HA monoclonal antibody (Figure 6-2a).
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Figure 6-1
Diagrammatic summary of functional domains in JMY
The primary amino acid sequence of JMY (983 amino acid residues). The 
S/T-P motifs in the amino-terminal region are underlined and the central p300 
binding domain in JMY (from residue 469 to 558) is highlighted in small box. The 
hydrophobic residues that conform to a heptad leucine-rich repeat and the 
adenovirus El A CR2-like motif, EVQFEILKCEE, are indicated in central region 
(residues in bold being conserved in El A CR2). The proline-rich region is 
highlighted in carboxy-terminal.
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The 1 lOkDa JMY polypeptide was detected in the p300 immunopreeipitation but not 
in the control treatment (Figure 6-2a, compare tracks 1 and 2), confirming that the 
interaction between the two proteins can occur in mammalian cells.
As the previous experiments were performed with cells expressing 
exogenous protein, I assessed whether endogenous JMY and p300 could associate 
in physiological conditions. For this, I used HeLa cells, which contain significant 
levels of the JMY polypeptide (Figure 6-2b), and determined whether JMY co- 
immunoprecipitated with p300. The endogenous JMY polypeptide could be 
detected in immunoprecipitates with endogenous p300 (Figure 6-2b), supporting the 
view that JMY and p300 associate in physiological conditions. Thus, JMY and p300 
exist as a complex in mammalian cells.
6-2.2. Two domains in p300 interact with JMY.
The region in p300 that is responsible for the interaction with JMY was 
determined using a mammalian two-hybrid assay and a panel of p300 deletion 
mutants fused to the Gal4 DNA binding domain (Figure 6-3). The interaction 
between JMY and p300 occurred with two regions in p300, one encompassed within 
residues 611 to 1257, and the other within 1572 to 2284, because when JMY-VP16 
was co-expressed with either G4-p300(^^ 1-1257 qj- Q4_p3Qol572-2284 
transcriptional activity of the reporter pG5-luc was far more efficient than that 
observed in the presence of the bait alone (Figure 6-3). Notably, although the 
intrinsic activity of G4-p300^^^^"^284 was considerably greater than G4-p300^^^" 
1257^  the induction of activity by JMY-VP16 was similar, about 6-fold for either 
p300 derivative (Figure 6-3). Other regions of p300, such as residues 1302 to 1572, 
failed to interact with JMY-VP16 (Figure 6-3).
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Figure 6-2
JMY interacts with p300.
a) Co-immunoprecipitation of JMY and p300 from U20S cells transfected with 
pG4 (30pg; track 1) or pG4 -p3 0 0 ^^  ”^^ 284 (30pg; track 2) together with pCMV-HA- 
JMY (30pg; tracks 1 and 2) as described. After extraction, immunopreeipitation 
was performed with anti~Gal4 monoclonal antibody followed by immunoblotting 
with anti-HA monoclonal antibody; the cell extract alone is shown in track 3. In 
tracks 4 and 5, the cell extract was immunoblotted with an anti-peptide JMY 
antibody in the absence (track 4) or presence (track 5) of competing homologous 
peptide. The JMY 1 lOkDa polypeptide is indicated.
b) Immunopreeipitation of JMY with p300 was performed from HeLa cell 
extracts with the control anti-HA monoclonal antibody 12CA5 (track 1) or the anti- 
p300 monoclonal antibody Ab-1 (track 2) and thereafter immunoblotted with an 
anti-peptide JMY antiserum. Track 3 indicates the JMY polypeptide in the HeLa 
cell nuclear extract.
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Figure 6-3
JMY interacts with two domains in p300.
Tw o-hybrid assay in m am m alian cells: the indicated pG 4-p300 expression 
vectors (Ip g )  were introduced into U 2 0 S  cells either alone or together w ith pVP16- 
JMY469-558 (5|Lig) and the reporter pG5-luc. The data shown represent the relative 
activity o f luciferase to p-galactosidase and are the average o f two treatm ents. Note 
that the activity o f both pG4-p300<5^ ^"^257 and pG 4-p300^^’^ 2-2284 undergoes a 6- 
fold increase in the presence o f pVPlô-JM Y^^^'^^^.
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6-2.3. JMY possesses the properties of a transcriptional co-activator.
Next, the possibility that JMY possesses the properties of a transcriptional 
regulator was examined by studying the effect of JMY on p53, a transcription factor 
which is a known tai'get for p300/CBP proteins (Lill et al, 1997; Gu et al, 1997; 
Avantaggiati ef «/., 1997; Lee n/., 1998). The transcriptional activity of p53 was 
assayed on the promoter taken from bax which encodes a protein that facilitates 
apoptosis and responds to p53 (Miyashita and Reed, 1995; Friedlander et al, 1996). 
The bax promoter was efficiently induced in the presence of exogenous p53 in 
SAOS-2 cells (Figure 6-4a). p53-dependent transcription was increased by the co­
expression of JMY, and a further enhancement occurred when p300 was co­
expressed with JMY (Figure 6-4a). The stimulation of transcription by JMY and 
p300 was dependent upon the integrity of the amino terminal trans activation 
domain, as a p53 derivative containing an inactive trans activation domain, p53^2/23 
(Lin et ai, 1994), was unresponsive to p300 and JMY (Figure 6-4a).
I obtained additional information on the co-activator properties of JMY by 
studying the effects of a truncated p300 molecule, namely which
behaves in a fashion expected for a dominant-negative effect (Figures 5-5, 5-6b and
6-4b). To study the influence of p300l^^2-l903 JMY, I employed the bax 
promoter where caused a significant reduction in activity (Figure 6-
4b, compare tracks 2 to 6 and 7). In conditions where JMY stimulated p53- 
dependent transcription the introduction of p3 0 0 1^^2-1903 caused a significant 
reduction in p53-dependent transcription (Figure 6-4b), thus supporting a 
requirement for p300 in transcriptional activation for JMY.
The data shown in Figure 6-4a support the idea that p300 and JMY increase 
the transcriptional activity of p53. However, it was possible that this occurred 
through altered protein levels. To assess this possibility, I measured p53, p300 and 
JMY in conditions where all three proteins were co-expressed.
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Figure 6-4
JMY possesses the properties of a co-activator for p53.
a) The p53 reporter pBax-luc (0.5|Lig) together with expression vectors for wild- 
type p53 (0.05pg) or p5323/23 (O.OSpg), together with JMY (5pg) or p300 (2.5|lg) 
were transfected into SAOS-2 cells as indicated. The values shown are the average 
of duplicate readings and represent the relative level of luciferase to the (3- 
galactosidase activity from the internal control.
b) The p53 reporter pBax-luc (Ijig) together with expression vectors for wild- 
type p53 (O.lpg), JMY (6pg) or p300l572-1903 (2 or 6pg) were transfected into 
SAOS-2 cells as indicated. The values shown represent the average of duplicate 
readings and represent the relative level of luciferase to the |3-galactosidase activity 
from the internal control.
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:6-2.4. JMY regulates p53-dependent apoptosis.
To explore the biological consequence of co-activation by JMY, I evaluated 
the effect of JMY on wild-type p53 activity which, when induced by genotoxic
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Significantly, co-expression of either p300 or JMY failed to affect the level of p53 
protein since by immunoblotting p53 was constant in conditions of increasing JMY 
or p300 concentration (Figure 6-5). A similar analysis on the levels of both p300 
and JMY proteins indicated that, like p53, p300 and JMY levels were not affected 
by the co-expression of each other or p53 (Figure 6-6). These data therefore indicate 
that JMY possesses the properties of a co-activator and suggest that it acts together 
with p300/CBP proteins in facilitating transcriptional activation by p53.
Since in the conditions of the assay co-expression of p300 and JMY 
efficiently stimulated the activity of bax promoter, I tried to detect the levels of 
endogenous Bax protein. Importantly, the expression of JMY and p300 was 
sufficient to increase the activity of endogenous genes as co-expression of JMY and 
p300 with p53 in SAOS-2 cells caused an increase in the level of the Bax protein 
(Figure 6-7), which was not apparent when p300 was expressed alone.
The co-activator properties of JMY were assessed on other p53-responsive 
promoters, namely those taken from the gadcl45 (Kastan et al., 1992; Chen et ai, 
1995), mdml (Momand et al, 1992; Juven et al,  1993) and Wafl/Cipl genes (El- 
Deiry et a l,  1993). In SAOS-2 cells, co-expression of JMY and p300 increased the 
activity of the gadd45 and Wafl/Cipl promoters, in a similar fashion to JMY and 
p300 on the bax promoter, the effect being greater when they were expressed 
together (Figure 6-8). In contrast, neither exogenous JMY nor p300 could augment 
the activity of the mdml promoter (Figure 6-8). These results strengthen the 
conclusion that JMY possesses the properties of a co-activator and, furthermore, 
imply that JMY preferentially activates some p53 target genes.
p300: -
J M Y :  -
p53: -  +  + +  +  + +  +  +  +  +
1 2 3 4 5 6 7 8 9  10 11
Figure 6-5
The protein expression level of p53 by p300 or JMY.
To assess the level of p53, expression vectors for wild-type p53 (0.3pg), 
JMY (1, 3 or 6pg) or p300 (1, 6 or 12pg) were transfected either alone or together as 
indicated into SAOS-2 cells. Extracts from control or transfected cells were 
prepared and immunoblotted for p53 as described. The p53 polypeptide is indicated.
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Figure 6-6
Levels of p300 and JMY
To assess the levels of p300 and JMY, expression vectors encoding p53 
(0.3|lg), JMY (1,3 and 6jLig in a), or 1 and 3pg in b)) or Gal4-p300 (1,6 and 12pg in
a), or 1 and 6flg in b)) were transfected into SAOS-2 cells as described. Extracts 
were prepared and in a) immunoblotted with an anti-Gal4 monoclonal antibody. In
b), extracts were firstly immunoprecipitated with the anti-Gal4 monoclonal antibody 
and thereafter immunoblotted with anti-p300. The vector encoding Gal4-p300 
contains the complete p300 protein. In c), expression vectors encoding p53 (0.3|ig), 
JMY (1,3 and 6]Ltg) or p300 (1,6 and 12pg) were transfected into SAOS-2 cells as 
described. Extracts were prepared and immunoblotted with an anti-JMY peptide 
antiserum.
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Figure 6-7
Induction of Bax protein by p300/JMY.
To assess the induction of endogenous Bax protein, expression vectors for 
wild-type p53 (lOpg) with or without JMY (40|_tg) and p300 (40p,g) were transfected 
as indicated into SAOS-2 cells. Extracts from transfected cells were prepared and 
immunoblotted for Bax and p53 as described. The Bax (upper panel) and p53 
(lower panel) polypeptides are indicated.
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stress can, in some circumstances, cause apoptosis (Crook et al, 1994; Miyashita 
and Reed, 1995; Sabbatini er a/., 1995; Ko and Prives, 1996). For this analysis I 
used SAOS-2 cells which become sensitive to apoptosis upon the introduction of 
wild-type p53 (Chen et al, 1996; Lee et al,  1998). Although apoptosis was evident 
with p53 alone, co-expression of JMY with p53 significantly enhanced the level of 
cell death which was not apparent in the absence of p53, indicating that the process 
is dependent upon p53 (Figures 6-9a and 6-9b and Table 6-1). In contrast, however, 
in the same conditions p300 failed to affect the apoptotic activity of p53, although 
the level of apoptosis was significantly greater when JMY and p300 were co­
expressed (Figure 6-9b and Table 6-1). Thus, in a similar fashion to its effects on 
transcription, JMY can augment p53-dependent apoptosis, and the induction of p53- 
dependent apoptosis caused by JMY can be enhanced by p300.
6-3. Conclusion.
p300/CBP transcriptional co-activators have been demonstrated to interact 
with a variety of sequence-specific transcription factors (Shikama et al, 1997), and 
in many cases act to nucleate the assembly of a multi-component co-activator 
complex that co-ordinates and integrates diverse signals with gene expression 
(Korzus et al, 1998; Kurokawa et al,  1998). From the data presented here, I 
conclude that JMY, a newly identified llOkDa polypeptides, forms a physical 
complex with p300 in vivo. By analysing the effects of JMY and p300 on p53, I 
have obtained data to support the conclusion that p300 and JMY together can effect 
the transcriptional activation of known target genes, sueh as bax. Moreover, the data 
also showed that JMY and p300 functionally co-operate promoting p53-dependent 
apoptosis, a result consistent with a contribution by the p53 trans activation domain 
to apoptosis (Sabbatini er a/., 1995; Friedlander er a/., 1996; Ko and Prives, 1996)
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Figure 6-8
JMY has selective effects on p53-target genes.
The p53 reporters pBax-luc, pGADD45-luc, pMDM2-luc or pWWP-luc 
(l.OjLig) together with expression vectors for wild-type p53 (O.OSpg), p300 (2.5pg) or 
JMY (5|ig) were transfected into SAOS-2 cells as indicated. The values shown 
represent the average of duplicate readings and represent the relative level of 
luciferase to the |3-galactosidase activity from the internal control.
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Figure 6-9
JMY augments p53-dependent apoptosis.
a) Expression vectors for p53 either alone (i and ii) or together with JMY (iii 
and iv) were introduced into SAOS-2 cells as described. Cells were fixed and 
treated with the anti-p53 monoclonal antibody 421 (i and iii) or assayed for the level 
of apoptosis by TUNEL (ii and iv); i and ii, and iii and iv, show respectively the 
same field of cells assayed for p53 and by TUNEL.
b) Quantitative comparison of the effect on apoptosis in SAOS-2 cells caused 
by JMY, p300 or both in the presence or absence of p53. On the left side, the 
percentage of p53-positive (determined by monoclonal antibody 421) cells that were 
TUNEL-positive was derived, and compared to values obtained in the presence of 
JMY, p300, or both together. In the data, both the absolute percentage level of 
apoptosis together with the percentage stimulation in apoptosis relative to p53 alone 
is presented. The level of apoptosing cells represent, the average of three 
independent readings. The TUNEL-positive population compared to the number of 
DAPI-positive cells in the absence of p53 was used to assess the level of apoptosis 
in the presence of JMY and p300, and the values shown were obtained from two 
separate assays.
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and thus with other studies implicating a role for p300/CBP in apoptosis (Muraoka 
et al., 1996; Shikama et al, 1997; Giles et al., 1998). Given the fact that JMY 
significantly activated p53-responsive genes and induced p53-dependent apoptosis, 
it is therefore possible that JMY may be a direct target for p53 transcription. Thus, I 
have pursued the issue of whether JMY can interact directly with p53. However, I 
have not been successful in showing a direct interaction between JMY and p53 using 
mammalian two-hybrid assays and co-immunoprecipitations. Therefore, the data 
support the notion that JMY through its interaction with p300 is an important 
effector molecule in directing the cellular response to p53.
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Chapter 7.Discussion
7-1, E2F family members exhibit distinct cellular distributions and functional 
properties.
It is known that individual E2F activities display distinct effects on cell 
proliferation and survival, coincident with their differential abilities to activate a 7
large array of endogenous genes that encode proteins important for DNA replication 
and cell cycle progression (Nevins, 1992; La Thangue, 1994; Muller, 1995). In 
particular, E2F-1, -2, and -3 can efficiently activité DNA synthesis in quiescent 
fibroblasts, E2F-4 does so only poorly and E2F-5 has little or no activity in S phase ï
induction (Lukas et al, 1996; DeGregori et al, 1997). The distinct roles for B2F 
family members, separating E2F-1, -2 and -3 from E2F-4 and -5, are reflected in 
various properties of the E2F proteins including their different cellular distributions 
(de la Luna et al, 1996; Allen et al, 1997; DeGregori et al, 1997).
By studying their intracellular distribution, it was possible to divide the E2F 
family into two distinct categories according to their ability to accumulate in nuclei.
The first group, examplified by E2F-1, underwent efficient nuclear accumulation 
whereas the second, which includes E2F-4 and -5, failed to do so and remained, for 
the most part, in the cytoplasm. E2F-4 and -5 are likely to rely on other proteins to 
be localized in nucleus, whereas E2F-1, -2 and -3 possess an intrinsic NLS (Kick et 
al,  1994; Magae et al, 1996; Allen et al, 1997). In addition, the presence of DP-1 
in nuclei, which lacks an intrinsic NLS, is likely therefore to be dependent upon an 
interaction with the appropriate E2F heterodimeric partner which subsequently 
causes the efficient nuclear accumulation of the heterodimers (this thesis and de la 
Luna et al, 1996). Interestingly, Allen et al (1997) reported that upon forming a 
heterodimer with either DP-3a or -38 (de la Luna et al, 1996), E2F-4 or -5 could
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undergo nuclear accumulation, indicating that in context of the E2F heterodimer, the 
NLS can be also provided by the DP partner. Furthermore, p i07 and p i30 could 
stimulate nuclear localization of E2F-4 and -5, either alone or in combination with 
DP-1 (Magae et al,  1996; Allen et al., 1997). Although the reason for this effect is 
not known, it is possible that pl07 and p i30 stabilize interactions of E2F-4 and -5 
with endogenous DP proteins, or facilitate the retention of E2F-4 and -5 within the 
nucleus (Magae et al, 1996; Allen et al, 1997). Overall, the combined conclusion 
from these data defines two distinct mechanisms which regulate the levels of nuclear 
E2F, one in which the NLS is provided by the DP partner and the other where the 
NLS is supplied by the physical association of a pocket protein.
7-2. All ability of E2F-1 to induce apoptosis.
It is apparent that the primary function of E2F-1 is to promote cell cycle 
progression from G1 to S phase through the transcriptional activation of genes 
required for DNA synthesis (Nevins, 1992; La Thangue, 1994; Lam and La 
Thangue, 1994). Nevertheless, E2F~H~ mice display a defect in thymocyte 
apoptosis (Field et al, 1996). In addition, these mice also develop a broad spectrum 
of tumours including reproductive tract sarcoma, lung adenocarcinoma, and 
lymphomas (Yamasaki et a l,  1996), suggesting E2F-1 endowed with tumour 
suppressor activity. These results indicate that the induction of apoptosis may be 
one of the mechanisms through which E2F-1 functions as a tumour suppressor.
Previous studies suggest that E2F-1 and p53 co-operate to mediate apoptosis 
(Qin et al, 1994; Wu and Levine, 1994; Kowalik et al, 1995; Shan et al, 1996; Lee 
et al, 1998). However, E2F-1 over-expression in SAOS-2 (p53-/-) cells can induce 
apoptosis and therefore this apoptotic activity is not dependent upon p53 (this study 
and Hsieh et al, 1997; Phillips et al, 1997; DeGregori et al, 1997; Lee et al, 1998). 
At present, I do not have candidates for the mediators of this E2F-1-induced p53-
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independent form of apoptosis. However, the expression of several cellular genes 
has been shown to be repressed through E2F-binding sites (Muller, 1995; Zwicker 
and Muller, 1997). For example, among these are the B-myb, cdc25C and cdc2, 
genes which are also involved in E2F-mediated trans activation during the certain 
stages of the cell cycle (Zwicker and Muller, 1997). Therefore, the importance of 
DNA-binding to the E2F-1-induced apoptosis described in this thesis suggests that 
this apoptotic activity may reflect the alleviation of E2F mediated transcriptional 
repression, rather than the activation of E2F-responsive genes.
I have described that the over-expression of p300 as a co-activator for E2F- 
1/DP-l heterodimer dramatically enhanced the E2F-1-induced apoptosis, in contrast 
to pRb suppressed the E2F-1-induced apoptosis. These results suggest that E2F-1 
may directly activaties the expression of some components of the cell death 
machinery or the genes important for cell survival. Alternatively, inappropriate S 
phase entry may indirectly trigger cell death, or perhaps increased proliferation may 
lead to the exhaustion of exogenous factors required for cell survival (Figure 7-1). 
Similarly, it has been shown that the E2F-1-induced apoptosis is observed following 
withdrawal of survival factors, and increasing levels of E2F overrides the ability of 
survival factors to suppress cell death (Hiebert et al, 1995). There is no evidence 
that E2F-1 regulates the expression of genes involved in apoptosis. However, it has 
recently been shown that E2F over-expression in Drosophila imaginai discs leads to 
ectopic proliferation, apoptosis and the induction of reaper, a known cell death 
regulator in the fly (Asano et al, 1996).
Interestingly, like p53, E2F-1 has been reported to bind MDM2 (Martin et 
al,  1995). Thus, E2F-1 could induce cell death by titrating MDM2 away from p53 
and stimulating trans activation of p53 target genes involved in apoptosis. Although 
most of apoptosis studies were carried out in p53-^' human cell line, this hypothesis 
still could be supported by the other observation that p73, a human p53-related 
protein, can also trigger apoptosis, and its amino-terminal trans activation domain
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enhanced 
cell survival
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tumourigenesis
(in th e  lo s s  o f n eg a tiv e  
reg u la tio n s)
Figure 7-1
The dual functions of E2F/DP on cell cycle control.
Activation of E2F/DP elicits either a proliferative response 
(left) or an apoptotic response (right). (See text for details)
7-3. pRb and p300 have different effects on E2F-1-mediated apoptosis.
Interestingly, recent studies of pRb'^~ mice in p53-' ~^ or backgrounds
have clearly demonstrated p53“iiidependent apoptosis mediated by loss of pRb 
(Macleod et ai, 1996), implying that this may occur from the E2F-1 deregulation 
mechanism. As this thesis shows that the trans activation and the apoptotic 
functions of E2F-1 are separable, the inhibition of E2F-1-induced apoptosis by pRb 
cannot be mediated by the suppression of the E2F-1 trans activation function. 
However, it has recently been shown that, when pRb and E2F-1 complex together, 
the pRb-E2F-1 complex can act as an active repressor to inhibit transcription of
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includes the potential MDM2 binding site (Kaghad et ai, 1997; lost et al,  1997).
Therefore, E2F-1 may also compete with MDM2 for p73 to stabilize p73 protein, 
and thus E2F-1 and p73 co-operate to mediate apoptosis.
Studies of E2F-1 expression have shown recently that E2F-1 can undergo 7
ubiquitination and that the carboxy-terminal region of E2F-1 confer protein 
instability, and deletion of this region or binding of pRb to this region stabilizes the 
protein (Hateboer et al, 1996; Hoffmann et al, 1996). Results reported in this study 
indicated that both E2F-1(1-413) and E2F-1(1-380) induced apoptosis much more 
strongly than that of the wild-type E2F-1. Therefore, increased stability of E2F-1 
caused by the carboxy-terminal truncation of E2F-1 may be responsible for the 
increased cell death. Deregulated expression of mutant forms of E2F-1 which are 
defective for pRb binding significantly increased cell death, as shown by the earlier 
presence and increased absolute number of dead cells observed compared with cells 
expressing wild-type E2F-1 under identical conditions (in this thesis). These 
observations are consistent with those of others which indicate that apoptosis 
induced by E2F-1 can be partially blocked by pRb (Shan et al,  1996; Hsieh et al,
1997).
reporters containing E2F-binding sites (Weintraub et al,  1995; Luo et a l,  1998). 
Therefore, the repression function of the pRb-E2F-l complex may be the 
mechanism through which pRb inhibits E2F-1-induced apoptosis. This hyphothesis 
suggests an active role for pRb in E2F-1-induced apoptosis, as well as the necessity 
for physical interaction between pRb and E2F-1. Nevertheless, it should be pointed 
out that most of these results were produced in SAOS-2 cells, which fail to express 
wild-type pRb. In these circumstances, repression of apoptotic target genes may 
also be carried out by E2F complexes containing other pocket proteins such as p i07 
and p i30.
Even though it was clear that the apoptotic function of E2F-1 requires DNA 
binding but not trans activation, the co-expression of E2F-1 and its transcriptional 
C O-activator, p300, dramatically enhanced the E2F-1 apoptotic activity, consistant 
with the idea that p300 enhances the transcriptional activity of E2F-1 (this thesis 
and Lee et al, 1998). Moreover, the interaction of p300 with E2F-1 is mediated 
through binding to the trans activation domain (this thesis and Lee et al,  1998). 
These results imply that E2F-1-mediated apoptosis can be also augmented by its 
transcriptional activation pathway. Similarly, it is known that the transcriptional 
activity of E2F-1 is stimulated through heterodimerization with its partner DP-1, 
and that this heterodimerization dramatically increased E2F-1-induced apoptosis.
Interestingly, the interacting sites for proteins such as MDM2, p300, and pRb 
have been mapped to within the last 60 amino acids of the E2F-1 trans activation 
domain (Helin et al, 1992; Hagemeier et al, 1993; Martin et al, 1995; Lee et a l,
1998) (Figure 7-2). It is not known whether these three proteins can bind to the 
trans activation domain of E2F-1 simultaneously. However, it is possible that E2F- 
1 as a common cellular target involved in three distinct pathways of growth control 
mediated through the binding of the MDM2, pRb or p300 (Chellappan et a l,  1991; 
Helin et a l,  1993; Flemington et al,  1993; Martin et al, 1995; Shan et al, 1996; 
Tronche et al, 1996; Hsieh et al, 1997; Kowalik et al, 1998; Lee et al, 1998; Luo 
et a l,  1998).
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Figure 7-2
The E2F-1 trans activation domain contains three distinct protein-binding sites.
An enlarged bars indicate the regions of E2F-1 required to bind MDM2 
(Martin et al, 1995), pRb (Helin et al, 1992; Hagemeier et a l,  1993) and p300 
(Tronche et al,  1996; Lee et al, 1998). The binding of MDM2, pRb or p300 to the 
E2F-1 trans activation domain (TAD) provides three distinct pathways through 
which E2F-1 could influence growth control.
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Therefore, it is also possible that the competition between these proteins for E2F-1 
may be involved in the regulation of E2F-1-induced apoptosis. The functional 
distinctions between pRb, MDM2 and p300 were exemplified in studies with 
knockout mice. pRb~^^' mice develop tumours of the pituitary and thyroid, and |
pRb~^- embryos die between 13 and 15 days of gestation, exhibiting defective 
erythropoiesis as well as excessive proliferation and cell death in the liver, lens and 
nervous system (Jacks et al, 1992; Clarke et a l,  1992; Lee et al, 1994). mdm2~ '^ 
mice result in an early embryonic lethality, however, this lethality can be rescued in 
the absence of p53 (Jones et a l ,  1995; Montes de Oca Luna et al, 1995). These 
results suggest that the primary role of MDM2 during the development is to 
negatively regulate p53, with p53 and MDM2 acting in concert to regulate the cell 
cycle during early development. However, Lundgren et al  (1997) reported that 
over-production of MDM2 during pregnancy and lactation results in defective 
development of the mammary gland in both the and p53'^' backgrounds,
demonstrating a role for MDM2 that is independent of p53 function. p300'^- mice
Î.die around mid-gestation despite the presence of normal quantities of highly 
homologous CBP (Yao et al, 1998). Interestingly, fibroblasts derived fromp300'^- 
embryos display specific transcriptional defects and poor proliferation, implying that 
p300 is essential for cell proliferation and development. Moreover, p300^^' / 
mice invariably die in utero (Yao et a l ,  1998), demonstrating an absolute 
requirement for a certain combined level of these two closely related proteins for 
normal animal development.
7-4. The p53 and pRb/E2F pathways of growth control are functionally 
integrated.
Previous studies with p53 have shown that protein levels can be of critical 
importance in determining whether a cell undergoes cell cycle arrest or apoptosis
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(Chen et al, 1996; Polyak et al, 1996; Macleod et al., 1995). Therefore, it would 
be interesting to know whether the ability of E2F-1 to promote cell cycle 
progression or apoptosis also depends on its protein level.
The DNA tumour viruses SV40, adenovirus, and HPV all encode a series of 
oncogene products that bind to the pRb protein and liberate an active E2F 
transcription factor (Nevins, 1992; Lam and La Thangue, 1994; Vousden, 1995). As 
a result, these viral oncogene products signal the cell to enter the replication phase of 
the cell cycle (Weinberg, 1995; Whyte, 1995; Vousden, 1995; La Thangue, 1994). 
In addition, each of these viruses encodes a protein which has been shown to bind to 
the p53 protein (Moran, 1993; Vousden, 1996) and inactivate its function as a 
transcription factor (Ko and Prives, 1996; Levine, 1997). It was thought that this 
function may inhibit the tumour-suppressor properties of p53 and facilitate viral 
transformation. Since activated E2F-1 and p53 co-operate to mediate apoptosis, it 
could well be that the important function of binding to the p53 protein by viral 
oncogene products is to block p53-mediated apoptosis as shown with the adenovirus 
LIA gene product (Debbas and White, 1993; Somasundaram and El-Deiry, 1997).
Several previous studies have shown that E2F-1 over-expression can induce 
DNA synthesis in otherwise quiescent cells (Kowalik et a l,  1995; Almas an et al,
1995). In contrast, the induction of p53 halts the cell cycle which then is believed to 
allow the cell to repair its DNA or to await more favourable growth conditions (El- 
Deiry et al, 1993; Dulic et a l ,  1994; Harper et al, 1993; Waldman et a l ,  1995; 
Chen et a l ,  1996). In addition, a considerable body of research evidence also 
suggests that the pathways regulated by E2F and p53 are integrated in a way that 
allows p53 to sense aberrant control of E2F activity. A particularly clear example of 
this phenomenon relates to the induction of p53-dependent apoptosis in conditions 
where E2F-1 is expressed at high levels in tissue culture eells (Qin et al, 1994; Wu 
and Levine, 1994). Other studies, including those where the expression of viral 
oncoproteins which inactivate pRb occurs in defined cells, such as lens fibre cells
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(Pan and Greip, 1994), and the targeted disruption of Rb where the apoptosis is 
dependent upon p53 (Morgenbesser et al, 1994), support this general idea.
The E2F-1 and p53 proteins are key regulators of cell cycle progression. 
Therefore, the balance between the activities of E2F-1 and p53 is likely to be crucial 
to ensure the progression of the cell cycle. In normal eells, the transcriptional 
activity of p53 and E2F-1 are believed to be regulated mainly at the protein level. 
Thus, the functional cross-talk between these proteins is very likely to be of great 
importance in the overall control of the cell cycle.
7-5. p53 physically and functionally associates with DP-1.
In this thesis, I have described the assoeiation between DP-1 and p53 in vitro 
and in vivo. The region in p53 required for the interaction with DP-1 exists within 
the amino-terminal 143 amino acid residues. The first 73 residues, which contains 
the MDM2 binding domain (Momand et al,  1992; Lin et al, 1994; Chen et al,  
1994), are not sufficient for the interaction. Although previous studies have 
suggested that MDM2 can interact with E2F-1 (Martin et al,  1995), our results 
imply that this interaction is unlikely to be responsible for the association of DP-1 
with p53. Interestingly, the region between residues 73 and 143 which is necessary 
for p53 to bind DP-1 contains residues frequently altered in human tumour cells 
carrying mutant p53 alleles, such as Lysl20, Lysl32 and Cysl35 mutations (Malkin, 
1993; Greenblatt et al, 1994; Ko and Prives, 1996). Based on the results presented 
here, a potential biological rationale for these mutations could be envisaged whereby 
they prevent p53 from interacting with DP-1 and thus relieve the negative regulation 
imposed by p53 on the formation of functional E2F heterodimers and hence cell 
cycle progression.
Although p53 can associated with DP-1, it was not possible to detect p53 in 
physiological E2F DNA-binding complexes (Sprensen et a l,  unpublished
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»observation). This is consistent with the interaetion of p53 with p55U, but not p55L, 
since p55U is a rare component of physiological E2F DNA-binding activity. The 
results derived from the in vitro assay in which p53 specifically binds to DP-1 
support these observations, since they also indicate that p53 binds to an 
immunochemically distinct form of DP-1. Overall, these data suggest that p53 
targets a sub-population of DP-1 and, further, that this form of DP-1 is an infrequent f
component of E2F DNA-binding complexes. Since it is known that DP-1 undergoes 
regulated phosphorylation (Bandara et ai, 1994; Krek et al, 1994), it is possible that 
p53 targets a particular post-translationally modified form of DP-1, although further 
studies are required to claiify this possibility.
Co-expression of p53 specifically inactivated transcription driven by the 
E2F-1/DP-1 heterodimer. A potential model to explain these results would be that 
p53 holds DP-1 in a state which prevents it interacting with an E2F family member 
to form E2F-1/DP-1 heterodimer. Indeed, the region in DP-1 required to interact 
with p53 is necessary to form aE2F-l/DP-l heterodimer (Sprensen et al, 1996), and 
thus binding of p53 to DP-1 could be mutually exclusive with the interaction of DP- 
1 with E2F family members. Evidence for such a possibility was obtained by 
demonstrating that p53 and E2F-1 can compete for DP-1 binding and, eonsequently, 
that p53 reduces the level of E2F-1/DP-1 DNA-binding activity (Sprensen et al,
1996). These data are compatible with a model in which p53 targets an 
immunochemically distinct form of DP-1, regulating the formation of E2F-1/DP-1 
heterodimers and hence the level of E2F DNA-binding activity (Figure 7-3).
Although p53 is believed to possess the properties of a transcription factor 
and to trans activate of target genes such as gadd45 and Wafl/Cipl (El-Deiry et al,
1993; Kastan cr fl/., 1992; Ko and Prives, 1996) thought to be important in 
p53-mediated growth arrest, the interaction of p53 with DP-1 provides another 
potential pathway through which p53 may influence cell cycle progression (Figure 
7-3). Thus, since many of the genes regulated by E2F encode proteins required for
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Figure 7-3
Repression of E2F/DP transcriptional activity by p53 may occur via tvro 
pathways.
p53 regulates the E2F/DP transcriptional activity by pRb-dependent (a) and 
“independent (b) pathways, (a) Upregulation of p21^4/7/G/;^ expression by p53 can 
inhibit cdk activities. As result of this inhibition, hypophosphorylated pRb 
accumulates, and a G1 arrest is induced by the consequent repression of E2F 
responsive genes, (b) p53, which interacts with a distinct form of DP-1 (p55U), 
competes with E2F-1 for DP-1 leading to a reduetion in the level of E2F-1/DP-1 
heterodimer transcriptional activity.
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cell cycle progression, their transcriptional down-regulation through the interaction 
of p53 with DP-1 may impede cell cycle progression.
Moreover, the interaction of DP-1 and p53 may help explain the mechanism 
through which DP-1 exerts high levels of proto-oncogenic activity, a property which 
is shared by other members of the DP family, and one manifest in the absence of a 
co-transfected E2F family member (Jooss et ai, 1995). It is possible the increased
;;;
level of DP-1 sequesters p53, titrating out its activity, and thus overriding the 
growth-regulating effects of p53. In these conditions, DP-1 may act in an analogous I
fashion to certain viral oncoproteins, such as the adenovirus ElB and papilloma 
virus E6 proteins, since their ability to inactivate p53 also correlates with oncogenic 
activity (Moran, 1993; Vousden, 1996).
7-6. Functional cross-talk between p53 and E2F-1 through co-activator p300.
In this thesis, I have also demonstrated a mechanism which can explain the |
functional interplay between E2F and p53 and which may, in part, influence the |
physiological outcome of aberrant levels of E2F. A mechanism was suggested when 
I observed that co-expression of E2F-1 caused a eoncomitant reduction in p53- 
dependent transcription, an effect which was overridden by co-expression of pRb.
This, combined with the evidence that the trans activation domains of E2F-1 and 
p53 were involved, raised the possibility that competition for a rate limiting 
transeription target may be responsible for the down-regulation of p53. The p300 
protein, which possesses the properties of a transcriptional co-activator and is 
involved in regulating the activity of a variety of sequence specific transcription 
factors (Shikama et a l ., 1997), overcame the down-regulation of p53 and, moreover, 
enhaneed the activity of both E2F-1 and p53-dependent transcription, an effect 
dependent on a physical association between the trans activation domain of each 
protein and p300. Thus, the data presented here strongly suggest that the reduced
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level of p53 transcriptional activity in the presence of E2F-1 is exerted through each 
trans activation domain competing for the p300 co-activator. That co-expression of 
pRb neutralized the effect of E2F-1 on p53 makes good sense in the light of the 
regulation of the E2F-1 trans activation domain by pRb (Flemington et a l,  1993; 
Helin et al, 1993; Kaelin et al, 1992).
The data clearly indicated that p300 acts co-operatively with p53 to stimulate 
transcription in a p53-dependent manner. The dominant-negative mutant of p300 
(p300l5^2-l903) containing the region required for the interaction with p53 prevents 
the activation of a p53-regulated promoter, implying that p300 is a crucial 
component of p53-directed transcription. In addition, p300 binds to the E2F-1 trans 
activation domain and stimulates the transcriptional activity of E2F-1. The 
identification of p300 as a component of p53- and E2F-1-mediated transcription, 
together with the notion that the concentration of p300 is rate limiting in cells 
(Kamei et a l,  1996; Avantaggiati et al, 1997), implies that the functional cross-talk 
between p53 and E2F-1 through p300 is an important regulatory pathway in cell 
cycle control. In keeping with my models, recent studies have suggested that a 25% 
drop in combined p300/CBP levels through the loss of one p300 or CBP allele is 
enough to interfere seriously with embryonic development, while a 50% drop results 
invariably in embryonic death (Yao et al, 1998).
Cell cycle arrest mediated by p53 is thought to rely on the ability of p53 to 
directly activate the transcription of target genes, such as p2 1  ^47^0^7^ which 
functions as an inhibitor of cyclin-dependent kinases (Chen et al, 1996; El-Deiry et 
al,  1993; Harper et al, 1993; Macleod et al, 1995) and thus likely occurs through 
the inactivation of G1 CDK activity and the maintenance of pRb and related proteins 
in a hypophosphorylated state. In this study, the results define a further level of 
control in the regulation of p21^4/V^^/^^, exerted through a positive autoregulatory 
feedback mechanism whereby p2 1 ^ 4 7YGp/ enhances the transcriptional activity of 
the p53/p300 co-activator complex. Although the precise mechanism of action 
remains to be determined, this effect of p21^‘3/’YCjp7 suggests that the activity of the
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p53/p300 co-activator complex is influenced in a negative fashion by CDK 
phosphorylation. The recent demonstration that p300 associates with cyclin 
E/CDK2 (Perkins et al, 1997) is consistent with this idea.
A recurring theme in the control of the cell cycle is that of positive 
autoregulation, which is believed to provide a mechanism for enabling the rapid 
accummulation of regulatory proteins involved in mediating cell cycle transitions. 
Numerous examples are known, such as in Saccharomyces cerevisiae, where a 
positive autoregulatory feedback control on transcription by the G1 cyclins favours 
the rapid induction of CDK activity and thus progression into S phase (Johnston, 
1992). Similarly, the mammalian E2F-1 gene is autoregulated by E2F activity 
(Johnson et al,  1994) and the product of the cyclinE gene, which is regulated by 
E2F, may positively regulate transcription of its own gene by antagonising the 
repressive effects of pRb and related proteins (Botz et al, 1996). The autoregulation 
of p53/p300 activity by p2l'^'VVG>7 provides another interesting example of such a 
mechanism which likely assists the rapid accummulation of  ^ thus
augmenting cell cycle arrest (Figure 7-4). Since it is widely believed that p53 
responds to environmental stress, a rapid cell cycle arrest clearly is a desirable 
response.
1-1. A central role for p300 in cell cycle control and apoptosis.
That p300 functions as a co-activator involved with E2F-1- and p53- 
dependent transcription and can influence the physiologieal consequence of p53 
induction suggests that p300 plays a central role in co-ordinating early cell cycle 
events. The results presented in this study demonstrated that p300 could enhance 
the ability of p53 to cause G1 arrest and, moreover, failed to induce p53-dependent 
apoptosis. These observations are consistent with a role for p300 as a p53 co­
activator in the transcription of p21^«/ /^^*7? ,^ and in turn suggest that p53 induction
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under conditions of limiting levels of p300 may be a signal which causes cells to 
enter apoptosis. It is known that transcriptionally inactive p53 proteins can induce 
apoptosis (Caelles et a l,  1994; Chen et a l,  1996; Haupt et al., 1995b) whereas 
transcriptional activity correlates with cell cycle arrest (Crook et ai, 1994). Further 
evidence suggests that the level of p53 may dictate the cellular response, with low 
levels of p53 causing cell cycle arrest and high levels apoptosis (Chen et ai, 1996; 
Polyak et al., 1996; Maeleod et al., 1995). Given the data presented in this study, it 
is possible that at high levels of p53, p300 levels become limiting which, suggested 
by the data presented here, provides an apoptotic signal.
Of course, some studies have suggested that transcription-dependent 
mechanisms are involved in p53-dependent apoptosis, and by no means is this study 
incompatible with this view. For example, the bax gene has been implieated as a 
direct target for p53 (Miyashita and Reed, 1995). However, although bax'^' 
thymocytes fail to respond to certain apoptotie stimuli, they are not deficient in p53- 
dependent DNA damage induced apoptosis (Knudson et al,  1995). It is likely 
therefore that p53 can influence apoptosis through different mechanisms. The model 
proposed in this study suggesting that apoptosis occurs in conditions of p53 
induction with limiting levels of p300 may account for one such mechanism. 
However, other recent studies have suggested that p300 plays a positive role in 
regulating p53-dependent apoptosis (Avantaggiati et al,  1997; Fill et a l,  1997; 
Somasundaram et a l,  1997). Nevertheless, it is possible that the activation and 
expression of and Bax may have not occurred at the same time.
Interestingly, my recent unpublished observations are eonsistent with this 
speculation, as I found that the aceumulation of by actinomycin D in
SAOS-2 and U20S cells only occurred at low concentration (InM) of treatment, 
whereas cell death was brought about at high concentrations (lOnM to IqM) (data 
not shown). This is consistent with other similar studies where it was noted that the 
low levels of p53 was dominant over the growth arrest pathway (Macleod et al, 
1995; Chen et a l,  1996; Polyak et a l,  1996). Therefore, it is possible that the
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experimental conditions in this thesis in which cells underwent 
mediEited cell cyele arrest may reflect insufficient levels of p53 to activate apoptotic 
genes such as bax. Thus, even though further experiments are required to clarify 
these issues, it is clear that the dependence of p53 activity on p53 concentration may 
be a contributory factor.
Although apoptosis is enhanced when p53 and E2F-1 are expressed together, 
E2F-1 alone was capable of inducing apoptosis in p53' -^ tiimom cells, suggesting 
that p5 3-dependent and -independent mechanisms contribute towards E2F-1 induced 
apoptosis (this thesis and Hsieh et al, 1997; Phillips at al, 1997). Inp53~ '^ cells, the 
co-expression of E2F-1 and p300 enhanced apoptosis, in contrast to the effect of 
p300 in cells expressing p53 and E2F-1 when there was a significant decrease in the 
proportion of apoptotic cells, suggesting that limiting levels of p300 favour p53- 
independent apoptosis. Moreover, it is interesting that the partial rescue of apoptosis 
by p300 is compatible with earlier reports indicating that p53-mediated apoptosis 
can be overcome by pRb (Haupt et al, 1995a) since, as explained, the presence of 
p300 will directly favour the maintenance of hypophosphorylated pRb. 
Interestingly, it is consistent with my models that Thomas and White (1998) have 
recently reported that rate limiting p300 is required specifically for trans activation 
of the mdm2 gene by p53 and for regulating p53-mediated apoptosis. In addition, 
cells expressing El A were unable to up-regulate MDM2, causing stabilization of 
high level of p53 that resulted in p53-dependent apoptosis. Furthermore, expressing 
of anti-apoptotic ElB 19K and Bcl-2 could bypass ElA inhibition of p300 function 
and restored mdm2 trans activation, thereby inhibited p53-dependent apoptosis 
(Thomas and White, 1998).
The results presented in this study, together with the documented role of p53- 
dependent transcription in cell cycle arrest, are consistent with a model in which the 
productive interaction between p53 and p300 and consequent activation of target 
genes like p2 1 ^ 4 /^^Ei/?/ important in eontrolling cell cycle arrest. However, it 
should be noted that a p2l'^^/^/^'/^^ deficiency does not completely abbrogate G1
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arrest due, for example, to irradiation (Brugarolas et a l, 1995; Deng et a l, 1993) 
whereas in p53''^' mice G1 arrest is completely absent (Donehower et a l, 1992). 
Thus, p53 likely has other targets in addition to p21^'^/^/^'7’^  which confer cell cycle 
arrest, or other factors may involve in the regulation of Wafl/Cipl gene. Recently, a 
new p53-related protein, namely p73, has been identified that has the potential to 
activate p53 target genes (Kaghad et a l, 1997; Jost et al, 1997). Interestingly, over- 
expression of p73 in SAOS-2 and U20S cells showed elevated levels of 
p 2 \"^afWCipl and GADD45 proteins (Lee and La Thangue, unpublished 
observation). Moreover, I assessed whether p73 also could utilise p300 as a 
transcriptional co-activator. The results from mammalian two-hybrid and 
immunoprécipitation assays have revealed that the amino-terminal trans activation 
domain of p73 directly interacts with the CH3 region of p300 (Lee and La Thangue, 
unpublished observation), suggesting that p300 is a bonafide component of p53 
family-mediated transcription in a network of eell cycle arrest and apoptosis.
When the induction of p53 causes cell cycle arrest, for example, in response 
to genotoxic stress, the data suggests that p53 activates transcription in concert with 
p300. Further evidence presented here showed that the over-expression of 
p2 ilFa///Q>/ enhances the transcriptional activity of the p53/p300 co-activator 
complex. At the same time, the inhibition of CDK activity by the induction of 
p2 i Wfl/7/C(>7 will retain pRb and related proteins in a hypophosphorylated state and 
thus, by virtue of excluding the E2F-1 trans activation domain, enhance the levels of 
p300 available for p53 (Figure 7-4b).
Previous studies suggest that the cellular level of p53 protein is crucial for 
determining whether cells arrest or apoptose (Macleod et a l, 1995; Chen et a l, 
1996; Polyak et a l, 1996). The apoptotic conditions were also caused by high levels 
of E2F-1 in conditions which are inappropriate for cell cycle progression or 
increased level of p53 (Figure 7-4c). However, I would like to emphasise that the 
data do not rule out the possibility that there are p53 target genes which need to be 
activated, perhaps through other co-activators, in order to achieve apoptosis.
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Figure 7-4
Model for cell cycle control by p300.
It is envisaged that during normal cell cycle progression (a) p53 
remains in a latent state and that p300 functions as a co-activator for transcription 
factors such as E2F-1. Upon activation and cell cycle arrest by p53 (b), p300 
functions as a co-activator for p53-dependent transcription, such as in the activation 
of the Wafl/Cipl gene. The activity of the p53/p300 co-activator complex is 
enhanced by through a positive autoregulatory feedback loop whilst the
activity of E2F declines due to the presenee of hypophosphorylated pRb. For (c), in 
conditions which are inappropriate for cell cycle progression aberrantly high levels 
of E2F compete for p300, resulting in the increased apoptosis. It is envisaged that 
the high levels of p53, together with E2F, provides a signal for apoptosis.
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With respect to this idea, it has been shown that p53 utilizes other co-activator 
molecules in transcriptional activation (Lu and Levine, 1995; Thut et a i, 1995) and 
thus it is possible that the regulation of p53 activity by p300 relates to a specific 
group of target genes.
It is noteworthy that the ability of E2F-1 to influence the physiological 
outcome of p53 activation may bear on the phenotype of the mice which
suffer thymic hyperplasia due to reduced levels of apoptosis during thymocyte 
ontogeny, together with an increased incidence of tumours in older animals (Field et 
a l, 1996; Yamasaki et a l, 1996). Based on the studies presented here, one scenario 
which may contribute to this phenotype in the absence of E2F-1 would be that a 
signal (provided by E2F-1) is lost which drives p53-dependent apoptosis, subverting 
the normal apoptotic process in thymocytes and thus giving rise to hyperplasia. 
Similarly, the loss of an apoptotic signal will encourage tumour progression, in a 
similar fashion to the phenotype observed in the p53-^' mice (Donehower et a l, 
1992).
7-8. ElA deregulates p53 and E2F-1 activity through its co-activator p300.
p300 was defined by studies on the mechanisms through which the 
oncogenic products of DNA tumour viruses subvert normal cellular growth control I
(Arany et a l, 1995). p300 interacts with a domain within the adenovirus E lA  |
protein which is essential for the protein to exert a range of biological effects on 
cells such as the induction of DNA synthesis and apoptosis (Moran, 1993).
Furthermore, the transcriptional activation by p300/CBP could be abolished directly 
and specifically by binding to ElA (Arany et a l, 1995; Yang et a l, 1996; Crook et 
a l,  1996). ElA  mutants which lack the p300 binding site lose the properties of 
ElA-driven cell cycle progression and cellular transformation (Moran, 1993).
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Taken together, therefore, these results indicate that p300/CBP are key regulators of 
cell cycle progression and cellular differentiation.
An important and highly interesting feature of p300/CBP is that germline 
inactivation of one allele or somatic translocation of the gene has been implicated as 
the cause of many diseases and cancers (Sakai et a l, 1992; Eckner et al, 1994; Giles 
et a l, 1995; Petrij et a l, 1995; Muraoka et a l, 1996; Ida et a l, 1997). Thus, it is 
argued that the level of p300/CBP is physiologically crucial and rate limiting in I
-C
cells, in consistent with recent studies that the decreased p300 or CBP protein level J
in p300’^ ~^ or mice significantly reduced viability and seriously interefered
embryonic development (Yao et a l, 1998). Whereas it plays a positive role in 
cellular differentiation, p53-mediated DNA repair/apoptosis, and E2F-1-mediated 
apoptosis, it is a negative regulator of cellular growth.
El A is known to inhibit p53 transcriptional activation function, and binds to 
the CH3 domain of p300/CBP (Chiou and White, 1997; Somasundaram and El- 
Deiry, 1997). In this study, it was shown that wild-type El A specifically inhibited 
p53-mediated activation, possibly through the interaction of p300/CBP, since the 
ElA  mutant (E1AA2-36) failed to repress p53-dependent transcription. Again, the |
result indicates that E lA  inhibition of p53-mediated transcriptional activation 
correlated with its ability to bind p300/CBP. Indeed, the data make good sense in 
the understanding of tumourigenesis. The stimulation and activation of p53 by 
cellular stress causes cell cycle arrest or apoptosis to allow DNA repair or to prevent 
tumourigenesis. But, the DNA viruses such as adenovirus deregulate p53 activity 
through its co-activator p300 so as to allow quiescent cells to undergo DNA 
replication, thereby providing an environment permissive for viral replication.
At the same time, it is known that oncoproteins encoded by these DNA 
tumour viruses contain a region which mediates binding to the pRb family of 
proteins to sequester this region from the E2F family, resulting in deregulated cell 
cycle progression (Weinberg, 1992; Lam and La Thangue, 1994; Vous den, 1995;
Wang, 1997). Thus, inappropriate cell cycle entry and deregulated E2F/DP activity
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trigger apoptosis (Qin et a i, 1994; Wu and Levine, 1994; Shan et a l, 1996; 
DeGregori e ta l, 1997; Hsieh e ta l,  1997; Phillips e ta l, 1997).
In this thesis, it was also demonstrated that E2F-1/DP-1 utilizes p300 as a co­
activator through binding to its transcriptional activation domain, resulting in the 
significant increase of E2F-1-mediated apoptosis. However, the fact that ElA  
represses E2F-1-mediated transcriptional activation by binding p300 (Tronche and 
Kouzarides, 1996) may leads to the loss of E2F-1-induced apoptosis, and in turn 
implies that these cellular conditions may facilitate viral transformation. Moreover, 
in some environmental circumstances, it is possible that the competition between 
p300 and pRb for the E2F-1 trans activation domain may result in distinct 
physiological outcomes.
7-9. A novel transcriptional co-activator, JMY, that interacts with p300,
p300/CBP likely plays a series of key regulatory roles in animal cells as 
described previously, given that binding of p300 by ElA leads to perturbation of the 
cell cycle, blockade of multiple differentiation processes, failure to suppress 
transformation, and loss of elements of transcriptional control (Shikama et a l,
1997). The biological activity of p300 family members may depend, at least in part, 
upon their ability to function as co-activators with transcriptional factors such as 
CREB, c-fos, c-Jun, MyoD, and E2F-1/DP-1 (Arias et al, 1994; Chrivia et al, 1993; 
Eckner et a l, 1996; Torchia et a l, 1997; Perkin et a l, 1997; Shikama et al, 1997; 
Lee et a l,  1998). Especially, I and others have demonstrated that p300/CBP also 
acts as a co-activator for p53 and potentiates its transcriptional activity in vivo (this 
study and Lill et a l, 1997; Gu et a l, 1997; Avantaggiati et a l, 1997; Lee et a l,
1998). Given this critical and highly specific interaction with this co-activator, it is 
possible that p300/CBP nucleates different factors so they may functionally interact 
either negatively or positively.
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7-10. JMY enhances p53-dependent transcription through co-activator p300.
To investigate the functional properties of JMY, it was considered that JMY 
together with p300 may modulate the activity of p53. An analysis of the role of 
p300 and JMY in regulating the bax promoter, a gene that responds to p53 
(Miyashita and Reed 1995), suggested that p300 and JMY co-operate in activating 
the transcription of the bax gene. In contrast, the effect of JMY on other p53 target 
genes was less striking and, in the case of mdm2, increased levels of JMY failed to 
significantly affect promoter activity. Thus, although this study has focused on a
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p300/CBP have been shown to have histone acetyltransferase activity, which 
can modify chromatin structure and enhance gene expression (Bannister and
:
Kouzarides, 1996; Ogryzko et a l, 1996). Recently, p300 also has been shown to
acetylate p53 itself (Gu and Roeder, 1997). The acétylation of p53 increases the
binding of p53 to specific consensus sequences in vivo, this activity may be required
for facilitating p53 tetramer interactions with the DNA template, thereby promoting 
.p53-inducible genes transcriptional activation. However, acétylation of p53 by p300 
may not be the only regulatory mechanism to control trans activation of p53- 
inducible genes. Interestingly, it has been known that p/CAF, P/CIP, SRC and 
ACTR interact with p300/CBP and regulate the p300/CBP activity (Kamei et a l,
1996; Yang et a l, 1996; Chen et a l, 1997; Li et a l, 1997; Torchia et a l, 1997).
Therefore, it is possible that different levels of regulation through other factors may 
play a role in transcriptional activation of p53-inducible genes.
Recently, Shikama et a l (1998) have focussed on the identification of 
additional molecules that functionally interact with p300 that may influence its 
effects on target transcription factors. In this thesis, it was shown that a novel co­
activator, JMY, physically and functionally interacts with p300 in transcriptional 
activation by p53.
7-11. JMY augments p53-dependent apoptosis.
Most previous studies support a correlation between transcriptional 
activation by p53 and the induction of cell cycle arrest, but the dependence of the 
apoptotic function of p53 on transcriptional activity is more complex. Some studies 
have found that apoptosis can occur when the p53 trans activation domain is 
compromised whereas other reports support a role for transcriptional activation 
(Caelles et a i, 1994; Crook et a l, 1994; Chen et al, 1996; Haupt et a l, 1995). The 
correlation between transcriptional activation of the bax promoter and induction of
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limited spectrum of p53-responsive genes, nevertheless the data do support the idea 
that the co-activator effects of JMY are more pronounced on certain p53 target 
genes, exemplified by the effect of JMY on bax. Overall, therefore, the results
:
suggest a model in which JMY plays a preferential role in mediating the 
transcriptional activation of a selective group of target genes. However, it should be 
considered that the activation and accumulation of MDM2 by p53-dependent 
transcription through its co-activators may lead to negative-regulatory feedback 
competition between MDM2 and p300 for binding to the p53 trans activation 
domain. Thus, although neither exogenous JMY nor p300 could augment the 
activity of the mdm2 promoter, it is highly possible that both p300 and JMY are key 
integrators of all transcriptional responses of p53.
Recent studies demonstrate that E lA  specifically inhibits m.dm2 trans 
activation and not other p53-inducible genes such as bax and Wafl/Cipl (Thomas 
and White, 1998). Therefore, these results suggest that p300 binding to p53 alone 
may not regulate the specificity of p53 trans activation for bax and Wafl/Cipl. As 
numerous protein interactions with p300 occur, JMY may determine the specificity 
of trans activation, accounting for differential regulation of p53-inducible genes by 
p300.
apoptosis suggests that the 6<3%-encoded protein may play a role in p53-mediated 
apoptosis. This suggestion is consistent with earlier reports (Miyashita and Reed, 
1995; Zhan et a i, 1994) and with the documented apoptotic effect of Bax over­
expression (Oltavi et a l, 1993). For example, the bax gene is transcriptionally 
activated by p53 and p53-dependent apoptosis, in some conditions, is compromised 
by experimental strategies that subvert and inactivate p300/CBP (Lill et a l 1997; 
Avantaggiati et a l 1997). It has been reported that expression of Bax can efficiently 
induce apoptosis in SAOS-2 cells (Ludwig et a l, 1996). In this thesis, it was shown 
that JMY can augment the level of p53-dependent apoptosis in SAOS-2 cells. In 
sharp contrast, when the effect of exogenous p300 was measured in similar assay 
conditions, little effect was apparent on apoptosis, suggesting that increasing the 
level of p300 is not sufficient to promote apoptosis. Rather, the results are 
consistent with the idea that p300 and JMY act together in the p53 response.
With regard to apoptosis, the need for trans activation by p53 appears to 
depend on cell type. More likely, cell type specific apoptosis may be related with 
the presence of sufficient amounts of downstream effector molecules of p53- 
mediated apoptosis, or any additional factors required to activate or modify the death 
gene products such as Bax. Although the role of p53 in the apoptotic mechanism 
remains to be elucidated, the data presented in this thesis suggests that both p300 
and JMY are potential mediators for p53-induced apoptosis.
Interestingly, I have found that the physiological consequences of p300 and 
JMY on p53 transcriptional activity can be distinguished from each other. Thus, 
combined with other results on the requirement for p300 in regulating p53 activity 
(Lill et a l,  1997; Gu et a l, 1997; Avantaggiati et a l, 1997; Lee et a l, 1998), I 
suggest a general model in which p300 and JMY function together in p53-dependent 
transcription and that p300 is necessary, but not sufficient, to augment apoptosis. 
Further, since JMY could augment apoptosis without additional p300, in turn the 
data suggest that in the conditions of the apoptosis assay JMY, rather than p300, is 
limiting.
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The mechanism of action through which JMY and p300 co-operate in the 
transcriptional activation of p53 target genes, and the basis of the different effects on 
promoters, have yet to be elucidated. Nevertheless, the results do point towards a 
level of control that is likely to be important in the regulation of p53 activity and, 
specifically, indicate that there are additional co-activator molecules, like JMY, that 
through an interaction with p300 have a significant impact on the transcriptional 
activity of target genes and thus physiological outcome.
I do not have any evidence to suggest that JMY is involved in the formation 
of basal transcriptional complex. However, it is possible that JMY may integrate 
p300/CBP proteins with components of the basal transcription apparatus, and 
thereby effect transcriptional activation perhaps through directly modulating basal 
transcription factor activity.
7-12. Overall conclusion.
In conclusion, I have defined a central role for the p300 co-activator in co­
ordinating the interplay between the pathways of control mediated by E2F-1/DP-1 
and p53. The data strongly support the idea that p300 functions as a negative 
regulator of cell cycle progression and that the competition between E2F-1/DP-1 and 
p53 for p300 is instrumental in influencing whether cell cycle progression, G1 arrest 
or apoptosis occurs (Figure 7-5). The recent identification of tumour suppressor-like 
mutations in p300 genes in human tumour cells provides support for such an idea 
(Muraoka et al, 1996; Sakai et al, 1992; Giles et a l, 1995; Ida et al, 1997).
Finally, a question of central importance relates to the mechanistic and 
physiological role of p300/CBP in regulating the p53 response. In this thesis, it was 
demonstrated that JMY, a novel p300 target protein, physically and functionally co­
operates with p300 in transcriptional activation by p53 (Figure 7-5). Thus, the data 
support the notion that JMY is an important effector molecule in directing the
202
cellular response to p53 and suggest that JMY behaves as a significant determinant 
in influencing the biological outcome of transcriptional activation by p53.
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Figure 7-5
Regulation of cell cycle and apoptosis by p53 and E2F-1/DP-1 through co­
activators p300 and JMY.
E2F/DP may be directly inducing death genes in the absence of pRb and the 
presence of co-activators. Alternatively, the transcriptional activation of E2F/DP 
through co-activators may be an indirect trigger for cell death by over-proliferation 
and exhaustion of survival factors. Activation of p53 transcription through co­
activators p300 and JMY can directly induce genes involving in cell cycle arrest and 
apoptosis. (See text for further details)
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